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ABSTRACT 37 
Background 38 
HIV disproportionately affects gay, bisexual, and other men who have sex with men (MSM) 39 
in Africa, where many countries criminalise same-sex behaviour. We assessed changes in 40 
the engagement of African MSM with HIV testing and treatment cascade stages over time, 41 
and the influence of anti-LGBT legislation and stigma. 42 
Methods 43 
We systematically searched the peer-reviewed literature to October 10th, 2018 for studies 44 
and extracted or derived estimates of HIV testing and/or engagement with the HIV treatment 45 
cascade among African MSM from published reports. We derived pooled estimates using 46 
inverse-variance random-effects models. We used subgroup and meta-regression analysis 47 
to assess associations between testing and status awareness outcomes and study and 48 
participant characteristics including the severity of country-level anti-LGBT legislation.  49 
Findings 50 
Our searches identified 75 independent eligible studies that provided estimates for 44,993 51 
MSM across one or more of five testing and treatment cascade outcomes. HIV testing 52 
increased significantly over time overall, with pooled overall proportions of MSM ever tested 53 
of 67·3% (95%Confidence interval 62·1-72·3%,N=44) and tested in the past 12 months of 54 
50·1% (42·4-57·8%,N=31) post-2011 – 14% and 18% points higher than pre-2011, 55 
respectively. Post-2011, ever testing was highest in Southern(80·0%) and lowest in 56 
Northern(34·4%) and Central(56·1%) Africa, with the greatest increase in Western 57 
Africa(from 42·4 to 70·9%). Levels of both testing outcomes and status awareness were 58 
statistically significantly lower in countries with the most severe anti-LGBT legislation.  59 
Few estimates were available for later stages of the treatment cascade. Available data post-60 
2011 suggest that the pooled proportion of MSM HIV-positive aware has remained low 61 
(18·5%, 12·5-25·3%,N=28) whereas proportions of current ART use were 23·7% (15·5-62 
33·0%,N=14) among all MSM living with HIV and 53·4% (36·9-69·5%,N=6) among MSM 63 
HIV-positive aware. Levels of viral suppression among MSM currently on ART were good 64 
(pooled: 75·6%, 64·4-85·5%,N=4), but low among all MSM living with HIV (pooled: 24·7%, 65 
18·8-31·2%,N=4).  66 
Interpretation 67 
 3 
Available data suggests that levels of HIV status awareness among MSM living with HIV in 68 
Africa remain low, despite recent improvements in HIV testing; limited data is available on 69 
levels of engagement in care, ART use and viral suppression. We found that severe anti-70 
LGBT legislation was associated with lower HIV testing and status awareness. Achieving 71 
UNAIDS 90-90-90 targets will require substantial improvements.  72 
Funding 73 
US National Institutes of Health and the UK Medical Research Council.  74 
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INTRODUCTION  75 
The development of highly active antiretroviral therapy (ART) in the 1990s transformed HIV 76 
from a fatal infection to a treatable chronic disease.1 People living with HIV (PLHIV) on 77 
suppressive ART can live as long as people without HIV.2 However, achieving viral 78 
suppression requires engagement in all stages of HIV care, from testing and early diagnosis, 79 
through the treatment cascade, including linkage into and retention in care, early ART 80 
initiation, and near-perfect adherence.3 Globally, however, ~1 million PLHIV still die from HIV 81 
annually because they cannot or do not complete this cascade.4,5  82 
UNAIDS has formulated the ‘90-90-90’ targets, aiming to have 90% of PLHIV aware of their 83 
status, 90% of PLHIV aware of their status on ART, and 90% of PLHIV on ART achieving 84 
viral suppression by 2020,6 with targets increasing to 95% by 2030.7 Therefore, by 2020 and 85 
2030, 73% and 86% of PLHIV should be virally suppressed, respectively.7 Engaging PLHIV 86 
in the cascade to meet these ambitious targets will have major implications for PLHIV and 87 
HIV prevention, improving mortality and morbidity outcomes,8 and reducing transmission 88 
risk.9,10 UNAIDS has highlighted the importance of reaching key populations, including gay, 89 
bisexual, and other men who have sex with men (MSM), however estimates of progress 90 
towards achieving 90-90-90 targets among MSM are very scarce, which compromises our 91 
ability to assess impact, adequately address needs and reduce barriers to uptake of 92 
services, and improve HIV prevention services for MSM.11,12 Globally, MSM are ~28 times 93 
more likely to be living with HIV than men in the general population – an inequality that is 94 
particularly apparent in sub-Saharan Africa, where the human rights of MSM are often 95 
violated.5,13–19 96 
Almost two-thirds of African countries still criminalise same-sex relations, many with long 97 
prison sentences and some with the death penalty.20 In this context, stigma, discrimination, 98 
and human rights violations of MSM that are linked to legislation have been widely 99 
documented.5,13–19 This includes blackmail, violence, reprisals from family and communities, 100 
denial of housing, healthcare, and access to justice, and lack of adequate and accessible 101 
services for MSM.21–23 These also create barriers to implementing effective HIV research, 102 
policy, and health programmes for MSM, through prohibition of activism and research, 103 
arbitrary arrests of healthcare providers, and disruption of services provided by community-104 
based and non-governmental organisations (NGOs).24–26 This may also explain why 105 
research on African MSM has lagged behind that in other parts of the world.15,17,25–28 106 
After South Africa led the first United Nations (UN) resolution on sexual orientation and 107 
gender in 2011, some positive changes in lesbian, gay, bisexual and transgender (LGBT) 108 
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rights protection were reported in parts of Africa, albeit inconsistently.29 For example, while 109 
Seychelles, São Tomé and Príncipe, Mozambique and Lesotho have decriminalised same-110 
sex relations, Uganda and Nigeria have increased the severity of their anti-LGBT 111 
legislation.20 112 
In this study, we (1) systematically reviewed published studies providing estimates of levels 113 
of HIV testing, diagnosis, and the treatment cascade among MSM in Africa; (2) assessed 114 
whether these outcomes have improved over time; and (3) explored the influence of 115 
participant and study characteristics, study quality, and two key structural factors – stigma 116 
and severity of anti-LGBT legislation – on each outcome.  117 
 6 
METHODS  118 
This systematic review and meta-analysis was reported in accordance with PRISMA and 119 
MOOSE guidelines.30,31 120 
Search strategy and selection criteria 121 
We searched Embase, Medline, Scopus, Global Health, and Web of Science for articles 122 
reporting on HIV testing and/or any HIV treatment cascade stages in Africa published 123 
between January 1st, 1980 and October 10th, 2018 using terms for HIV, MSM, and Africa 124 
(see appendix p 1 for full search terms). 125 
We screened by abstract and title, then screened potentially relevant full-texts for studies 126 
directly reporting estimates or sufficient data to self-calculate proportions of MSM engaging 127 
in HIV testing and/or treatment cascade stages. We only included peer-reviewed cross-128 
sectional or longitudinal studies recruiting at least 10 MSM. We excluded mathematical 129 
modelling studies, qualitative studies, conference abstracts and reviews, and studies 130 
reporting cascade outcomes using self-reported HIV status (instead of confirmed biological 131 
test) to derive the number of MSM living with HIV in the denominator. We did not exclude 132 
articles based on language. 133 
For included studies, we extracted or self-calculated proportions of MSM: 1) who self-134 
reported having ever or recently received an HIV test; 2) testing positive in the study (“MSM 135 
living with HIV” hereafter) who self-reported being HIV positive before testing (“MSM HIV+ 136 
aware” hereafter); 3) living with HIV who self-reported being ever or currently engaged in 137 
care or linked to care following diagnosis; 4) living with HIV or HIV+ aware who self-reported 138 
ever or currently taking ART; and 5) living with HIV, HIV+ aware, or currently on ART who 139 
were virally suppressed (based on viral load testing). We excluded estimates based on 140 
fewer than 10 MSM. One of four study authors contacted provided estimates of MSM ever 141 
and recently tested and of MSM living with HIV virally suppressed.32 142 
For each study, we extracted information on participant characteristics (e.g. population, 143 
region of Africa, HIV prevalence among MSM participants tested in the study, proportion 144 
sold sex), stigma (e.g. proportion who disclosed their MSM status to healthcare workers or 145 
family, or were blackmailed), study characteristics and quality indicators (e.g. study year, 146 
study design, sampling and interview methods).  147 
We used country-specific data from International Lesbian, Gay, Bisexual, Trans and Intersex 148 
Association (ILGA) reports, country constitutions, and UN reports to construct four 149 
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composite “anti-LGBT legislation” variables, one global anti-LGBT legislation index, and one 150 
“arrests” variable for each study country.20,33–35  151 
The four anti-LGBT legislation variables are: repressive legislation (same-sex relations, 152 
sexual orientation-related NGOs, or LGBT promotion are illegal, age of consent differs for 153 
same-sex relationships, or legislation prohibits same-sex marriage and/or adoption; score 0-154 
5), lack of protective legislation (LGBT people are not protected from discrimination, or 155 
incitement to hatred based on sexual orientation is not illegal; score 0-2), lack of progressive 156 
legislation (same-sex marriage and/or adoption are not legally recognised; score 0-2), and a 157 
penalties variable (the harshest punishment receivable for consensual same-sex relations 158 
varying from no punishment to the death penalty; score 0-5). Our global anti-LGBT 159 
legislation index summed the scores of these four legislation variables(score 0-14), for each 160 
study country at the time the study was conducted. Higher scores reflected less progressive 161 
legislation. The binary arrests variable captured if arrests for consensual same-sex relations 162 
had been documented in the country between 2014 and 2017 (the only such data 163 
available).20 See appendix p 2-3 for additional details. 164 
JS, ED, and RS independently performed all stages of screening and data extraction. 165 
Discrepancies were resolved by KM. 166 
Data analysis 167 
We pooled independent study estimates and calculated 95% confidence intervals (CI) and 168 
95% prediction intervals (PrI) using random-effects models based on the DerSimonian-Laird 169 
inverse-variance method and the Freeman-Tukey transformation for proportions36. We 170 
provide estimates on the original scale. Heterogeneity across estimates was assessed using 171 
the I2 statistic.37,38 Where multiple articles estimated the same outcome for the same study 172 
population, we preferentially used estimates from the largest sample, or used the most 173 
recent estimates if sample sizes were equal. From these, we preferentially used weighted 174 
estimates accounting for clustering (e.g. from RDS studies) over crude estimates, where 175 
available (see appendix p 3-4 for details). For studies conducted in multiple locations, we 176 
preferentially extracted estimates for separate locations if reported; otherwise we used the 177 
combined estimate. For studies reporting on both MSM and transgender women (TGW), we 178 
included estimates for MSM alone if disaggregated data were available, otherwise we used 179 
estimates from the whole sample. 180 
We assessed whether study estimates varied by study year, region, or other study, 181 
participant, or structural variables (e.g. population, MSM HIV prevalence, proportion sold 182 
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sex, stigma, anti-LGBT legislation (see appendix p 21-26 for full list)), and study quality 183 
using univariate meta-regression for study outcomes with ≥20 estimates. Additionally, we 184 
assessed whether time trends differed by region (using a model with region*study year 185 
(continuous) interaction) and country if there were ≥3 estimates at different time points. If 186 
study year was significantly (p<0·05) associated with the outcome in univariate meta-187 
regression, we also conducted bivariate (time-adjusted) meta-regression (adjusting for time 188 
as a continuous variable). We presented pooled estimates of outcomes stratified by 189 
variables statistically significantly associated in time-adjusted meta-regression in forest plots 190 
stratified by study year. We also conducted leave-one-out sensitivity analyses to explore 191 
how sensitive associations between ever testing and the global anti-LGBT legislation index 192 
were to the exclusion of individual countries and studies. 193 
We further assessed study quality using subgroup analysis stratified by pre-defined quality 194 
indicators based on the AXIS tool for appraising cross-sectional studies,39 including study 195 
design, reporting bias, publication bias, and a quality score summing the responses to three 196 
key quality criteria (see appendix p 5). We further assessed publication bias using funnel 197 
plots and Egger’s test for asymmetry.40 198 
We conducted all analyses with R 3.5.1 using the metafor package.41,42 199 
Role of the funding source 200 
The funder had no role in study design, data collection, data analysis, data interpretation, or 201 
writing of the report. The corresponding author had full access to all the data in the study 202 
and had final responsibility for the decision to submit for publication.  203 
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RESULTS 204 
We included 113 articles reporting on 75 independent studies providing estimates (or data to 205 
self-calculate estimates) of the testing and cascade outcomes(Figure 1). The number of 206 
relevant studies conducted, and articles published, increased markedly from 2007 and 2010 207 
onwards, respectively (see appendix p 6).  208 
Table 1 summarises the outcomes, participant characteristics, structural variables, and study 209 
characteristics of included studies (see appendix p 7-15 for additional details). 210 
Most studies provided proportions of MSM ever HIV tested(number of studies [Ns]=54, 211 
number of estimates [Ne]=81
32,43–95 recently tested (Ns=33, Ne=51)
32,43,46,48–51,62,73,76,78,80,82,85,96–212 
109, and HIV+ aware (Ns=23, Ne=35).
 32,43,48,51,58,62,68,87,88,110–122 Very few studies provided 213 
proportions of MSM engaged in care68,116,118,123,124 on ART (ever48,116,122,124, 214 
currently32,68,102,116,118,119,125–128), or virally suppressed 32,116,122,125,128–130 (Table 1a).  215 
Over half the studies were conducted after 2011 (Table 1e). Studies provided estimates for 216 
28 countries predominantly from Eastern,32,43–61,77,97,108–111,121,122,124,125 Western,88-92,94–97,99–217 
106,108,115-117,129–134,139–141 and Southern57,66–76,97,100–104,111–115,121,125,127 Africa (Table 1b, appendix 218 
p 19). Study participants were mainly recruited from the general population of MSM32,43–45,47–219 
51,53,56–59,62–70,72–84,86,88–96,98–101,103,104,106,107,109–120,122,123,127–130 (Table 1b). Various definitions of 220 
MSM were used for study inclusion, with the period of sexual activity with men varying 221 
between 3 months and lifetime and different types of sexual activity specified (e.g. anal sex 222 
only, anal or oral, anal/oral/masturbatory). HIV prevalence (1-69%) and the proportion 223 
ever/recently selling sex (11–82%) varied across studies. Face-to-face interviews were used 224 
approximately three times more frequently than confidential interview methods (e.g. audio 225 
computer-assisted self-interview). Most studies used respondent driven sampling (RDS; 226 
Ns=30; Table 1e). Sample sizes ranged from 26 to 2,453 participants.  227 
Only 22 studies reported on stigma,32,46,48,56,57,59,65,66,69,79,82–84,92,98,104,111,112,114,118,120,128–130 228 
including proportions of MSM who disclosed their MSM status to healthcare workers, or 229 
family or had been blackmailed (Table 1c, appendix p 7-15). Most studies were conducted in 230 
countries where same-sex relations were illegal (Ns=55).
32,43–52,54–65,77–81,83,85–87,89–231 
100,103,104,106,108–111,113,116,118–125,128–130 Forty-three studies were conducted in countries with 232 
documented arrests related to consensual same-sex relations in 2014-2017 (Table 1d).32,43–233 
45,47–49,51,52,54–61,63–65,77,78,80,81,87,90–94,96–100,103,108–111,113,116,118,120–122,124,125,128–130 Global anti-LGBT 234 
legislation scores ranged from 0 to 12 and were lower in countries where same-sex relations 235 
were legal than illegal (Table 1d, appendix p 16-18).  236 
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Study estimates, pooled estimates and 95% CI of all outcomes are summarised in Figures 237 
2-8 and Table 2 and 95% PrI are presented in appendix p 20. Overall, the pooled proportion 238 
of MSM ever tested for HIV was 61·0% (95%CI 56·2–65·7%,Ne=81,I
2=98%), and was 239 
highest in Southern and lowest in Northern Africa (Figure 2, appendix p 21-22). The 240 
proportion of MSM tested in the past 12 months (pooled=46·2%,95%CI 39·6–241 
52·9%,Ne=39,I
2=97%) was similar to the proportions tested in the past 6 and 3 months, and 242 
was highest in Southern and lowest in Eastern Africa (Figure 3, appendix p 23-24). The 243 
proportion of MSM HIV+ aware was much lower (pooled=18·2%,95%CI 13·0–244 
23·9%,Ne=35,I
2=91%) especially in Eastern Africa (Figure 4, appendix p 25-26). 245 
Overall, the pooled proportions of MSM living with HIV linked to care within 30 days of 246 
diagnosis, ever engaged or currently engaged in care, were low and varied between 15·3% 247 
and 40·4% (Figure 5). The overall pooled proportions of MSM living with HIV ever or 248 
currently on ART were below 24%, and between 37-53% among MSM HIV+ aware (Figures 249 
6-7). Overall, an estimated 24·7%, 34·4%, and 75·6% of MSM living with HIV, MSM HIV+ 250 
aware, and MSM currently on ART were virally suppressed, respectively (Figure 8).  251 
HIV testing ever (p=0·0025) and in the past 12 months (p=0·0015) increased continuously 252 
over time (Figures 2-3, appendix p 21-24), and by 14·8% and 17·9% percentage points, 253 
respectively, after 2011 compared with before (appendix p 27). Only time trends in ever 254 
tested differed between regions (year*region interaction: p<0·0001), with greater increases 255 
in Eastern and Western Africa, and significant within-county increases in Kenya, Uganda 256 
and Nigeria (Figure 2, appendix p 28-29). Testing in the past 12 months increased 257 
significantly over time in South Africa (appendix p 30). Post-2011, the proportions tested 258 
(ever or in the past 12 months) were highest in Southern and lowest in Northern and Eastern 259 
Africa, respectively (appendix p 27). The proportion of MSM HIV+ aware did not increase 260 
over time overall (p=0·38), or by region (year*region interaction: p=0·80)(Figure 4, appendix 261 
p 25-28), but increased in South Africa (appendix p 30). Too few estimates were available 262 
for the other cascade outcomes to assess time trends. 263 
In time-adjusted meta-regression, higher proportions of MSM tested ever and in the past 12 264 
months were associated with living in Southern Africa(p=0·0011; p=0·040) and less severe 265 
penalties for same-sex relations(p=0·0010; p=0·00024)(appendix p 21 and 23). Ever testing 266 
was also higher with more protective(p=0·0015) and progressive(p=0·016) legislation, no 267 
LGBT-related arrests from 2014-2017(p=0·020) and decreased by 2% (95%CI 1-4%) for 268 
each point increase on the global anti-LGBT legislation index(continuous; 269 
p=0·0026)(appendix p 21 and 31-32). The magnitude of the association was sensitive 270 
(approximately halved and no longer significant) to excluding all South African studies only, 271 
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but not to the exclusion of any single South African study (appendix p 31-32). Testing in the 272 
past 12 months was also higher with less repressive legislation (p=0·023) and with the 273 
lowest global anti-LGBT legislation index scores (categorical; p=0·010)(appendix p 23). In 274 
subgroup analysis, differences in testing ever and in the past 12 months by global anti-LGBT 275 
legislation score were reduced after 2011 (appendix p 33-35). In univariate meta-regression, 276 
a higher proportion of MSM HIV+ aware was associated with not living in Eastern Africa 277 
(p=0·046), less repressive legislation (p=0·014), less severe penalties for same-sex relations 278 
(p=0·00023), and a lower global anti-LGBT legislation index (categorical; 279 
p=0·0050)(appendix p 25). 280 
Among the few studies reporting on stigma, testing ever and in the past 12 months were 281 
higher with greater disclosure of MSM status to healthcare workers in time-adjusted meta-282 
regression (p<0·0001 and p=0.034, respectively)(appendix p 21-24). The proportion of MSM 283 
tested in the past 12 months (time-adjusted meta-regression: p=0·015) and HIV+ aware 284 
(univariate meta-regression: p=0·031) were higher with higher proportions of MSM being 285 
blackmailed (appendix p 23-26). Other outcomes had too few estimates to assess 286 
associations using meta-regression. 287 
The influence of study quality was assessed for the three HIV testing and awareness 288 
outcomes with ≥20 study estimates (appendix p 36-42). Pooled estimates of all three 289 
outcomes differed with sampling method and were significantly higher in studies that did not 290 
use a complex study design or did not use statistical adjustment for complex study design 291 
(appendix p 21-26 and 40-42). Pooled estimates were also higher for studies specifically 292 
designed to estimate the outcome of interest (ever tested), with less adequate response 293 
rates (ever tested), that used more confidential interview methods (ever tested, tested in the 294 
past 12 months), that adequately described their methods and/or basic data (tested in the 295 
past 12 months), did not sufficiently describe their methods (MSM HIV+ aware) and with 296 
study populations not representative of wider MSM (MSM HIV+ aware). Although not 297 
statistically significant, higher rates of ever testing and HIV status awareness were observed 298 
for studies with a quality score of 0 (appendix p 40 and 42). 299 
There was no evidence of publication bias for the proportions of MSM tested ever or in the 300 
past 12 months or HIV+ aware from funnel plots and Egger’s asymmetry test (appendix p 301 
43). Pooled proportions of MSM HIV+ aware were significantly higher for the subset of 302 
directly reported study estimates than those self-calculated (p=0·0045; appendix p 42).   303 
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DISCUSSION 304 
Our results suggest that levels of engagement in HIV testing and particularly treatment 305 
cascade stages for African MSM remain sub-optimal, below those needed to achieve 306 
UNAIDS 90-90-90 targets.  307 
From 2011 onwards, only 50% of MSM reported testing in the past 12 months, 19% were 308 
HIV+ aware, and 53% of MSM HIV+ aware were on ART. 76% of MSM on ART were virally 309 
suppressed, suggesting that once on ART, MSM can achieve fairly high viral suppression 310 
levels. However, since levels of diagnosis and ART access remain poor, levels of ART use 311 
(24%) and viral suppression (25%) among all MSM living with HIV are critically low, meaning 312 
HIV spread within these populations will continue. 313 
We observed significant regional differences in HIV testing and status awareness. After 314 
2011, levels of MSM ever tested, tested in the past 12 months and HIV+ aware were highest 315 
in Southern Africa and lowest in Northern, Eastern, and Eastern Africa, respectively. The 316 
greatest improvements in testing over time occurred in Eastern and Western Africa. These 317 
differences may reflect different levels of expansion of community-based testing and national 318 
HIV testing campaigns across regions.131,132 Further expansion of community-led services, 319 
access to rapid and home-based testing, along with increased treatment support or 320 
counselling from LGBT-friendly organisations, will be essential to engage more MSM with 321 
HIV testing and treatment.132  322 
We found evidence of statistically significant negative associations between testing and HIV 323 
status awareness and the severity of anti-LGBT legislation, which may, but do not 324 
necessarily, reflect causal relationships. These appeared to be mediated by negative 325 
associations between ever testing and a lack of protective or progressive legislation, or 326 
harsher penalties for same-sex relations, and between recently testing/HIV status 327 
awareness and repressive legislation or harsher penalties for same-sex relations. However, 328 
the strength of the association between our anti-LGBT legislation index and ever testing was 329 
influenced by South African estimates, which had the lowest anti-LGBT legislation scores. 330 
Thus, other country-level factors (e.g. healthcare- or epidemic-related) may partly confound 331 
this association.  332 
Despite limited data availability, HIV testing and status awareness were lower in studies with 333 
lower disclosure of MSM status to healthcare workers, consistent with studies reporting 334 
associations between stigma and limited care cascade access.56,133 Training for healthcare 335 
workers will be important to tackle the intersection of HIV-related stigma with discrimination 336 
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towards MSM and improve levels of testing and status awareness.134 Consistent with other 337 
studies, we observed a positive association between ever testing and MSM HIV 338 
prevalence.135 Higher prevalence could encourage MSM to test for HIV (as previous studies 339 
show that low threat perception can impede testing) or reflect targeting of testing services to 340 
more HIV-prevalent areas.136 341 
Our pooled estimate of testing in the past 12 months pre-2011 (overall 33%) agreed with the 342 
2008 UNGASS estimate of 30% among MSM in sub-Saharan Africa (from only one country 343 
however).97 Available UNAIDS estimates of HIV status awareness among MSM in African 344 
countries – based on unpublished and/or more recent data – tended to be higher than our 345 
estimates, but UNAIDS ART coverage estimates for MSM living with HIV were mostly similar 346 
to ours.12 Our results suggest a worse situation for MSM in Africa than elsewhere. Our 347 
cascade estimates for 2011 onwards are far below those from a study in six European and 348 
Central Asian countries, which reported that in 2016 83%, 70%, and 63% of MSM living with 349 
HIV were aware of their status, on ART, and virally suppressed,137 respectively, compared 350 
with 19%, 24% and 25% from our study. A recent literature review showed higher levels of 351 
status awareness for high-income Western countries (72-100%) than we found, somewhat 352 
higher levels (44%) for India, another low-income setting, but similar levels (20%) for Russia, 353 
which enforces harsh anti-LGBT legislation.25  354 
There are marked differences in HIV testing and ART coverage for African MSM compared 355 
with all men (see appendix p 44-46). Although levels of testing ever and in the past 12 356 
months are consistently higher for MSM than all men across regions, self-reported HIV 357 
status awareness and ART coverage are substantially lower among MSM than 358 
corresponding estimates among men living with HIV (Mathieu Maheu-Giroux personal 359 
communication and appendix p 46).138 360 
Our review has several strengths and limitations, partly due to data and study quality, which 361 
may reflect the challenges of conducting research among key populations that face 362 
substantial stigma.133 363 
We reported new pooled estimates for 44,993 MSM across five outcomes from studies 364 
conducted between 2004 and 2017 and explored changes over time, by region and country. 365 
We self-calculated additional study estimates, increasing the sample size and minimising 366 
publication bias. We explored heterogeneity due to participant and study characteristics, 367 
additionally assessing the influence of anti-LGBT legislation using a novel index. ILGA 368 
publish the Rainbow Index for European countries139, but to our knowledge no similar tools 369 
exist for African countries. Despite increases over time, studies on the treatment cascade 370 
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among MSM in Africa remain scarce, particularly for Central and Northern Africa. Studies 371 
were missing from 26 countries, 13 where same-sex relations are illegal. Therefore, our 372 
overall pooled estimates may not be representative of MSM across Africa and may 373 
misestimate engagement, especially for ART use and viral suppression, which were based 374 
on very few estimates. Small numbers of studies in Central and Northern Africa limit our 375 
ability to assess regional levels and trends in HIV testing.  376 
Heterogeneity across study estimates was substantial and could only be explored in meta-377 
regression for the outcomes with the most study estimates (ever testing, testing in past 12 378 
months, HIV+ aware). Not all studies reported key participant characteristics including age, 379 
HIV prevalence and selling sex, with stigma the most poorly reported variable. Future 380 
studies should report on stigma alongside testing and treatment outcomes. 381 
Our analysis included studies of generally moderate quality, and reporting biases were 382 
possible as most outcomes were self-reported, and most studies used non-confidential 383 
interview methods. Pooled estimates were influenced by study quality and in particular 384 
tended to be lower for studies that adjusted for complex study design (e.g. weighted RDS), 385 
with less confidential interview methods (testing outcomes) or with higher quality scores 386 
(albeit not significantly). Under-reporting has been previously documented among African 387 
MSM, for example in HPTN 075, 22% of MSM living with HIV self-reported a positive status, 388 
however ARVs were detected in 58%.121 One study in Uganda found that approximately half 389 
of virally suppressed MSM (likely due to suppressive ART) reported not knowing their HIV-390 
positive status.32 Thus, our pooled estimates may underestimate true levels of status 391 
awareness and ART use. Obtaining representative samples of MSM is difficult, even with 392 
RDS sampling, with samples often biased towards younger, more visible MSM.140 However, 393 
our pooled estimates did not differ by mean age. Many of the RDS studies included here did 394 
not report weighted estimates, potentially, but not necessarily, reducing their 395 
representativeness.141  396 
Included studies used varied definitions of MSM and most did not disaggregate TGW from 397 
MSM, which however did not influence pooled study outcome estimates. However, it would 398 
be preferable in future to provide disaggregated estimates to gain a better understanding of 399 
the health needs of TGW. There was no evidence of publication bias for any outcome except 400 
status awareness, and only in subgroup analysis comparing directly reported and self-401 
calculated estimates. 402 
Our anti-LGBT legislation index only captures information about legislation, not how 403 
legislation is implemented. Only recent arrests after 2013 were available to measure 404 
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implementation, and for few African nations,20 therefore we may not have fully captured the 405 
influence of changes in legislation implementation. More implementation data is needed. 406 
Nonetheless, our novel anti-LGBT legislation index reflected complex African legislation over 407 
time and enabled detailed analysis of our data in a legal context. Although no other 408 
measures or indexes are currently available specifically for Africa, our index correlates well 409 
with the recent global Homophobic Climate Index (data not shown).142 410 
Engagement with the HIV treatment cascade among MSM in Africa remains low, despite 411 
recent improvements in HIV testing. Lower testing and status awareness levels were 412 
associated with more hostile legislation. More studies are needed on HIV testing and 413 
particularly the HIV treatment cascade for MSM across Africa, especially Northern and 414 
Central Africa. Future studies should use confidential interview methods to reduce reporting 415 
biases and collect standardised stigma data.  416 
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ABSTRACT 38 
Background 39 
HIV disproportionately affects gay, bisexual, and other men who have sex with men (MSM) in 40 
Africa, where many countries criminalise same-sex behaviour. We assessed changes in the 41 
engagement of African MSM with HIV testing and treatment cascade stages over time, and 42 
the influence of anti-LGBT legislation and stigma. 43 
Methods 44 
We systematically searched the peer-reviewed literature to  October 10th, 2018 for studies 45 
reporting and extracted or derived estimates of HIV testing and/or engagement with the HIV 46 
treatment cascade among African MSM from published reports. We derived pooled estimates 47 
using inverse-variance random-effects models. We used subgroup and meta-regression 48 
analysis to assess associations between testing and status awareness outcomes and study 49 
and participant characteristics including the severity of country-level anti-LGBT legislation.  50 
Findings 51 
Our searches identified 75 independent eligible studies that provided estimates for 44,993 52 
MSM across one or more of five testing and treatment cascade outcomes. HIV testing 53 
increased significantly over time overall, with pooled overall proportions of MSM ever tested 54 
ever of 67·3% (95%Confidence interval 62·1-72·3%,N=44) and tested in the past 12 months 55 
of 50·1% (42·4-57·8%,N=31) post-2011 – 14% and 18% points higher than pre-2011, 56 
respectively. Post-2011, ever testing was highest in Southern(80·0%) and lowest in 57 
Northern(34·4%) and Central(56·1%) Africa, with the greatest increase in Western Africa(from 58 
42·4 to 70·91%). Levels of both testing outcomes and status awareness were statistically 59 
significantly lower in countries with the most  severe anti-LGBT legislation.  60 
Few estimates were available for later stages of the treatment cascade. From aAvailable data 61 
post-2011 suggest that, the pooled proportion of MSM HIV-positive aware has remained low 62 
(18·59%, 12·53-25·3%,N=28) whereas proportions of current ART use were 23·74% (15·56-63 
33·0%,N=14) among all MSM living with HIV and 53·4% (36·97-69·5%,N=6) among MSM 64 
HIV-positive aware. Levels of viral suppression among MSM currently on ART were good 65 
(pooled: 75·66%, 64·4-85·56%,N=4), but low among all MSM living with HIV (pooled: 24·75%, 66 
18·89-31·2%,N=4).  67 
Interpretation 68 
 4 
Available data suggests that levels of HIV status awareness among MSM living with HIV in 69 
Africa remain low, despite recent improvements in HIV testing; limited data is available on 70 
levels of engagement in care, ART use and viral suppression. We found that severe anti-LGBT 71 
legislation was associated with lower HIV testing and status awareness. Achieving UNAIDS 72 
90-90-90 targets will require substantial improvements.  73 
Funding 74 
US National Institutes of Health and the UK Medical Research Council. 75 
  76 
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INTRODUCTION  77 
The development of highly active antiretroviral therapy (ART) in the 1990s transformed HIV 78 
from a fatal infection to a treatable chronic disease.1 People living with HIV (PLHIV) on 79 
suppressive ART can live as long as people without HIV.2 However, achieving viral 80 
suppression requires engagement in all stages of HIV care, from testing and early diagnosis, 81 
through the treatment cascade, including linkage into and retention in care, early ART 82 
initiation, and near-perfect adherence.3 Globally, however, ~1 million PLHIV still die from HIV 83 
annually because they cannot or do not complete this cascade.4,5  84 
UNAIDS has formulated the ‘90-90-90’ targets, aiming to have 90% of PLHIV aware of their 85 
status, 90% of PLHIV aware of their status on ART, and 90% of PLHIV on ART achieving viral 86 
suppression by 2020,6 with targets increasing to 95% by 2030.7 Therefore, by 2020 and 2030, 87 
73% and 86% of PLHIV should be virally suppressed, respectively.7 Engaging PLHIV in the 88 
cascade to meet these ambitious targets will have major implications for PLHIV and HIV 89 
prevention, improving mortality and morbidity outcomes,8 and reducing transmission risk.9,10 90 
UNAIDS has highlighted the importance of reaching key populations, including gay, bisexual, 91 
and other men who have sex with men (MSM), however estimates of progress towards 92 
achieving 90-90-90 targets among MSM are very scarce, which compromises our ability to 93 
assess impact, adequately address needs and reduce barriers to uptake of services, and 94 
improve HIV prevention services for MSM.11,12 Globally, MSM are ~28 times more likely to be 95 
living with HIV than men in the general population – an inequality that is particularly apparent 96 
in sub-Saharan Africa, where the human rights of MSM are often violated.5,13–19 97 
Almost two-thirds of African countries still criminalise same-sex relations, many with long 98 
prison sentences and some with the death penalty.20 In this context, stigma, discrimination, 99 
and human rights violations of MSM that are linked to legislation have been widely 100 
documented.5,13–19 This includes blackmail, violence, reprisals from family and communities, 101 
denial of housing, healthcare, and access to justice, and lack of adequate and accessible 102 
services for MSM.21–23 These also create barriers to implementing effective HIV research, 103 
policy, and health programmes for MSM, through prohibition of activism and research, 104 
arbitrary arrests of healthcare providers, and disruption of services provided by community-105 
based and non-governmental organisations (NGOs).24–26 This may also explain why research 106 
on African MSM has lagged behind that in other parts of the world.15,17,25–28 107 
After South Africa led the first United Nations (UN) resolution on sexual orientation and gender 108 
in 2011, some positive changes in lesbian, gay, bisexual and transgender (LGBT) rights 109 
protection were reported in parts of Africa, albeit inconsistently.29 For example, while 110 
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Seychelles, São Tomé and Príncipe, Mozambique and Lesotho have decriminalised same-111 
sex relations, Uganda and Nigeria have increased the severity of their anti-LGBT legislation.20 112 
In this study, we (1) systematically reviewed published studies providing estimates of levels 113 
of HIV testing, diagnosis, and the treatment cascade among MSM in Africa; (2) assessed 114 
whether these outcomes have improved over time; and (3) explored the influence of 115 
participant and study characteristics, study quality, and two key structural factors – stigma and 116 
severity of anti-LGBT legislation – on each outcome.  117 
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METHODS  118 
This systematic review and meta-analysis was reported in accordance with PRISMA and 119 
MOOSE guidelines.30,31 120 
Search strategy and selection criteria 121 
We searched Embase, Medline, Scopus, Global Health, and Web of Science for articles 122 
reporting on HIV testing and/or any HIV treatment cascade stages in Africa published between  123 
1st January 1st, 1980 and 10th October 10th, 2018 using terms for HIV, MSM, and Africa (see 124 
appendix p 1 for full search terms in Table S1). 125 
We screened by abstract and title, then screened potentially relevant full-texts for studies 126 
directly reporting estimates or sufficient data to self-calculate proportions of MSM engaging in 127 
HIV testing and/or treatment cascade stages. We only included peer-reviewed cross-sectional 128 
or longitudinal studies recruiting at least 10 MSM. We excluded mathematical modelling 129 
studies, qualitative studies, conference abstracts and reviews, and studies reporting cascade 130 
outcomes using self-reported HIV status (instead of confirmed biological test) to derive the 131 
number of MSM living with HIV in the denominator. We did not exclude articles based on 132 
language. 133 
For included studies, we extracted or self-calculated proportions of MSM: 1) who self-reported 134 
having ever or recently received an HIV test; 2) testing positive in the study (“MSM living with 135 
HIV” hereafter) who self-reported being HIV positive before testing (“MSM HIV+ aware” 136 
hereafter); 3) living with HIV who self-reported being ever or currently engaged in care or 137 
linked to care following diagnosis; 4) living with HIV or HIV+ aware who self-reported ever or 138 
currently taking ART; and, 5) living with HIV, HIV+ aware, or currently on ART who were virally 139 
suppressed (based on viral load testing). We excluded estimates based on fewer than 10 140 
MSM. One of four study authors contacted provided estimates of MSM ever and recently 141 
tested and of MSM living with HIV virally suppressed.32 142 
For each study, we extracted information on participant characteristics (e.g. population, region 143 
of Africa, HIV prevalence among MSM participants tested in the study, proportion sold sex), 144 
stigma (e.g. proportion who disclosed their MSM status to healthcare workers or family, or 145 
were blackmailed), study characteristics and quality indicators (e.g. study year, study design, 146 
sampling and interview methods).  147 
We used country-specific data from International Lesbian, Gay, Bisexual, Trans and Intersex 148 
Association (ILGA) reports, country constitutions, and UN reports to construct four composite 149 
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“anti-LGBT legislation” variables, one global anti-LGBT legislation index, and one “arrests” 150 
variable for each study country.20,33–35  151 
The four anti-LGBT legislation variables are: repressive legislation (same-sex relations, sexual 152 
orientation-related NGOs, or LGBT promotion are illegal, age of consent differs for same-sex 153 
relationships, or legislation prohibits same-sex marriage and/or /adoption; score 0-5), lack of 154 
protective legislation (LGBT people are not protected from discrimination, or incitement to 155 
hatred based on sexual orientation is not illegal; score 0-2), lack of progressive legislation 156 
(same-sex marriage and/or /adoption are not legally recognised; score 0-2), and a penalties 157 
variable (the harshest punishment receivable for consensual same-sex relations varying from 158 
no punishment to the death penalty; score 0-5). Our global anti-LGBT legislation index 159 
summed the scores of these four legislation variables(score 0-14), for each study country at 160 
the time the study was conducted. Higher scores reflected less progressive legislation. The 161 
binary arrests variable captured if arrests for consensual same-sex relations had been 162 
documented in the country between 2014 and 2017 (the only such data available).20 See 163 
appendix p 2-3 for aAdditional details are provided in the Supplementary Methods pages 1-164 
2). 165 
JS, ED, and RS independently performed all stages of screening and data extraction. 166 
Discrepancies were resolved by KM. 167 
Data analysis 168 
We pooled independent study estimates and calculated 95% confidence intervals (CI) and 169 
95% prediction intervals (PrI) using random-effects models based on the DerSimonian-Laird 170 
inverse-variance method and the Freeman-Tukey transformation for proportions36 (see details 171 
in Supplementary Methods page 2). We provide estimates on the original scale. Heterogeneity 172 
across estimates was assessed using the I2 statistic.37,38 . Where multiple articles estimated 173 
the same outcome for the same study population, we preferentially used estimates from the 174 
largest sample, or used the most recent estimates if sample sizes were equal. From these, 175 
we preferentially used weighted estimates accounting for clustering (e.g. from RDS studies) 176 
over crude estimates, where available (see appendix p 3-4 for details). For studies conducted 177 
in multiple locations, we preferentially extracted estimates for separate locations if reported; 178 
otherwise we used the combined estimate. For studies reporting on both MSM and 179 
transgender women (TGW), we included estimates for MSM alone if disaggregated data were 180 
available, otherwise we used estimates from the whole sample were used. 181 
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We assessed whether study estimates varied by study year, region (and country if there were 182 
≥3 estimates at different time points), or other study, participant, or structural variables (e.g. 183 
population, MSM HIV prevalence, proportion sold sex, stigma, anti-LGBT legislation (see 184 
appendix p 21-26 for full list in Tables S6-8)), and study quality using univariate meta-185 
regression for study outcomes with ≥20 estimates. Additionally, we assessed whether time 186 
trends differed by region (using a model with region*study year (continuous) interaction) and 187 
country if there were ≥3 estimates at different time points. If study year was significantly 188 
(p<0.·05) associated with the outcome in univariate meta-regression, we also conducted 189 
bivariate (time-adjusted) meta-regression (adjusting for time as a continuous variable). We 190 
presented pPooled estimates of outcomes stratified by variables statistically significantly 191 
associated in time-adjusted meta-regression were presented in forest plots stratified by study 192 
year. We also conducted leave-one-out sensitivity analyses to explore how sensitive 193 
associations between ever testing and the global anti-LGBT legislation index were to the 194 
exclusion of individual countries and studies. 195 
We further assessed study quality using subgroup analysis stratified by pre-defined quality 196 
indicators based on the AXIS tool for appraising cross-sectional studies,39 including study 197 
design, reporting bias, publication bias, and a quality score summing the responses to three 198 
key quality criteria (details in Table S2see appendix p 5). We further assessed pPublication 199 
bias was further assessed using funnel plots and Egger’s test for asymmetry.40 200 
All analyses Wwere conducted all analyses with R 3.5.1 using the metafor package.41,42 201 
Role of the funding source 202 
The funder had no role in study design, data collection, data analysis, data interpretation, or 203 
writing of the report. The corresponding author had full access to all the data in the study and 204 
had final responsibility for the decision to submit for publication.  205 
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RESULTS 206 
Search results and study characteristics 207 
We included 113 articles reporting on 75 independent studies providing estimates (or data to 208 
self-calculate estimates) of the testing and cascade outcomes(Figure 1). The number of 209 
relevant studies conducted, and articles published, increased markedly from 2007 and 2010 210 
onwards, respectively (Figure S1see appendix p 6).  211 
Table 1 summarises the outcomes, participant characteristics, structural variables, and study 212 
characteristics of included studies (see appendix p 7-15 for additional details in Tables S3-213 
S4). 214 
Most studies provided proportions of MSM ever HIV tested(number of studies [Ns]=54, number 215 
of estimates [Ne]=8132,43–95 recently tested (Ns=33, Ne=51)32,43,46,48–51,62,73,76,78,80,82,85,96–109, and 216 
HIV+ aware (Ns=23, Ne=35). 32,43,48,51,58,62,68,87,88,110–122 Very few studies provided proportions of 217 
MSM engaged in care68,116,118,123,124 on ART (ever48,116,122,124, currently32,68,102,116,118,119,125–128), or 218 
virally suppressed 32,116,122,125,128–130 (Table 1a).  219 
Over half the studies were conducted after 2011 (Table 1e). Studies provided estimates for 220 
28 countries predominantly from Eastern,32,43–61,77,97,108–111,121,122,124,125 Western,88-92,94–97,99–221 
106,108,115-117,129–134,139–141 and Southern57,66–76,97,100–104,111–115,121,125,127 Africa (Figure 2, Table 1b, 222 
appendix p 19). Study participants were mainly recruited from the general population of 223 
MSM32,43–45,47–51,53,56–59,62–70,72–84,86,88–96,98–101,103,104,106,107,109–120,122,123,127–130 (Table 1b). Various 224 
definitions of MSM were used for study inclusion, with the period of sexual activity with men 225 
varying between 3 months and lifetime and different types of sexual activity specified (e.g. 226 
anal sex only, anal or oral, anal/oral/masturbatory). HIV prevalence (1-69%) and the 227 
proportion ever/recently selling sex (11–82%) varied across studies. Face-to-face interviews 228 
were used approximately three times more frequently than confidential interview methods (e.g. 229 
audio computer-assisted self-interview). Most studies used respondent driven sampling (RDS; 230 
Ns=30; Table 1e). Sample sizes ranged from 26 to 2,453 participants.  231 
Only 22 studies reported on stigma,32,46,48,56,57,59,65,66,69,79,82–84,92,98,104,111,112,114,118,120,128–130 232 
including proportions of MSM who disclosed their MSM status to healthcare workers, or family 233 
or had been blackmailed (Table 1c, Table S3appendix p 7-15). Most studies were conducted 234 
in countries wheren same-sex relations were illegal (Ns=55).,32,43–52,54–65,77–81,83,85–87,89–235 
100,103,104,106,108–111,113,116,118–125,128–130 Forty-three studies 32,43–45,47–49,51,52,54–61,63–65,77,78,80,81,87,90–236 
94,96–100,103,108–111,113,116,118,120–122,124,125,128–130 were conducted in countries with documented 237 
arrests related to consensual same-sex relations in 2014-2017 (Table 1d).32,43–45,47–49,51,52,54–238 
 11 
61,63–65,77,78,80,81,87,90–94,96–100,103,108–111,113,116,118,120–122,124,125,128–130. Global anti-LGBT legislation 239 
scores ranged from 0 to 12 and were lower in countries where same-sex relations were legal 240 
than illegal (Table 1d, Table S4appendix p 16-18).  241 
Meta-analysis results 242 
Study estimates, pPooled estimates and 95% CI of all outcomes are summarised in Figures 243 
2-8 and Table 2 and, Figure 3 and Table S5. 95% PrI are presented in Table S5appendix p 244 
20. Overall, the pooled proportion of MSM ever tested for HIV was 61.·0% (95%CI 56.·2–245 
65.·7%,Ne=81,I2=98%), and was highest in Southern and lowest in Northern Africa (Figure 246 
23a, Table S6appendix p 21-22). The proportion of MSM tested in the past 12 months 247 
(pooled=46.·2%,95%CI 39.·6–52.·9%,Ne=39,I2=97%) was similar to the proportions tested in 248 
the past 6 and 3 months, and was highest in Southern and lowest in Eastern Africa (Figure 249 
33b, Table S7appendix p 23-24). The proportion of MSM HIV+ aware was much lower 250 
(pooled=18.·2%,95%CI 13.·0–23.·9%,Ne=35,I2=91%) especially in Eastern Africa (Figure 4, 251 
appendix p 25-263c).  252 
Overall, tThe pooled proportions of MSM living with HIV linked to care within 30 days of 253 
diagnosis, ever engaged or currently engaged in care, were low and varied between 15.·3% 254 
and 40.·4% (Figure 53d). The overallThe pooled proportions of MSM living with HIV ever or 255 
currently on ART were below 24%,  and between 37-53% among MSM HIV+ aware (Figures 256 
6-7 3e,f). Overall, an estimated 24.·7%, 34.·4%, and 75.·6% of MSM living with HIV, MSM 257 
HIV+ aware, and MSM currently on ART were virally suppressed, respectively (Figure 83g).  258 
Trends over time overall and by region 259 
HIV testing ever (p=0.·0025) and in the past 12 months (p=0.·0015) increased continuously 260 
over time (Figures 2-33a,b, Figure S2a,bappendix p 21-24), and by 14.·8% and 17.·9% 261 
percentage points, respectively, after 2011 compared with before (Figure 4a,bappendix p 27). 262 
Only time trends in ever tested differed between regions (year*region interaction: p<0.·0001), 263 
with greater increases in Eastern and Western Africa, and significant within-county increases 264 
in Kenya, Uganda and Nigeria (Figures 23a, S2a,S3aappendix p 28-29). Testing in the past 265 
12 months increased significantly over time in South Africa (Figure S3bappendix p 30). Post-266 
2011, the proportions tested (ever or in the past 12 months) were highest in Southern and 267 
lowest in Northern and Eastern Africa, respectively (Figure 4a,bappendix p 27). The proportion 268 
of MSM HIV+ aware did not increase over time overall (p=0.·38), or by region (year*region 269 
interaction: p=0.·80)(Figure 4, Figure 3c,4c, Table S8appendix p 25-28), but increased in 270 
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South Africa (Figure S3cappendix p 30). Too few estimates were available for the other 271 
cascade outcomes to assess time trends. 272 
Influence of participant characteristics and structural variables 273 
In time-adjusted meta-regression, higher proportions of MSM tested ever and in the past 12 274 
months were associated with being living in Southern Africa(p=0.·0011; p=0.·040) and less 275 
severe penalties for same-sex relations(p=0.·0010; p=0.·00024)(Tables S6-7appendix p 21 276 
and 23). Ever testing was also higher with more protective(p=0.·0015) and 277 
progressive(p=0.·016) legislation, no LGBT-related arrests from 2014-2017(p=0.·020) and 278 
decreased by 23% (95%CI 12-4%; Figure S4) for each point increase on the global anti-LGBT 279 
legislation index(continuous; p=0.·0026)(Table S6appendix p 21 and 31-32). The magnitude 280 
of the association was sensitive (approximately halved and no longer significant) to excluding 281 
all South African studies only (Figure S4a), but not to the exclusion of any single South African 282 
study (Figure S4bappendix p 31-32). Testing in the past 12 months was also higher with less 283 
repressive legislation (p=0.·023) and with the lowest global anti-LGBT legislation index scores 284 
(categorical; p=0.·010)(Table S7appendix p 23). In subgroup analysis, differences in testing 285 
ever and in the past 12 months by global anti-LGBT legislation score were reduced after 2011 286 
(Figure S5appendix p 33-35). In univariate meta-regression, a higher proportion of MSM HIV+ 287 
aware was associated with not being living in Eastern Africa (p=0.·046), less repressive 288 
legislation (p=0.·014), less severe penalties for same-sex relations (p=0.·00023), and a lower 289 
global anti-LGBT legislation index (categorical; p=0.·0050)(Table S8appendix p 25). 290 
Among the few studies reporting on stigma, testing ever and in the past 12 months were higher 291 
with greater disclosure of MSM status to healthcare workers in time-adjusted meta-regression 292 
(p<0.·0001 and p=0.034, respectively5,)( Tables S6-7appendix p 21-24). The proportion of 293 
MSM tested in the past 12 months (time-adjusted meta-regression: p=0.·015) and HIV+ aware 294 
(univariate meta-regression: p=0.·031) were higher with higher proportions of MSM being 295 
blackmailed (Tables S7-8appendix p 23-26). Other outcomes had too few estimates to assess 296 
associations using meta-regression. 297 
Study quality and potential sources of bias 298 
The influence of study quality was assessed for the three HIV testing and awareness 299 
outcomes with ≥20 study estimates (Figure S6, Table S9appendix p 36-42). Pooled estimates 300 
of all three outcomes differed with sampling method and were significantly higher in studies 301 
that did not use a complex study design or did not use statistical adjustment for complex study 302 
design (Figure S6, Tables S6-8appendix p 21-26 and 40-42). Pooled estimates were also 303 
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higher for studies specifically designed to estimate the outcome of interest (ever tested), with 304 
less adequate response rates (ever tested), that used more confidential interview methods 305 
(ever tested, tested in the past 12 months), that adequately described their methods and/or 306 
basic data (tested in the past 12 months), did not sufficiently describe their methods (MSM 307 
HIV+ aware) and with study populations not representative of wider MSM (MSM HIV+ aware). 308 
Although not statistically significant, higher rates of ever testing and HIV status awareness 309 
were observed for studies with a quality score of 0 (Figure S6appendix p 40 and 42). 310 
There was no evidence of publication bias for the proportions of MSM tested ever or in the 311 
past 12 months or HIV+ aware from funnel plots and Egger’s asymmetry test (Figure S7a-312 
cappendix p 43). Pooled proportions of MSM HIV+ aware were significantly higher for the 313 
subset of directly reported study estimates than those self-calculated (p=0.·0045; Figure 314 
S6cappendix p 42).   315 
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DISCUSSION 316 
Our results suggest that levels of engagement in HIV testing and particularly treatment 317 
cascade stages for African MSM remain sub-optimal, below those needed to achieve UNAIDS 318 
90-90-90 targets.  319 
From 2011 onwards, only 50% of MSM reported testing in the past 12 months, 19% were 320 
HIV+ aware, and 53% of MSM HIV+ aware were on ART. 76% of MSM on ART were virally 321 
suppressed, suggesting that once on ART, MSM can achieve fairly high viral suppression 322 
levels. However, since levels of diagnosis and ART access remain poor, levels of ART use 323 
(24%) and viral suppression (25%) among all MSM living with HIV are critically low, meaning 324 
HIV spread within these populations will continue. 325 
We observed significant regional differences in HIV testing and status awareness. After 2011, 326 
levels of MSM ever tested, tested in the past 12 months and HIV+ aware were highest in 327 
Southern Africa and lowest in Northern, Eastern, and Eastern Africa, respectively. The 328 
greatest improvements in testing over time occurred in Eastern and Western Africa. These 329 
differences may reflect different levels of expansion of community-based testing and national 330 
HIV testing campaigns across regions.131,132 Further expansion of community-led services, 331 
access to rapid and home-based testing, along with increased treatment support or 332 
counselling from LGBT-friendly organisations, will be essential to engage more MSM with HIV 333 
testing and treatment.132  334 
We found evidence of statistically significant negative associations between testing and HIV 335 
status awareness and the severity of anti-LGBT legislation, which may, but do not necessarily, 336 
reflect causal relationships. These appeared to be mediated by negative associations between 337 
ever testing and a lack of protective or progressive legislation, or harsher penalties for same-338 
sex relations, and between recently testing/HIV status awareness and repressive legislation 339 
or harsher penalties for same-sex relations. However, the strength of the association between 340 
our anti-LGBT legislation index and ever testing was influenced by South African estimates, 341 
which had the lowest anti-LGBT legislation scores. Thus, other country-level factors (e.g. 342 
healthcare- or epidemic-related) may partly confound this association.  343 
Despite limited data availability, HIV testing and status awareness were lower in studies with 344 
lower disclosure of MSM status to healthcare workers, consistent with studies reporting 345 
associations between stigma and limited care cascade access.56,133 Training for healthcare 346 
workers will be important to tackle the intersection of HIV-related stigma with discrimination 347 
towards MSM and improve levels of testing and status awareness.134 Consistent with other 348 
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studies, we observed a positive association between ever testing and MSM HIV prevalence.135 349 
Higher prevalence could encourage MSM to test for HIV (as previous studies show that low 350 
threat perception can impede testing) or reflect targeting of testing services to more HIV-351 
prevalent areas.136 352 
Our pooled estimate of testing in the past 12 months pre-2011 (overall 33%) agreed with the 353 
2008 UNGASS estimate of 30% among MSM in sub-Saharan Africa (from only one country 354 
however).97 Available UNAIDS estimates of HIV status awareness among MSM in African 355 
countries – based on unpublished and/or more recent data – tended to be higher than our 356 
estimates, but UNAIDS ART coverage estimates for MSM living with HIV were mostly similar 357 
to ours.12 Our results suggest a worse situation for MSM in Africa than elsewhere. Our cascade 358 
estimates for 2011 onwards are far below those from a study in six European and Central 359 
Asian countries, which reported that in 2016 83%, 70%, and 63% of MSM living with HIV were 360 
aware of their status, on ART, and virally suppressed,137 respectively, compared with 19%, 361 
24% and 25% from our study. A recent literature review showed higher levels of status 362 
awareness for high-income Western countries (72-100%) than we found, somewhat higher 363 
levels (44%) for India, another low-income setting, but similar levels (20%) for Russia, which 364 
enforces harsh anti-LGBT legislation.25  365 
There are marked differences in HIV testing and ART coverage for African MSM compared 366 
with all men (see Figure S8a-cappendix p 44-46). Although levels of testing ever and in the 367 
past 12 months are consistently higher for MSM than all men across regions, self-reported 368 
HIV status awareness and ART coverage (Figure S8c) are substantially lower among MSM 369 
than corresponding estimates among men living with HIV (Mathieu Maheu-Giroux personal 370 
communication and appendix p 46).138 371 
 372 
Strengths and limitations 373 
Our review has several strengths and limitations, partly due to data and study quality, which 374 
may reflect the challenges of conducting research among key populations that face substantial 375 
stigma.133 376 
We reported new pooled estimates for 44,993 MSM across five outcomes from studies 377 
conducted between 2004 and 2017 and explored changes over time, by region and country. 378 
We self-calculated additional study estimates, increasing the sample size and minimising 379 
publication bias. We explored heterogeneity due to participant and study characteristics, 380 
additionally assessing the influence of anti-LGBT legislation using a novel index. ILGA publish 381 
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the Rainbow Index for European countries139, but to our knowledge no similar tools exist for 382 
African countries. Despite increases over time, studies on the treatment cascade among MSM 383 
in Africa remain scarce, particularly for Central and Northern Africa. Studies were missing from 384 
26 countries, 13 where same-sex relations are illegal. Therefore, our overall pooled estimates 385 
may not be representative of MSM across Africa and may misestimate engagement, 386 
especially for ART use and viral suppression, which were based on very few estimates. Small 387 
numbers of studies in Central and Northern Africa limit our ability to assess regional levels 388 
and trends in HIV testing.  389 
Heterogeneity across study estimates was substantial and could only be explored in meta-390 
regression for the outcomes with the most study estimates (ever testing, testing in past 12 391 
months, HIV+ aware). Not all studies reported key participant characteristics including age, 392 
HIV prevalence and selling sex, with stigma the most poorly reported variable. Future studies 393 
should report on stigma alongside testing and treatment outcomes. 394 
Our analysis included studies of generally moderate quality, and reporting biases were 395 
possible as most outcomes were self-reported, and most studies used non-confidential 396 
interview methods. Pooled estimates were influenced by study quality and in particular tended 397 
to be lower for studies that adjusted for complex study design (e.g. weighted RDS), with less 398 
confidential interview methods (testing outcomes) or with higher quality scores (albeit not 399 
significantly). Under-reporting has been previously documented among African MSM, for 400 
example in HPTN 075, 22% of MSM living with HIV self-reported a positive status, however 401 
ARVs were detected in 58%.121 One study in Uganda found that approximately half of virally 402 
suppressed MSM (likely due to suppressive ART) reported not knowing their HIV-positive 403 
status.32 Thus, our pooled estimates may underestimate true levels of status awareness and 404 
ART use. Obtaining representative samples of MSM is difficult, even with RDS sampling, with 405 
samples often biased towards younger, more visible MSM.140 However, our pooled estimates 406 
did not differ by mean age. Many of the RDS studies included here did not report weighted 407 
estimates, potentially, but not necessarily, reducing their representativeness.141  408 
Included studies used varied definitions of MSM and most did not disaggregate TGW from 409 
MSM, which however did not influence pooled study outcome estimates. However, it would 410 
be preferable in future to provide disaggregated estimates to gain a better understanding of 411 
the health needs of TGW. There was no evidence of publication bias for any outcome except 412 
status awareness, and only in subgroup analysis comparing directly reported and self-413 
calculated estimates. 414 
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Our anti-LGBT legislation index only captures information about legislation, not how legislation 415 
is implemented. Only recent arrests after 2013 were available to measure  implementation, 416 
and for few African nations,20 therefore we may not have fully captured the influence of 417 
changes in legislation implementation. More implementation data is needed. Nonetheless, our 418 
novel anti-LGBT legislation index reflected complex African legislation over time and enabled 419 
detailed analysis of our data in a legal context. Although, nofew other measures or indexes 420 
are currently available specifically for Africa, but our index correlates well with the recent global 421 
Homophobic Climate Index (data not shown).142 422 
Conclusions  423 
Engagement with the HIV treatment cascade among MSM in Africa remains low, despite 424 
recent improvements in HIV testing. Lower testing and status awareness levels were 425 
associated with more hostile legislation. More studies are needed on HIV testing and 426 
particularly the HIV treatment cascade for MSM across Africa, especially Northern and Central 427 
Africa. Future studies should use confidential interview methods to reduce reporting biases 428 
and collect standardised stigma data.  429 
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Research in context 
Evidence before this study 
Gay, bisexual and other men who have sex with men (MSM) are disproportionately burdened with 
HIV globally, with particularly high prevalence in Africa. MSM living with HIV on suppressive 
antiretroviral therapy (ART) do not transmit infection to their sexual partners. However, achieving and 
maintaining viral suppression depends on engagement in all stages of the HIV treatment cascade 
including testing, status awareness, engagement in care, and ART use. This may be particularly 
challenging in many African countries where existing legislation criminalises same-sex relations. 
Although several studies have reported negative effects of specific anti-LGBT legislation on HIV 
treatment and care in countries including Uganda and Nigeria, no study has systematically reviewed 
the evidence on the influence of legislation on HIV testing and the treatment cascade across Africa. 
Additionally, although the HIV treatment cascade has been summarised among MSM in developed 
countries including the US, UK and Canada, it has never been comprehensively reviewed and 
summarised for MSM in Africa. The most recent literature review of the treatment cascade among key 
populations (conducted in 2015) reported on MSM, sex workers and people who inject drugs globally, 
but only three studies on MSM in Africa were included. As more studies have been published in 
recent years, we aimed to fill this gap by conducting the first systematic review and meta-analysis of 
the engagement of MSM in Africa with HIV testing and all stages of the HIV treatment cascade, and 
by assessing progress over time and the relationship between HIV testing and treatment and the 
severity of anti-LGBT legislation. We searched Embase, Global Health, MEDLINE, Scopus and Web 
of Science between January 1
st
, 1980, and October 10
th
, 2018, for studies reporting on HIV testing 
and the HIV treatment cascade among MSM in Africa. 
Added value of this study 
We included data from 75 independent studies from 28 countries and estimated pooled proportion of 
HIV testing, status awareness, engagement in care, ART use, and viral suppression for 44,993 MSM. 
Our analysis of available HIV testing data over time suggests that after 2011, pooled estimates of 
levels of testing ever (67%) and in the past 12 months (50%) were significantly higher than before 
2011, with the greatest increases in Western Africa. Despite this, pooled estimates of status 
awareness after 2011 suggest that this is still low (18%). Our pooled post-2011 estimates also 
suggested that MSM on ART can achieve relatively high levels of viral suppression (76%). However, 
among all MSM living with HIV, current ART use (24%) and viral suppression (25%) remains 
extremely low. We found that more severe anti-LGBT legislation was statistically significantly 
associated with lower levels of testing and status awareness. We also showed that despite a 
substantial increase in the number of studies on the HIV treatment cascade among MSM in Africa 
over the past few years, data remains scarce for all outcomes except HIV testing, especially from 
Central and Northern Africa.  
Implications of all the available evidence 
Research in context
Click here to download Necessary additional data: Research in Context_CLEAN.docx
Despite improvements in HIV testing among MSM in Africa, particularly in recent years, and levels of 
testing among MSM exceeding those among all men in all regions, HIV status awareness, ART 
coverage and overall viral suppression have remained very low, with HIV status awareness and ART 
coverage much lower than levels among all men, despite higher testing. Additional efforts are urgently 
needed to reach the UNAIDS 90-90-90 targets among MSM across Africa. Furthermore, our findings 
support previous evidence suggesting an association between anti-LGBT legislation and access to 
testing and treatment. Further research is needed to assess the effect of repealing such legislation on 
access to HIV services for MSM. Additionally, in spite of an increase over time in the number of 
studies, more data is still needed on the engagement of MSM in all stages of the HIV treatment 
cascade, particularly status awareness, engagement in care, ART use and viral suppression, and 
more research needs to be done in Northern and Central Africa, where few data were available.  
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Figures Legends for Main Text 
 
Figure 1. PRISMA flowchart  
We included 113 articles reporting on 75 independent studies in the principal meta-analysis. (Ns=Number of 
studies, Na=Number of articles). Na can exceed Ns since more than one article can be published on the 
same study. One study estimating ART use only among “all MSM” was excluded. Abstracts of non-English 
articles were translated, where possible, and full-texts received and translated, if potentially relevant. We 
did not make exclusions based on language.  
Figure 2. Forest plot of the proportions of African MSM ever tested 
Weighted (blank squares) and unweighted (filled squares) study estimates and their 95% CIs and pooled 
estimates (diamonds) and their 95% CIs are shown for proportions of MSM in Africa ever tested for HIV, 
overall and stratified by region of Africa. Numerators and denominators of weighted study estimates were 
derived from the effective sample size (see appendix p 3-4). All testing history was self-reported. Estimates 
that were self-calculated are indicated by a *. 
 
Figure 3. Forest plot of the proportions of African MSM recently tested in the past 12, 6, and 3 
months 
Weighted (blank squares) and unweighted (filled squares) study estimates and their 95% CIs and pooled 
estimates (diamonds) and their 95% CIs are shown for proportions of MSM in Africa recently tested for HIV 
in the past 12 months (black), 6 months (red), and 3 months (blue), overall and stratified by region of Africa. 
Numerators and denominators of weighted study estimates were derived from the effective sample size 
(see appendix p 3-4). All testing history was self-reported. Estimates that were self-calculated are indicated 
by a *. 
 
Figure 4. Forest plot of the proportions of African MSM HIV+ aware 
Weighted (blank squares) and unweighted (filled squares) study estimates and their 95% CIs and pooled 
estimates (diamonds) and their 95% CIs are shown for proportions of MSM in Africa HIV+ aware, overall 
and stratified by region of Africa. MSM HIV+ aware are those who reported living with HIV before testing 
positive during the study. Numerators and denominators of weighted study estimates were derived from the 
effective sample size (see appendix p 3-4). Estimates that were self-calculated are indicated by a *. 
 
Figure 5. Forest plot of the proportions of African MSM living with HIV ever or currently engaged in 
care, or linked to care within 30 days of diagnosis 
Study estimates and their 95% CIs and pooled estimates (diamonds) and their 95% CIs are shown for 
proportions of MSM in Africa living with HIV ever or currently engaged in care, or linked to care within 30 
days of diagnosis, overall and stratified by region of Africa. All study estimates were unweighted. All 
engagement in care was self-reported. MSM living with HIV are those who tested positive during the study. 
Numerators and denominators of weighted study estimates are rounded to the nearest whole number. 
Estimates that were self-calculated are indicated by a *. 
 
Figure 6. Forest plot of the proportions of African MSM living with HIV ever or currently on ART 
Weighted (blank squares) and unweighted (filled squares) study estimates and their 95% CIs and pooled 
estimates (diamonds) and their 95% CIs are shown for proportions of MSM in Africa living with HIV ever or 
currently on ART, overall and stratified by region of Africa. All ART use was self-reported. MSM living with 
HIV are those who tested positive during the study. Numerators and denominators of weighted study 
estimates were derived from the effective sample size (see appendix p 3-4). Estimates that were self-
calculated are indicated by a *. 
 
Figure 7. Forest plot of the proportions of African MSM HIV+ aware ever or currently on ART 
Weighted (blank squares) and unweighted (filled squares) study estimates and their 95% CIs and pooled 
estimates (diamonds) and their 95% CIs are shown for proportions of MSM in Africa HIV+ aware ever or 
currently on ART, overall and stratified by region of Africa. All ART use was self-reported. MSM HIV+ 
aware are those who reported living with HIV before testing positive during the study. Numerators and 
denominators of weighted study estimates were derived from the effective sample size (see appendix p 3-
4). Estimates that were self-calculated are indicated by a *. 
 
Figure 8. Forest plot of the proportions of African MSM living with HIV, HIV+ aware, and currently on 
ART that were virally suppressed 
Figure legends for main text
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 2 
Weighted (blank squares) and unweighted (filled squares) study estimates and their 95% CIs and pooled 
estimates (diamonds) and their 95% CIs are shown for proportions of MSM in Africa living with HIV, HIV+ 
aware, and currently on ART that were virally suppressed, overall and stratified by region of Africa. All ART 
use was self-reported. MSM living with HIV are those who tested positive during the study. MSM HIV+ 
aware are those who reported living with HIV before testing positive during the study. Numerators and 
denominators of weighted study estimates were derived from the effective sample size (see appendix p 3-
4). Viral suppression was measured within studies with viral load testing using thresholds defined by the 
study authors. Estimates that were self-calculated are indicated by a *. 
 
7,438 records after duplicates removed
7,438 records screened 6,882 records 
excluded
556 full-text articles 
assessed for eligibility
443 full-text articles 
excluded
238 No data on the 
HIV care cascade
77 No MSM/too few 
MSM
66 Conference 
abstracts/posters
55 Not in Africa
7 Reviews
113 articles (75 
independent studies) 
included in meta-analysis
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through database searching
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TABLES 
Table legends: 
Table 1. Summary of (a) HIV testing and treatment cascade outcomes, (b) participant 
characteristics; (c) stigma variables; (d) anti-LGBT legislation variables of studies 
included in the analyses, and (e) study characteristics and quality indicators.  
Table 2. Pooled estimates of the proportions of African MSM accessing HIV testing 
and different stages of the treatment cascade.  
Tables for main text
Click here to download Necessary additional data: MSM_Review_Tables2_CLEAN.docx
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Table 1. 
 Total unique 
studies*
 
(Ns=75)
 
References 
a. Testing and Treatment Cascade Outcomes 
HIV testing   
Ever 54 
32,43–95 
Recently tested 33  
Past 12 months 28 
32,46,48–51,62,73,78,82,85,96–107 
Past 6 months 8 
43,46,76,78,80,101,106,108 
Past 3 months 4 
46,62,106,109 
HIV+ Aware 23  
Self-reported 23 
32,43,48,51,58,62,68,87,88,110–122 
Engagement in Care 5  
Ever 2 
116,118 
Currently 2 
123,124 
Linked within 30 days of diagnosis 1 
68 
ART use 13  
MSM living with HIV 12  
Ever 4 
48,116,122,124 
Currently 9 
32,68,102,116,118,119,125,126 
MSM HIV+ aware 8  
Ever 3 
48,116,122 
Currently 6 
32,68,116,119,127,128 
Viral suppression 5  
MSM living with HIV 4 
32,122,125,129 
MSM HIV+ aware 3 
32,122,128 
MSM currently on ART 4 
32,116,125,130 
b. Participant Characteristics 
Population   
General MSM 60 
32,43–45,47–51,53,56–59,62–70,72–84,86,88–96,98–101,103, 
104,106,107,109–120,122,123,127–130 
High-risk MSM
† 
9 
52,54,55,71,102,103,121,124–126 
Low-risk MSM
‡ 
1 
85 
MSM organisations
§
 2 
46,87 
NR 3 
61,97 
Region of Africa
¶ 
  
Central 7 
43,62–64,98,99,126 
Eastern 27 
32,43–61,77,97,108–111,121,122,124,125 
Northern 2 
65,10 
Southern 19 
57,66–76,98,101–104,111–115,121,125,127 
Western 23 
78–82,84–95,97,105–107,116–120,123,128–130 
Mean or median age
¶ 
  
≤25 40 
32,46–48,50,52,53,55–57,60,61,63,64,66,67,69,73,76–80,82, 
83,85,86,88–91,93,96,97,99,100,103,107,108,110–114, 
116–120,126 
>25 37 
44,45,49,51,54,57–59,65,68,70–
73,75,81,84,87,92,94,95,98,101,102,104,105,109,111,115,119, 
121–125,127–130 
NR 4 
43,62,97 
HIV prevalence
¶ 
  
≤20% 26 
32,43,48–51,54,56,57,62,66,68,74,78,79,82–
84,88,90,93,100,101,103,107,111–113,115,117,119,120,122 
>20% 22 
45,47,48,51,52,57,58,63,66–68,70,81,85,87,90,94,99,101, 
102,105,110–112,114,116,118,126,128–130 
NR 33 
44,46,53,55,59–61,64,65,69,71–73,75–77,80,86,89,91,92, 
95–98,104,106,108,109,121,123–125,127 
Proportion ever sold sex
¶ 
  
≤35% 9 
53,57,59,60,68,69,101,104,108,111,114,127 
>35% 9 
32,44,49,56,57,74,80,87,92,109,111,115 
NR 58 
43,45–52,54,55,58,61–67,70–73,75–79,81–86,88–91,93–100, 
102,103,105–107,110,112,113,116–126,128–130 
Proportion sold sex recently
¶ || 
  
≤41% 12 
50,53,66,72,82,88,91,93,97,100,102,103,107,112,113,117,122 
>41% 10 
44,49,50,54,58,90–92,105,109 
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NR 55 
32,43,45–48,51,52,55–57,59–65,67–71,73–81,83–87,89,94–99, 
101,104,106,108,110,111,114–116,118–121,123–130 
c. Stigma Variables 
Proportion disclosed MSM status to healthcare workers
¶ 
≤20% 6 
57,66,82–84,111,112,114,117,119 
>20% 8 
32,48,56,57,81,98,104,111,118,128-130 
NR 62 
43–55,58–65,67–80,85–103,105–110,113,115,116,120–127 
Proportion disclosed MSM status to family
¶ 
≤20% 4 
32,57,66,82,111,112,117 
>20% 12 
48,57,65,69,79,81,92,98,103,104,111,113,118,128–130 
NR 60 
43–56,58–64,67,68,70–78,80,83–91,93–97,99–102,105–109, 
110,114–116,119–127 
Proportion blackmailed because MSM
¶ 
≤20% 6 
46,57,59,81,82,111,117,118,120,128–130 
>20% 7 
57,66,83,98,103,104,111–113,119 
NR 63 
32,43–45,47–56,58,60–65,67–80,84–102,105–109,110, 
114–116,119,121–127 
d. Anti-LGBT Legislation   
Same-sex relations illegal
¶
   
Yes 55 
32,43–52,54–65,77–81,83,85–87,89–100,103,104,106,108–111, 
113,116,118–125,128–130 
No 21 
53,66–76,82,83,88,101,102,105,107,112,114,115,117,119,121, 
125–127 
Repressive
¶ 
  
0 13 
66–74,101,102,112,114,115,121,125,126 
1 13 
75,76,82,84,88,90–93,97,104,105,107,117,119 
2 35 
43,44,50–52,54,55,57,58,60,62–64,79,83,85–87,89,91,93–99, 
103,106,108,109,111,113,116,119–125 
3 – 5 20 
32,43,45–49,56,57,59,61,65,77,78,80,81,97,100,110–111,118, 
121,125,128–130 
Indeterminable 1 
127 
Lack of Protective
¶ 
  
0 14 
67–76,101,102,114,115,121,125 
1 – 2 62 
32,43–52,54–66,77–100,103–113,116–126,127–130 
Indeterminable 1 
127 
Lack of Progressive
¶ 
  
0 11 
67–74,101,102,114,115,121,125 
1 – 2 64 
32,43–66,75–100,103–113,116–126,128–130 
Indeterminable 1 
127 
Penalties
¶ 
  
0 23 
53,57,66–
76,82,84,88,101,102,104,105,107,111,112,114,115,117,119, 
121,125,126 
1 3 
43,50,62 
2 39 
44,46,51,52,54,55,57,58,63–65,78–81,83,85–87,89–100,103, 
106,109,111,113,116,118–125,128–130 
3 – 5 17 
32,43,45,47–49,56,57,59–61,77,91,93,97,108,110,111,121,125 
Indeterminable 1 
127 
Arrests 2014-2017
¶ 
  
Yes 43 
32,43–45,47–49,51,52,54–61,63–65,77,78,80,81,87,90–94, 
96–100,103,108–111,113,116,118,120–122,124,125,128–130 
No 35 
43,46,50,53,57,62,66–76,79,82,83–86,88,89,95,97,101,102, 
104–107,111,112,114,115,117,119,121,123,125–127 
Global score
¶ 
  
≤5 21 
53,66–76,82,84,88,101,102,104,105,107,112,114,115,117,119, 
121,125,126 
6 – 8 37 
43,44,50–52,54,55,57,58,62–64,83,85–87,89–99,103,106,109, 
111,113,116,119–125 
≥9 23 
32,43,45–49,56,57,59–61,65,77,78,80,81,91,93,97,100,108, 
110–111,118,121,125,128–130 
Indeterminable 1 
127 
e. Study Characteristics and Quality Indicators 
Study year   
Pre-2011 30 
49,51–55,57–60,64,70–76,90–94,97,100,104,108,111,114, 
115,124 
2011 onwards 41 
32,43–50,56,62,63,65–69,77–89,96,98,99,101–103,105–107, 
109–110,112,113,116–123,125,128–130 
 4 
NR 4 
61,95,126,127 
Study design
¶
   
Cross-sectional 64 
32,43–51,53,55–57,59–77,79,80,82–86,88–100,102–117,119, 
120,123,126,127 
Cohort – baseline 10 
52,54,58,78,81,87,101,118,121,122,124,125,128–130 
NR 2 
97 
Sampling method   
RDS 30 
32,45,47–51,56,60,62,63,66,68,72,74,79,81–85,88,90,91,93, 
97–101,103,105,107,108,110,112,113,115,117–119,128–130 
Cluster/time-venue 3 
43,44,55,108 
Snowball 18 
53,57,59,64,67,77,78,86,89,94,96,98,104,106,111,120–122, 
124,125 
Purposive/convenience 17 
46,54,58,65,69–71,73,75,80,92,95,102,114,123,126,127 
Mix 3 
52,76,116 
NR 4 
61,87,97 
Interview method
¶ 
  
FTFI 54 
43,45,48–55,57–60,62–64,66–68,72,74,76–79,81–85,88,89, 
91–105,107,108,110–120,123,126,128–130 
Confidential
**
 16 
32,44,46,47,56,65,69–
71,73,75,80,86,106,109,110,121,122,125,127 
ACASI/FTFI mix 2 
90,124 
NR 4 
61,87,97 
ACASI, audio computer-assisted self-interview software; ART, anti-retroviral therapy; FTFI, face-to-face interview; 
LGBT, lesbian, gay, bisexual and transgender; MSM, men who have sex with men; MSW, male sex workers; NR, 
not reported; PBS, polling booth survey; PWID, people who inject drugs; RDS, respondent-driven sampling; SAQ, 
self-administered questionnaire 
 
Continuous variables were dichotomised at the median value.  
 
* number of referenced articles differs from the number of studies when multiple articles report on the same study 
and provide different estimates for different testing and/or cascade outcomes or a single article reports on multiple 
studies 
†
 
high-risk MSM includes male sex workers, people who inject drugs, MSM recruited from drinking venues and 
STI clinics, and MSM identified as high-risk by study authors 
‡ low-risk MSM includes non-PWID and MSM self-reported to be HIV-negative 
§ MSM organisations includes MSM recruited from MSM/LGBT organisations/prevention activities 
¶
 
same study included in more than one subcategory when a study reports multiple estimates across different 
levels of the variable 
||
 
proportion sold sex recently includes MSM who have sold sex in the past 12, 6 or 3 months 
** confidential interview methods include ACASI (N=5), pooling booth surveys (N=1), and self-administered 
questionnaires (N=10). All continuous variables dichotomised at the median 
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Table 2. 
Cascade outcome Ne Pooled estimate (%) 95% CI I
2 
HIV testing (among all MSM) 132    
Ever 81 61·0 56·2 – 65·7 98% 
Recently 51    
past 12 months 39 46·2 39·6 – 52·9 97% 
past 6 months 8 38·8 26·0 – 52·4 96% 
past 3 months 4 44·9 11·3 – 81·3 99% 
HIV+ aware 35    
Among MSM living with HIV 35 18·2 13·0 – 23·9 91% 
Engagement in Care (among MSM living with HIV) 6    
Ever*
 
2 33·7 0·0 – 92·5 99% 
Current
†
 2 40·4 0·9 – 91·0 97% 
Linked within 30 days of diagnosis 2 15·3 9·3 – 22·3 26% 
ART use 29    
Among MSM living with HIV 20    
Ever 6 2·0 0·0 – 6.9 91% 
Current 14 23·9 15·7 – 33·1 90% 
Among MSM HIV+ aware 9    
Ever 3 37·3 0·0 – 90·3 94% 
Current 6 53·4 36·9 – 69·5 86% 
Viral suppression 11    
Among MSM living with HIV 4 24·7 18·8 – 31·2 50% 
Among MSM HIV+ aware 3 34·4 28·3 – 40·7 0% 
Among MSM currently on ART 4 75·6 64·4 – 85·5 45% 
ART, antiretroviral therapy; CI, confidence interval; HIV, human immunodeficiency virus; MSM, men who have sex with men; Ne, number of 
estimates 
 
HIV status of MSM living with HIV and MSM HIV+ aware was confirmed in the studies with an HIV test. 
 
* includes ever received a CD4 test 
† includes currently using cotrimoxazole and engaged in care at the start of the study 
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Supplementary material 
HIV testing and engagement with the HIV treatment cascade among men who have sex with men in 
Africa: A systematic review and meta-analysis 
James Stannah1*, Elizabeth Dale1*, Jocelyn Elmes1,2, Roisin Staunton1, Chris Beyrer3, Kate M Mitchell1,4†, Marie-
Claude Boily1,4†§.  
SUPPLEMENTARY METHODS: 
 
Table S1. Search terms for the different databases by domain  
a. Embase search strategy  
Search conducted 10/10/18 – 3,018 articles retrieved 
HIV domain (exp Human immunodeficiency virus/ OR exp acquired immune deficiency syndrome/ OR exp Human immunodeficiency virus infection/ OR 
exp Human immunodeficiency virus antibody/ OR exp Human immunodeficiency virus prevalence/ OR exp HIV test/ OR "hiv*".ab,ti,kw. OR Human 
immun#deficiency virus.ab,ti,kw. OR Human immun# deficiency virus.ab,ti,kw. OR acquired immun#deficiency syndrome.ab,ti,kw. OR acquired immun# 
deficiency syndrome.ab,ti,kw. OR "Aids*".ab,ti,kw. OR (SIDA OR syndrome d'immunodeficience acquise).ab,ti,kw. OR (VIH or virus de 
l'immunodeficience humaine).ab,ti,kw.) 
AND MSM domain (exp male homosexuality/ OR exp bisexuality/ OR gay.ab,kw,ti. OR MSM.ab,kw,ti. OR men who have sex with men.ab,kw,ti. OR men 
that have sex with men.ab,kw,ti. OR (HRSH or hommes quiont des relations sexuelles avec d'autres hommes).ab,kw,ti. OR same-sex.ab,kw,ti. OR 
queer.ab,kw,ti. OR "bisex*".ab,kw,ti. OR money boy.ab,kw,ti. OR "male sex work*".ab,kw,ti. OR same gender.ab,kw,ti. OR (meme sex* or meme 
genre*).ab,kw,ti. OR "homosex*".ab,kw,ti. OR "male adj2 sex worker*".ab,kw,ti.). 
AND Africa domain (exp "Africa south of the Sahara"/ OR exp South Africa/ OR exp Africa/ OR exp North Africa/ OR exp Central Africa/ OR exp 
african/ OR (Africa* or Afriq*).ab,kw,ti. OR (Algeri* or Angola*).ab,kw,ti. OR (Benin* OR Botswana* OR Motswana* OR Batswana* OR Burkina* OR 
Burundi*).ab,kw,ti. OR (Cabo Verde* OR Cap-Vert* OR Cape verde* OR Camero* OR Central African Republic* OR Republique centrafricaine OR 
Chad* OR Tchad* OR Comor* OR Cote d'Ivoire OR Ivory Coast OR Ivorian*).ab,kw,ti. OR (Djibouti* OR Democratic Republic of Congo OR 
Congo*).ab,kw,ti. OR (Egypt* OR Equatorial Guinea* OR Guinee Equatoriale OR Equatoguinean* OR Eritrea* OR Erythree* OR Ethiop*).ab,kw,ti. OR 
(Gabon* OR Gambi* OR Ghana* OR Guine*).ab,kw,ti. OR "Kenya*".ab,kw,ti. OR (Lesotho* OR Bathoso* OR Liberia* OR Liby*).ab,kw,ti. OR 
(Madagas* OR Malawi* OR Mali* OR Mauritani* OR Mauri* OR Moroc* OR Maroc* OR Mozambi*).ab,kw,ti. OR (Namibi* OR Niger*).ab,kw,ti. OR 
(Rwanda* OR Rouanda* OR Ruanda*).ab,kw,ti. OR (Sao* OR Senegal* OR Seychel* OR Sierra Leone* OR Somali* OR South Africa* OR Afrique du 
Sud OR South Sudan* OR Soudan du sud OR Sudan* OR Soudan* OR Swazi*).ab,kw,ti. OR (Tanzani* OR Togo* OR Aller* OR tunisi*).ab,kw,ti. OR 
(Uganda* OR Ouganda*).ab,kw,ti. OR (Zambi* OR Zimbabwe*).ab,kw,ti.)  
AND limit to yr="1980 -Current" 
b. MEDLINE search strategy 
Search conducted 10/10/18 – 2,460 articles retrieved 
HIV domain (exp HIV/ OR exp hiv infections/ OR exp acquired immunodeficiency syndrome/ OR "hiv*".ab,ti,kw. OR Human immun#deficiency 
virus.ab,ti,kw. OR Human immun# deficiency virus.ab,ti,kw. OR acquired immun#deficiency syndrome.ab,ti,kw. OR acquired immun# deficiency 
syndrome.ab,ti,kw. OR Aids*.ab,ti,kw. OR (SIDA OR syndrome d'immunodeficience acquise).ab,ti,kw. OR (VIH or virus de l'immunodeficience 
humaine).ab,ti,kw.)  
AND MSM domain (exp Homosexuality, Male/ OR exp Bisexuality/ OR "homosex*".ab,ti,kw. OR gay.ab,ti,kw. OR MSM.ab,ti,kw. OR men who have sex 
with men.ab,ti,kw. OR men that have sex with men.ab,ti,kw. OR (HRSH OR hommes quiont des relations sexuelles avec d'autres hommes).ab,ti,kw. OR 
same-sex.ab,ti,kw. OR queer.ab,ti,kw. OR "bisex*".ab,ti,kw. OR money boy.ab,ti,kw. OR "male adj2 sex work*".ab,ti,kw. OR "male sex work*".ab,ti,kw. 
OR same gender.ab,ti,kw. OR (meme sex* OR meme genre*).ab,ti,kw.) 
AND Africa domain (exp Africa/ OR (Africa* OR Afriq*).ab,ti,kw. OR (each country listed above).ab,ti,kw  
AND limit to yr="1980 -Current" 
c. Scopus search strategy. 
Search conducted 10/10/18 - 4,379 articles retrieved 
HIV domain (TITLE-ABS-KEY( aids* ) OR TITLE-ABS-KEY("acquired immune deficiency syndrome") OR TITLE-ABS-KEY("acquired 
immun?deficiency syndrome") OR TITLE-ABS-KEY("acquired immun? deficiency syndrome") OR TITLE-ABS-KEY(hiv*) OR TITLE-ABS-
KEY("Human immun?deficiency virus") OR TITLE-ABS-KEY("Human immun? deficiency virus") OR TITLE-ABS-KEY(sida) OR TITLE-ABS-
KEY("syndrome d'immunodeficience acquire") OR TITLE-ABS-KEY(vih) OR TITLE-ABS-KEY("virus due l'immunodeficience humane")) 
AND MSM domain (TITLE-ABS-KEY(homosex*) OR TITLE-ABS-KEY(bisex*) OR TITLE-ABS-KEY("men who have sex with men") OR TITLE-
ABS-KEY("men that have sex with men") OR TITLE-ABS-KEY("same sex") OR TITLE-ABS-KEY("same-sex") OR TITLE-ABS-KEY(gay) OR TITLE-
ABS-KEY(msm) OR TITLE-ABS-KEY(queer) OR TITLE-ABS-KEY("money boy") OR TITLE-ABS-KEY("male sex work*") OR TITLE-ABS-
KEY("male W/2 sex work*") OR TITLE-ABS-KEY("same gender") OR TITLE-ABS-KEY("meme sex*") OR TITLE-ABS-KEY("meme genre*") OR 
TITLE-ABS-KEY(hrs) OR TITLE-ABS-KEY("homes quint des relations seychelles avec d'autres homes")) 
AND Africa domain (TITLE-ABS-KEY(africa*) OR TITLE-ABS-KEY(afriq*) OR TITLE-ABS-KEY(each country listed above) 
AND PUBYEAR > 1980 
d. Global Health search strategy.  
Search conducted 10/10/18 - 1,497 articles retrieved 
HIV domain (exp human immunodeficiency viruses/ OR exp human immunodeficiency virus 1/ OR exp human immunodeficiency virus 2/ OR exp human 
immunodeficiency viruses/ OR exp acquired immune deficiency syndrome/ OR exp aids related complex/ OR exp hiv infections/ OR exp hiv-1 infections/ 
OR exp hiv-2 infections/ OR "hiv*".ab,ti,mp. OR Human immun#deficiency virus.ab,ti,mp. OR Human immun# deficiency virus.ab,ti,mp. OR acquired 
immun#deficiency syndrome.ab,ti,mp. OR acquired immun# deficiency syndrome.ab,ti,mp. OR "Aids*".ab,ti,mp. OR (SIDA OR syndrome 
d'immunodeficience acquise).ab,ti,mp. OR (VIH OR virus de l'immunodeficience humaine).ab,ti,mp.)  
AND MSM domain (exp homosexuality/ OR exp homosexual transmission/ OR exp men who have sex with men/ OR exp bisexuality/ OR gay.ab,ti,mp. 
OR MSM.ab,ti,mp. OR men who have sex with men.ab,ti,mp. OR men that have sex with men.ab,ti,mp. OR (HRSH OR hommes quiont des relations 
sexuelles avec d'autres hommes).ab,ti,mp. OR same-sex.ab,ti,mp. OR queer.ab,ti,mp. OR "bisex*".ab,ti,mp. OR money boy.ab,ti,mp. OR "male sex 
work*".ab,ti,mp. OR "male adj2 sex work*".ab,ti,mp. OR same gender.ab,ti,mp. OR (meme sex* OR meme genre*).ab,ti,mp. OR "homosex*".ab,ti,mp.) 
AND Africa domain (exp africa/ OR exp "africa south of sahara"/ OR exp east africa/ OR exp west africa/ OR exp central africa/ OR exp north africa/ OR 
exp southern africa/ OR (Africa* OR Afriq*).ab,ti,mp. OR (each country listed above).ab.ti.mp 
AND limit to yr="1980 -Current" 
Appendix
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e. Web of Science search strategy. 
Search conducted 10/10/18 - 3,375 articles retrieved 
HIV domain (TS= Aids* OR TS=”acquired immune deficiency syndrome” OR TS="acquired immun?deficiency syndrome" OR TS="acquired immun? 
deficiency syndrome" OR TS= HIV* OR TS="Human immun?deficiency virus" OR TS="Human immun? deficiency virus" OR TS=SIDA OR 
TS="syndrome d'immunodeficience acquise" OR TS=VIH OR TS="virus de l'immunodeficience humaine")  
AND MSM domain (TS=homosex* OR TS=bisex* OR TS="men who have sex with men" OR TS="men that have sex with men" OR TS="same sex" OR 
TS="same-sex" OR TS=gay OR TS=MSM OR TS=queer OR TS="money boy" OR TS="male sex work*" OR TS=(male NEAR/2 "sex work*") OR 
TS="same gender" OR TS="meme sex*" OR TS="meme genre*" OR TS=HRSH OR TS="hommes quiont des relations sexuelles avec d'autres hommes")  
AND Africa domain (TS=Africa* OR TS=Afriq* OR TS=each country listed above 
AND Timespan=1980-2018 
 
 
Search strategy and selection criteria: Dealing with non-English articles  
 
The search strategy did not exclude articles based on language. During the screening process, we translated the abstracts of non-
English articles, where possible. We screened and translated potentially relevant non-English full-texts according to the criteria laid 
out in the methods. 
 
Data Analysis: Anti-LGBT Legislation Index 
In the index, scores were assigned to individual countries based on legislation concerning same-sex relations and stratified into four 
domains (as detailed in table S4).  
1. The repressive domain consisted of 5 areas of legislation that were considered repressive, each area receiving one point if 
true, meaning the domain could receive a maximum of 5 points.  
a. The repressive legislation variable (score 0-5) summed the score of five binary indicators, receiving one point 
each if true: i) same-sex relations are illegal, ii) establishing sexual orientation-related NGOs is illegal, iii) 
LGBT promotion is illegal (“propaganda laws”), iv) age of consent differs for opposite- and same-sex 
relationships, and v) legislation prohibits same-sex marriage or adoption. 
2. The lack of protective domain consisted of 2 areas of protective legislation, and a point was awarded to each if the protective 
legislation was absent, giving a maximum of 2 points for this domain.  
a. The lack of protective legislation variable (score 0-2) summed two binary indicators: i) LGBT people are not 
protected from discrimination, and ii) incitement to hatred based on sexual orientation is not illegal. 
3. Similarly, the lack of progressive domain assessed the lack of progressive legislation, with 2 areas each receiving a point 
if the legislation was absent giving a maximum of 2 points for this domain.  
a. The lack of progressive legislation variable (score 0-2) summed two binary indicators: same-sex i) marriage, 
and ii) adoption, are not legally recognised. 
As the areas of legislation covered by the second and third domains in the scale concern positive rather than negative 
legislation, we used the lack rather than presence of legislation for the scale to remain consistent with the other domains, 
to give a score that increased with an increase in negative legislation.  
4. The fourth domain, penalties, assessed the most severe punishments LGBT people could receive within countries, ranging 
from 0-5. A maximum of 5 points could be given representing the presence of the most severe punishment – the death 
penalty – and a minimum of 0 points could be given, representing no punishment.  
a. The penalties variable (score 0-5) reflected the harshest punishment receivable for consensual same-sex 
relations: 0 for no punishment, 1 for fines/community service, 2 for prison sentences <20 years, 3 for prison 
sentences ≥20 years, 4 for corporal punishment, and 5 for the death penalty. 
The global anti-LGBT legislation index: Altogether, the sum of the scores of these 4 domains gave what we termed the 
“global anti-LGBT legislation index”, which assessed the anti-LGBT legislation overall within countries using a score that 
could range from 0-14, with lower scores representing the countries with the least severe and most progressive legislation, 
and higher scores representing the countries with the most severe and most repressive legislation.  
5. Using the only information and time period available, an additional binary fifth domain assessed whether arrests had 
occurred in the 3 years before the latest ILGA report was published (2014-2017),1 which also applied to each country but 
did not contribute to the global score.  
a. The binary arrest variable reflected whether arrests related to consensual same-sex relations were documented in 
the country between 2014 and 2017.1 
Studies were attributed the same scores - for each legislative domain and overall - as the countries they were conducted in. As 
studies were not all conducted in the same year, but over a time period ranging from 2004-2016, we also took into account changes 
in LGBT-related legislation within this period, whereby studies would receive different scores depending on whether they were 
conducted prior to or following the change.  
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In two of the 28 countries in which studies included in our review were conducted, changes to more progressive legislation occurred: 
in South Africa same-sex marriage was legalised in 2006, and in Lesotho same-sex relations were legalised in 2010. Therefore, 
studies could receive two scores for each of these two countries, depending on whether they were conducted before or after the 
changes in legislation.  
Different scores could also occur for a single country where there were regional differences in legislation. This only affected the 
scores given for studies conducted in Nigeria, in which Sharia law has been adopted in the Northern States since the early 2000s, 
which punishes same-sex relations with the death penalty. As a result, the studies conducted in the Northern States received a higher 
score on the anti-LGBT legislation index than studies conducted elsewhere in Nigeria. Additionally, Nigeria introduced the Same-
Sex Marriage Ban in 2013 across the whole country, which explicitly punishes attempts by same-sex couples to marry, therefore 
studies conducted in all of Nigeria after the introduction of this legislation received a higher score on the anti-LGBT legislation 
index than studies conducted before (as no included studies were conducted in the Northern States after this change this only affected 
studies conducted outside of the Northern States). 
In our analysis, same-sex relations were treated as illegal in Egypt, as even though they are not explicitly illegal, LGBT persons 
have been liberally criminalised under public-morality legislation in recent years and face up to five years in prison.1 Additionally, 
arrests have been documented in the past 3 years (2014-2017)1. 
Data analysis: Meta-regression  
We pooled independent study estimates and calculated 95% confidence intervals (CI) using random-effects models based on the 
DerSimonian-Laird inverse-variance method and the Freeman-Tukey transformation for proportions using R 3.5.1 metafor 
package.2,3,4 Heterogeneity across estimates was assessed using the I2 statistic.5,6 The 95% prediction intervals (PrI) are also provided 
in Table S5 for completeness.  
To conduct the analysis using the Freeman-Tukey transformation for proportions in R requires specifying the numerator (n) and 
denominator (N), which are then used to derive the proportion and its 95% confidence interval for each study before pooling. As 
these calculations do not take into account design effect, extra steps were needed to be able to use estimates from RDS and TLC 
studies that reported weighted proportion that also took into account clustering (which typically have a large 95% CI than the 
corresponding crude estimate (n/N) due to the design effect). In practice, this only applied to RDS studies.  
To include RDS-weighted estimates which accounted for clustering in the analysis, we derived the effective sample size from the 
information reported in each study on the RDS weighted point estimate (prds) and RDS adjusted 95%CI reported (95%CIRDS) as 
follows.  
Including RDS-weighted estimates which accounted for clustering 
To include RDS-weighted estimates in the meta-analysis we needed an estimate of the effective sample size, including the numerator 
(nRDS) and denominator (NRDS) of the relevant study outcome.  
To estimate the effective sample size (which takes into account the design effect), we need an estimate of the design effect (deffrds), 
which we can obtain from the ratio of variances of the RDS-weighted proportion and the simple random sample (SRS) proportion.  
We used the following steps using the information on n, N, prds, 95%CIRDS reported in each RDS study: 
1) Derive the variance of the RDS-weighted proportion from the 95%CIRDS: 
𝑣𝑎𝑟𝑟𝑑𝑠 = (
𝑝𝑟𝑑𝑠𝑢𝑐𝑖 − 𝑝𝑟𝑑𝑠𝑙𝑐𝑖
3·92
)
2
 
where varrds : variance of the RDS weighted proportion taking into account clustering 
𝑝𝑟𝑑𝑠𝑢𝑐𝑖  and 𝑝𝑟𝑑𝑠𝑙𝑐𝑖are the upper and lower confidence limits of the 95%CIRDS 
2) Derive the variance of the SRS proportion, using the RDS-weighted proportion and the crude sample size, N: 
  
      𝑣𝑎𝑟𝑠𝑟𝑠 =
𝑝𝑟𝑑𝑠∗(1−𝑝𝑟𝑑𝑠)
𝑁
 
where varsrs : variance of the RDS proportion not taking into account clustering (as in a simple random sample) 
3) Derive the design effect (the ratio of the variances of the RDS-weighted and SRS proportions): 
𝑑𝑒𝑓𝑓𝑟𝑑𝑠 =
𝑣𝑎𝑟𝑟𝑑𝑠
𝑣𝑎𝑟𝑠𝑟𝑠
 
 where deffrds: design effect 
4) Derive the effective sample size from the crude sample size and the design effect: 
𝑁𝑟𝑑𝑠 =
𝑁
𝑑𝑒𝑓𝑓𝑟𝑑𝑠
 
where Nrds: effective sample size 
4 
5) Finally, derive the numerator for the RDS-weighted estimates: 
𝑛𝑟𝑑𝑠 = 𝑁𝑟𝑑𝑠 ∗ 𝑝𝑟𝑑𝑠 
6) Use nrds and Nrds in the analysis 
Numerators and denominators of weighted proportions were derived from the effective sample size and when presented in forest 
plots were rounded to the nearest whole number.  
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Table S2. Table of indicators used to explore the influence of study quality. For each question, yes is a positive response 
indicating higher quality and no is a negative response indicating lower quality. 
 
 Indicator of potential study quality and sources of biases  
Study design  
1 Was the study specifically designed to estimate the cascade outcome of interest?  YES/NO 
Selection bias  
2 
Was the sampling method used appropriate for capturing a representative sample 
of the target population? (yes for cluster/time-venue or RDS/snowball, no for 
other e.g. convenience/purposive) YES/NO 
3 
Did the study use a complex study design with appropriate statistical adjustment 
for study design? (yes for cluster/time-venue/RDS studies where derived estimates 
take into account the weights and clustering, no otherwise)  YES/NO 
4 
Were the inclusion/exclusion criteria given clearly defining which type of 
participants the authors were trying to recruit? YES/NO 
5 
Did the sampled population of MSM reflect members of the wider MSM 
community?* YES/NO 
6 
Were the study participants MSM only or were transgender women included (yes 
if MSM only, no if transgender women included or NR) YES/NO 
7 
Was the response rate adequate to prevent concerns about non-response bias? (yes 
if ≥60%, no if <60% or NR)  YES/NO 
8 Were measures taken to address and categorise non-responders? YES/NO 
Measurement error  
9 Was the study based on confidential interview methods? YES/NO 
10 
Were outcomes (numerator or denominator) confirmed with a biological test (yes) 
or were they self-reported (no)?  YES/NO 
Reporting bias  
11 Were the methods sufficiently described to be repeatable? YES/NO 
12 Were the basic data adequately described?  YES/NO 
13 Were the results internally consistent†? YES/NO 
Publication bias  
14 Were proportions self-calculated (yes) or directly reported (no)? YES/NO 
15 Was the outcome first reported in the text (yes) or abstract (no)? YES/NO 
16 
Quality score: 
― No to questions 5 and 9 and 13 
― One yes to either questions 5 and 9 and 13 
― Two yes to either questions 5 and 9 and 13  
― Yes to all questions 5 and 9 and 13 
0 
1 
2 
3 
* Included whether the study aimed to recruit MSM from the wider community of MSM of from a specific 
risk-group of MSM (e.g. male sex workers, MSM recruited from drinking venues or STI clinics) 
† Results determined to be internally consistent if estimates reported were not different from the same 
estimates self-calculated from reported numerators and denominators 
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Figure S1. Plots of (a) the number of independent studies included in the review reporting HIV testing outcomes (dark blue), HIV 
treatment cascade outcomes (light blue) and all testing and treatment outcomes combined (red) among MSM conducted each year, 
(b) the cumulative number of independent studies conducted over time, (c) the number of articles published reporting data on HIV 
testing and treatment cascade outcomes from those studies over time, and (d) the cumulative number of articles published over time. 
Two studies (and their two articles) did not report study years. 
 
 
  
Population* MSM Definition
TGW 
excluded N Country City
Median 
age
Mean 
age
HIV 
prevalence 
among 
MSM
Proportion 
of MSM 
sold sex
Period sex 
work 
reported over 
(ever, past 12, 
6, 4, 3, 2, 1 
month(s))
Study 
Year‡
Study 
design
Sampling 
method§
Interview 
method¶
Proportion 
disclosed 
they were 
MSM to 
healthcare 
workers
Proportion 
disclosed 
they were 
MSM to 
family 
Proportion 
blackmailed 
for being 
MSM
Ever 
test (self-
reported
)
Recent 
test 
(self-
reported
)
Period 
of 
recent 
test 
(months)
HIV+ status 
awareness 
(status confirmed 
with biological 
test and answered 
"yes" to question 
"are you HIV+?"
Engagement 
in care 
(self-reported)
ART use 
(denominator)
(self-reported)
Period 
of ART 
use 
(ever or 
current)
Viral 
suppression 
(denominator) 
(confirmed 
with biological 
test)
Viral 
threshold 
(selected by 
study authors)
Included 
in meta-
analysis
Testing/
cascade 
outcome 
included in 
meta-analysis
Central Africa
Bouassa 
201846
STI clinic
approved of as 
having sex with 
men by his peers
N 42
Central 
African 
Republic
Bangui NR 23·2 69.0% NR NR NR CS purposive FTFI NR NR NR NR NR NR NR NR 34·4% (HIV+ MSM)
Current NR NR Y ART use
256 Benguela NR NR 3·0%‖ NR NR CS time-venue FTFI NR NR NR 36.0% 17.0% 6 7.0% NR NR NR NR NR
457 Luanda NR NR 2·0%‖ NR NR CS time-venue FTFI NR NR NR 47.0% 6.0% 6 28.0% NR NR NR NR NR
general 272 Douala 23 26·0† 25·7%‖ NR NR CS RDS FTFI NR NR NR 77·5%‖ NR NR NR NR NR NR NR NR
general 239 Yaoundé 25 26·9† 44·0%‖ NR NR CS RDS FTFI NR NR NR 79·7%‖ NR NR NR NR NR NR NR NR
31·7% 12
25·6% 3
Lorente 
201249
general NR NR 165 Cameroon Douala 25 NR NR NR NR 2008 CS snowball FTFI NR NR NR 81.0% NR NR NR NR NR NR NR NR Y Ever test
general 306 Cameroon Yaoundé NR 27·5† NR NR NR 2015 CS RDS FTFI NR 59·5% 36·9% NR 55·5%‖ 12 NR NR NR NR NR NR Y Recent test
general 259 Cameroon Yaoundé NR 31·1† NR NR NR 2013 CS snowball FTFI NR 45·5% 45·3% NR 88·7% 12 NR NR NR NR NR NR Y Recent test
general 268 Douala NR 26·9† NR NR NR CS RDS FTFI NR NR NR 77·5%‖ 63·2%‖ 12 NR NR NR NR NR NR
general 238 Yaoundé NR 27·1† NR NR NR CS RDS FTFI NR NR NR 79·9%‖ 54·3%‖ 12 NR NR NR NR NR NR
Eastern Africa
Adam 
20097
NR NR NR 50 Mauritius NR NR NR NR NR NR 2004 NR NR NR NR NR NR NR 16.0% 12 NR NR NR NR NR NR Y Recent test
Ahaneku 
20168
general
sex with another 
man in the past 6 
months
N 205 Tanzania
Dar es 
Salaam, 
Tanga
NR 24·7 25.0% NR NR 2012 CS RDS SAQ NR NR NR 78·6% NR NR NR NR NR NR NR NR N NA
Anderson 
20159
general NR Y 200 Tanzania Dar es Salaam 23 28·3† 30·2% NR NR 2012 CS RDS SAQ NR NR NR 77·8% NR NR NR NR NR NR NR NR N NA
Baral 
200910
general ever anal sex 
with another man N
201 Malawi Blantyre and Lilongwe
25 25·6 19·7% 62·6% ever 2008 CS snowball FTFI 18.0% 8·96% 17.0% 35·2% NR NR 4·7% NR NR NR NR NR Y HIV+ status awareness
Beyrer 
201011
general ever sex with 
another man N
537
Malawi/
Namibia/
Botswana
NR 24·9 17·4% 34·5% ever 2008 CS snowball FTFI NR NR NR 56.0% NR NR NR NR NR NR NR NR N NA
Bhattacharjee
201512
general NR N 1308 Kenya
Nairobi, 
Mombasa, 
Nakuru, 
Thika, 
Kisumu
NR 26·3† NR 58·9% 3 months 2013 CS cluster PBS NR NR NR 91·8% 73·7% 3 NR NR NR NR NR NR Y Ever test, recent test
Chapman 
201113
general
anal or oral sex 
with another man 
in the past 12 
months
N 99 Rwanda Kigali 24 26.0 NR 30·6% ever 2009 CS snowball FTFI NR NR NR 62·5% NR NR NR NR NR NR NR NR Y Ever test
86·3% 12
86·3% 6
68·6% 3
anal sex with 
another man in 
the past 6 
months
Y
anal or oral sex 
with another man 
in the past 12 
months
N
anal sex with 
another man in 
the past 6 
months
N
anal sex with 
another man in 
the past 12 
months
N
anal or oral sex 
with another man 
in the past 12 
months
N
Park 
201451
MSM 
engaged in 
prevention 
activities
Coulaud 
201614
general
Holland 
201547
Kendall 
201448
NRNR351 Angola Luanda
Cameroon
NR
51 Burundi Bujumbura 25·5†23 NR NR
Cameroon
NR
2011
NRCS convenience NR NR96·1%SAQ
CS RDS FTFI
NR NR
NRNR37.0% NR
NR Y
PARTICIPANT CHARACTERISTICS STUDY CHARACTERISTICS 
AND QUALITY INDICATORS
NR3·7%‖
NR
NRNR NR NR 38·1%
NR 8.0%
2011
2014
STIGMA VARIABLES TESTING AND CASCADE OUTCOMES META-ANALYSIS
Reference
Ever test, recent 
test
Y
Recent test
2011
NR
Herce 
201819
general Angola 2017
Ever test, HIV+ 
status 
awareness
Y
Ever test, recent 
test, HIV+ 
status 
awareness
Y Ever test
Y
Rao 
201750
NR N
7
Table S3. Detailed participant characteristics, stigma variables, study characteristics and quality indicators, and study estimates of the HIV testing and treatment cascade outcomes and whether they were
included in the meta-analysis, ordered by region of Africa, of the 113 articles retrieved in the search. Multiple articles often reported estimates on the same study population, in which case only the estimate
from the largest sample was included. If the sample was the same size, the most recent estimate was included.
Dahoma 
201115
general
anal sex with 
another man in 
the past 3 
months
N 509 Tanzania Zanzibar 28 31·1† 12·3%‖ 79·6% ever 2007 CS RDS FTFI NR NR NR 19·2%‖ NR NR NR NR NR NR NR NR N NA
Fay 
201116
general ever anal sex 
with another man N
202 Malawi Blantye, Lilongwe
NR 25·7 19·7% NR NR 2008 CS snowball FTFI 18.0% 9.0% 6.0% 35·2% NR NR NR NR 2·0% (all MSM) Current NR NR Y Ever test
28 Kenya Kisumu NR NR NR NR NR cohort snowball CASI NR NR NR NR NR NR 35·7% NR NR NR NR NR
27 Malawi Blantyre NR NR NR NR NR cohort snowball CASI NR NR NR NR NR NR 33·3% NR NR NR NR NR
Graham 
201318
HIV+ high 
risk
sex with another 
man reported at 
enrolment or 
during follow-up
N 108 Kenya NR 30† NR 70·4% NR 2008 cohort snowball
ACASI/
FTFI
NR NR NR NR NR NR NR
15·2% 
(current 
cotrimoxazole 
use)
6·8% (HIV+ 
MSM)
Ever NR NR Y Engagement in care, ART use
Herce 
201819
general
anal sex with 
another man in 
the past 3 
months
Y 119 Malawi Zomba NR NR 2·0%‖ NR NR 2017 CS time-venue FTFI NR NR NR 75.0% 54.0% 6 50.0% NR NR NR NR NR Y Ever test
Hladik 
201220
general
anal sex with 
another man in 
the past 3 
months
N 295 Uganda Kampala 25 29·7† 13·7%‖ 45·4% ever 2008 CS RDS ACASI 41·1% NR NR 43·4%‖ NR NR NR NR NR NR NR NR Y Ever test
19·3% (HIV+ 
MSM)‖
<1000 copies 
per mL
50·0% (Aware 
of HIV+ 
status)
<1000 copies 
per mL
58·3% (MSM 
currently on 
ART)
<1000 copies 
per mL
general 493 Maputo NR 22·3 NR 50.0% 12 months CS RDS FTFI NR NR NR 58.0% 30·4%‖ 12 NR NR NR NR NR NR
general 572 Beira NR 22.0 NR 36·6% 12 months CS RDS FTFI NR NR NR 65·9% 42·1%‖ 12 NR NR NR NR NR NR
general 347 Nampula/
Nacala
NR 21·9 NR 50·4% 12 months CS RDS FTFI NR NR NR 53·6% 29·8%‖ 12 NR NR NR NR NR NR
Johnston 
201023
general
anal sex with 
another man in 
the past 3 
months
N 509 Tanzania Zanzibar NR 29·7† 10·6%‖ 67·7% 1 month 2007 CS RDS FTFI NR NR NR 21·4%‖ NR NR NR NR NR NR NR NR N NA
Kajubi 
200824
gay/bi-
identifying 
only
men who 
responded 'gay' 
or 'bisexual' to 
the question 
"would you 
describe yourself 
as gay, bisexual, 
straight or 
heterosexual?"
N 224 Uganda Kampala NR 27·5† NR 28.0% ever 2004 CS RDS FTFI NR NR NR 24·0%‖ NR NR NR NR NR NR NR NR Y Ever test
general 509 Tanzania Zanzibar NR 31·5† 12·3%‖ 78·4% 12 months 2007 CS RDS FTFI NR NR NR 18·8%‖ 11·3%‖ 12 NR NR NR NR NR NR Y Ever test, recent test
general 344 Tanzania Zanzibar NR 27·0† 2·6%‖ 82.0% 12 months 2011 CS RDS FTFI NR NR NR 68·2%‖ 55·3%‖ 12 NR NR NR NR NR NR Y Ever test, recent test
2·7% (HIV+ 
MSM)
Ever 31·1% (HIV+ 
MSM)
<1000 copies 
per mL
9·5% (MSM 
aware of HIV+ 
status)
Ever
33·3% 
(Aware of 
HIV+ status)
<1000 copies 
per mL
Luchters 
201127
MSW
men who 
currently sell sex 
to men in 
exchange for 
money or goods
N 442 Kenya Mombasa NR 24·6 NR 100.0% current 2008 CS time-venue FTFI NR NR NR 64.0% NR NR NR NR NR NR NR NR Y Ever test
Never sex with another man
anal or oral sex 
with another man 
in the past 6 
months
N
HIV+ status 
awarenessY
Y Ever test, recent test
Kunzweiler 
201726
24 3 months36·9%
65·1%‖everN
sex with another 
man in the past 6 
months
anal or oral sex 
with another man 
in the past 12 
months
10·5%26·8†
23
ART use, viral 
suppressionY
NR
75·0% (MSM 
aware of HIV+ 
status)
70·9%‖ Y
Ever test, recent 
test, HIV+ 
status 
awareness, 
ART use, viral 
suppression
Kisumu snowballcohort2016 NR
Current
2016
19·4% NRRDS ACASI 20·3%CS 1246·7%
28.0%NRNRNRNRNRNRACASI
Fogel 
201817
HIV+ MSM
201325·6†
Khatib 
201725
12·2%‖ 40·4%607general
Horth 
201522
2011Mozambique
Uganda Kampala
711
N
N
anal sex with 
another man in 
the past 3 
months
Hladik 
201721
general Kenya
8
McKinnon 
201328
MSW NR NR 507 Kenya Nairobi 27 NR 40·0% 86·7% current 2010 cohort snowball/venue-based
FTFI NR NR NR 85·8% NR NR NR NR NR NR NR NR Y Ever test
Mmbaga 
201829
general
at times, or 
regularly, have 
sex with a man 
(or men)
NR 753 Tanzania Dar es Salaam NR 26·5 22·3% NR NR 2014 CS RDS FTFI NR NR NR 62·7% NR NR NR NR NR NR NR NR Y Ever test
Moller 
201530
high-risk 
MSM
anal sex with 
another man 
during follow-up
N 561 Kenya Kilifi 25·2 NR 16·4% 71·5% 3 months 2008 cohort convenience FTFI NR NR NR 47·4% NR NR NR NR NR NR NR NR Y Ever test
Muraguri 
201531
general
anal or oral sex 
with another man 
in the past 6 
months
N 563 Kenya Nairobi NR 31·8† 25·6% 48·5% 2 months 2010 CS RDS FTFI NR NR NR 71·4% 47·6% 12 34.0% NR NR NR NR NR Y
Ever test, recent 
test, HIV+ 
status 
awareness
1308 Kenya NR 25·9† NR NR NR 2014 CS cluster PBS NR NR NR 91·8% NR NR NR NR NR NR NR NR
1254 Kenya NR 25·6† NR 69.0% ever 2015 CS cluster PBS NR NR NR 94.0% 77.0% 3 NR NR NR NR NR NR
Ntata 
200833
general NR NR 97 Malawi
Blantyre, 
Zomba, 
Lilongwe, 
Machinga, 
Mangochi, 
and Dedza
NR 27·4† NR 23·7% ever 2006 CS snowball FTFI NR NR 6·2% 58·8% NR NR NR NR NR NR NR NR Y Ever test
Nyoni 
201234
NR NR NR 271 Tanzania Dar es Salaam 24 NR NR NR NR NR CS NR NR NR NR NR 60·5% NR NR NR NR NR NR NR NR Y Ever test
Raymond 
200935
gay/bi-
identifying 
only
self-identifying 
as gay or 
bisexual
N 215 Uganda Kampala NR 24·9† NR NR NR 2004 CS RDS FTFI NR NR NR NR 23·7%‖ 6 NR NR NR NR NR NR Y Recent test
Romijnders 
201636
general NR NR 300 Tanzania
Dar es 
Salaam, 
Tanga
23 NR 23·7% NR NR 2012 CS RDS SAQ NR NR NR 77·7% NR NR NR NR NR NR NR NR Y Ever test
Ross 
201437
general NR NR 300 Tanzania
Dar es 
Salaam, 
Tanga
23 24·7† 23·7% 81·7% 1 month 2012 CS RDS SAQ NR NR NR 78.0% NR NR 8·1% NR NR NR NR NR Y HIV+ status awareness
Sanders 
200738
general
anal sex with 
another man in 
the past 3 
months
N 285 Kenya Mombasa NR 29·2† 24·6% 73·7% 3 months 2006 cohort convenience FTFI NR NR NR 25·3% NR NR 10.0% NR NR NR NR NR Y
Ever test, HIV+ 
status 
awareness
general 457 Maputo 22 NR 9·2% 47·8% 12 months CS RDS FTFI NR NR NR 59·1% NR NR NR NR NR NR NR NR N NA
general 538 Beira 21 NR 9·1% 27·4% 12 months CS RDS FTFI NR NR NR 65·4% NR NR NR NR NR NR NR NR N NA
general 330 Nampula/
Nacala
21 NR 3·3% 44·5% 12 months CS RDS FTFI NR NR NR 53·9% NR NR NR NR NR NR NR NR N NA
Shangani 
201740
general
anal or oral sex 
with another man 
in the past 6 
months
N 89 Kenya Eldoret NR 29·2† NR NR NR 2014 CS chain-referral FTFI NR NR NR NR 74·2% 12 NR NR NR NR NR NR Y Recent test
Stahlman 
201641
general
anal or oral sex 
with another man 
in the past 12 
months
N 334 Malawi Blantyre NR NR 12·8%‖ NR NR 2011 CS RDS FTFI NR 20·7% 20·4% 60·2% NR NR 3·0%‖ NR NR NR NR NR N NA
Wanyenze 
201642
general self-identified 
MSM N
85 Uganda NR 24·2 NR NR NR 2013 CS snowball FTFI NR NR NR 89·4% NR NR NR NR NR NR NR NR Y Ever test
Wirtz 
201343
general
anal or oral sex 
with another man 
in the past 12 
months
N 338 Malawi Blantyre 25·1 28·4† 15·4% NR NR 2011 CS RDS FTFI 20·8% 20·4% NR 60·1% 32·7% 12 NR NR NR NR NR NR N NA
NR NR
anal or oral sex 
with another man 
in the past 12 
months
N
Ygeneral
Musyoki 
201832
Recent test
2011
Sathane 
201639
Mozambique
9
1·2% (HIV+ 
MSM)
Ever NR NR
50·0% (MSM 
aware of HIV+ 
status)
Ever NR NR
338 Blantyre 24 26·7† 12·5%‖ NR NR 2011 CS RDS FTFI 20·8% 20·4% NR 48·3%‖ 19·4%‖ 12 3·2%‖ NR 0·8% (HIV+ MSM)‖
Ever NR NR Y
Ever test, recent 
test, HIV+ 
status 
awareness, 
ART use
350 Chikwana 24 26·7† 20·5%‖ NR NR 2014 CS RDS FTFI NR NR NR 27·9%‖ 6·8%‖ 12 NR NR NR NR NR Y Ever test, recent test
363 Lilgongwe 24 26·7† 17·7%‖ NR NR 2013 CS RDS FTFI NR NR NR 46·9%‖ 39·8%‖ 12 0·1%‖ NR 0·1% (HIV+ MSM)‖
Ever NR Y
Ever test, recent 
test, HIV+ 
status 
awareness, 
ART use
351 Mangochi 24 26·7† 22·4%‖ NR NR 2014 CS RDS FTFI NR NR NR 51·6%‖ 17·5%‖ 12 0·6%‖ NR NR NR NR Y
Ever test, recent 
test, HIV+ 
status 
awareness
349 Mulanje 24 26·7† 24·5%‖ NR NR 2014 CS RDS FTFI NR NR NR 41·0%‖ 27·6%‖ 12 1·3%‖ NR NR NR NR Y
Ever test, recent 
test, HIV+ 
status 
awareness
353 Mzuzu 24 26·7† 4·1%‖ NR NR 2013 CS RDS FTFI NR NR NR 43·3%‖ 24·4%‖ 12 0·1%‖ NR 0·1% (HIV+ MSM)‖
Ever NR Y
Ever test, recent 
test, HIV+ 
status 
awareness, 
ART use
350 Nkhata Bay 24 26·7† 20·6%‖ NR NR 2014 CS RDS FTFI NR NR NR 59·4%‖ 36·3%‖ 12 NR NR NR NR NR Y Ever test, recent test
28 Kenya Kisumu NR NR NR NR NR cohort snowball CASI NR NR NR NR NR NR NR NR 67·9% (HIV+ MSM)
Current NR NR
27 Malawi Blantyre NR NR NR NR NR cohort snowball CASI NR NR NR NR NR NR NR NR 37·0% (HIV+ MSM)
Current NR NR
Northern Africa
Elmahy 
201852
general
described 
themselves as 
homosexual or 
bisexual
N 461 Egypt NR 26·6 NR 1·1% current 2016 CS online SAQ NR 20·2% NR 34·5% NR NR NR NR NR NR NR NR Y Ever test
Valadez 
201353
general
anal sex with 
another man in 
the past 6 
months
N 227 Libya Tripoli NR 24·1† 3·1%‖ 30·4% 6 months 2010 CS RDS FTFI NR NR NR NR 45·6%‖ 12 NR NR NR NR NR NR Y Recent test
Southern Africa
Arnold 
201354
general NR N 377 South Africa Soweto
NR 24·24 13·2%‖ NR NR 2008 CS RDS FTFI NR NR NR 41·9% NR NR 37·5% NR NR NR NR NR Y Ever test
general 117 Botswana Gaborone 24 25·8 21·4% 29·3% ever CS snowball FTFI 26·5% 24·1% 60·3% 82·9% NR NR 17·4% NR NR NR NR NR Y HIV+ status awareness
general 218 Namibia Windhoek 23 24·4 12·4% 37·3% ever CS snowball FTFI 21·3% 21·6% 44·5% 59·4% NR NR 59·3% NR NR NR NR NR Y HIV+ status awareness
Baral 
201155
general ever anal sex 
with another man Y
200 South 
Africa Cape Town
24 26·1 25·5% 12.0% ever 2009 CS convenience FTFI 10·5% NR NR NR NR NR 6.0% NR NR NR NR NR Y HIV+ status awareness
Baral 
201156
general ever anal sex 
with another man Y
249 Lesotho NR 26·3 NR 22·2% ever 2009 CS snowball FTFI 21·3% 24·4% 32·5% NR 54·5% 12 NR NR NR NR NR NR Y Recent test
Baral 
201357
general
anal sex with 
another man in 
the past 12 
months
N 313 eSwatini NR 23·1 13·4%‖ NR NR 2011 CS RDS FTFI NR 30·4% 53·4% NR 54.0% 12 29.0% NR NR NR NR NR N NA
Batist 
201358
general reported to have 
sex with men N
98 South 
Africa Cape Town
24·5 NR NR 24.0% ever 2012 CS convenience SAQ NR 61·5% NR 93·8% NR NR NR NR NR NR NR NR Y Ever test
RDS
Baral 
200910
2008ever anal sex 
with another man N
HIV+ MSM
Wirtz 
201744
general
20132453
Zhang 
201845
Malawi
All regions NRNR
2016
FTFICSNR N NANR NR 45·9%‖ 24·9%‖ NR 0·9%‖ NR26·7†24
ART useY
18·2%‖
ever anal sex 
with another man N
anal or oral sex 
with another man 
in the past 12 
months
N
10
Brown 
201659
general
anal sex with 
another man in 
the past 12 
months
N 326 eSwatini NR 23·2 17.0% NR NR 2011 CS RDS FTFI NR NR NR NR NR NR 34·5% NR NR NR NR NR Y HIV+ status awareness
Cloete 
200860
general NR NR 92 South Africa Cape Town
NR 28·7† NR 28.0% ever NR CS convenience SAQ NR NR NR NR NR NR NR NR
27·2% (MSM 
aware of HIV+ 
status)
Current NR NR Y ART use
Eaton 
201361
drinking 
venues NR NR
143 South 
Africa Cape Town
NR 28·51 NR 17·6% 4 months 2010 CS convenience SAQ NR NR NR 62·7% NR NR NR NR NR NR NR NR Y Ever test
general 117 Botswana Gaborone NR 24·6 21·3% NR NR CS snowball FTFI 26·5% 24·1% 32·8% 82·9% NR NR NR NR 0·9% (all MSM) Current NR NR
general 218 Namibia Windhoek NR 24·4 12·4% NR NR CS snowball FTFI 21·3% 21·6% 36·2% 59·5% NR NR NR NR 8·3% (all MSM) Current NR NR
44 Cape Town NR NR NR NR NR cohort snowball CASI NR NR NR NR NR NR 22·7% NR NR NR NR NR
84 Soweto NR NR NR NR NR cohort snowball CASI NR NR NR NR NR NR 45·2% NR NR NR NR NR
Grover 
201662
general
anal sex with 
another man in 
the past 12 
months
Y 326 eSwatini NR 23·22 NR NR NR 2011 CS RDS FTFI NR NR NR NR 54·3% 12 NR NR NR NR NR NR Y Recent test
Knox 
201163
general
anal, oral, or 
masturbatory sex 
in the past 12 
months
N 300 South Africa Pretoria
NR 26·1 NR NR NR 2008 CS convenience ACASI NR NR NR 67·7% 41·4% 12 NR NR NR NR NR NR Y Ever test, recent test
Knox 
201364
general
anal, oral, or 
masturbatory sex 
in the past 12 
months
N 300 South Africa Pretoria
NR 26·1 NR NR NR 2008 CS convenience ACASI NR NR NR 69·6% 42·4% 12 NR NR NR NR NR NR N NA
Lane 
200865
general
ever anal, oral, 
or masturbatory 
sex with another 
man
N 147 South Africa
NR 28·6† NR NR NR 2004 CS snowball/
venue-based
FTFI NR NR NR 67·3% 31·3% 6 NR NR NR NR NR NR Y Ever test, recent test
Lane 
201166
general
anal or oral sex 
with another man 
in the past 6 
months
N 363 South Africa Soweto
NR 27·1† 10·9%‖ 48·4% ever 2008 CS RDS FTFI NR NR NR 37·9%‖ NR NR 11·6% NR NR NR NR NR Y HIV+ status awareness
13·6% (HIV+ 
MSM)
48·4% (MSM 
aware of HIV+ 
status)
9·7% (HIV+ 
MSM)
66·7% (MSM 
aware of HIV+ 
status)
70·9% 12
20.0% 6
62·5% 12
51·4% 6
general 326 eSwatini Manzini NR 25·8† NR NR NR 2011 CS RDS FTFI 30·3% 53·5% NR NR 52·1%‖ 12 NR NR NR NR NR NR N NA
general 173 eSwatini Manzini NR 29·5† NR NR NR 2014 CS snowball FTFI 21·3% 44·5% NR NR 89.0% 12 NR NR NR NR NR NR Y Recent test
Rebe 
201569
STI clinic
anal, oral sex or 
anilingus with 
another man in 
the past 12 
months
N 200 South Africa Cape Town
32 NR 44.0% 26.0% 12 months 2012 CS convenience FTFI NR NR NR NR 53·5% 12 NR NR 52·3% (HIV+ 
MSM)
Current NR NR Y Recent test, ART use
Risher 
201370
general
anal sex with 
another man in 
the past 12 
months
Y 320 eSwatini 22 23·1 16·9% NR NR 2011 CS RDS FTFI NR 31·3% NR NR 54·4% 12 33·3% NR NR NR NR NR N NA
Sandfort 
200871
general NR NR 1045 South Africa
NR 29·9 NR NR NR 2004 CS purposive SAQ NR NR NR 69·7% NR NR NR NR NR NR NR NR Y Ever test
Siegler 
201572
general
anal sex with 
another man in 
the past 6 
months
N 34 South Africa
Cape Town, 
Port Elizabeth
25 29·5† 23·5% NR NR 2012 CS snowball FTFI NR NR NR 97·1% NR NR NR NR NR NR NR NR Y Ever test
CS
Lippman 
201868
Rao 
201750
Gert Sibande ever FTFI NR
Fay 
201116
2008
18·6%28·3%‖
Lane 
201467
2012South 
Africa
Ehlanzeni
NR307
72
127
298
South 
Africa
anal or oral sex 
with another man 
in the past 6 
months
N
sexually active 
with another man 
in the past 6 
months
N
anal sex with 
another man in 
the past 12 
months
N
ever anal sex 
with another man N
ever sex with 
another man
26·2†NR NR
FTFI
RDS
RDS
cohort
cohort
NR
NR
NR
NR
27·1† NR
NR
65·8%‖ NR
NR
11·3% (linked 
to care within 
30 days of 
diagnosis)
RDSCS
14·5%NRRDS FTFI NRever11·4%13·7%‖general
general
Y
NR
NR
28·2%NRNR
25·5†
2015
Recent test
Recent testY
NR69·3%‖ Current
Current NR
18·2% (linked 
to care within 
30 days of 
diagnosis)
NR
NR
NR
NR
Y
NR
NR
NR
general
NR
NR
81·8%
Y
Ever test, HIV+ 
status 
awareness, 
engagement in 
care, ART use
4.0%
6.0%25·2†
NR
NR
Gert Sibande
Ehlanzeni
FTFI
87·5%
NR
NRNR
NR
NR
NR
Fogel 
201817
HIV+ MSM 2016 Y HIV+ status awareness
South 
Africa
Ever test
NR NR
N
NR
11
general 530 Lesotho Maseru, Maputsoe
23 NR 32·6% 32·1% 12 months 2014 CS RDS FTFI 18·8679245% NR NR 69·1% NR NR NR NR NR NR NR NR Y Ever test
general 322 eSwatini Manzini 22 NR 17·1% 26·1% 12 months 2011 CS RDS FTFI NR NR NR NR 50.0% 12 NR NR NR NR NR NR N NA
Stahlman 
201574
general
anal sex with 
another man in 
the past 12 
months
N 527 Lesotho Maseru, Maputsoe
NR 26·4† 32·8% NR NR 2014 CS RDS FTFI 18·8% NR NR NR NR NR 40·1% NR NR NR NR NR Y HIV+ status awareness
general 318 Lesotho Maseru 22 NR 18·0%‖ NR NR 2014 CS RDS FTFI NR 12·3% 38·7% 79·1%‖ NR NR 53·7%‖ NR NR NR NR NR N NA
general 310 eSwatini Manzini 22 NR 12·6%‖ NR NR 2011 CS RDS FTFI NR 30·3% 53·6% NR 54·2% 12 43·7%‖ NR NR NR NR NR N NA
Stephenson 
201275
general
at least one male 
sex partner in the 
past 12 months
N 449 South Africa
NR 31·3 NR NR NR 2010 CS online SAQ NR NR NR 86·7% NR NR NR NR NR NR NR NR N NA
Tun 
201276
general NR N 307 South Africa Pretoria
24 26·1† NR 14·3% 6 months 2009 CS RDS FTFI NR NR NR 71·1%‖ NR NR NR NR NR NR NR NR Y Ever test
Wagenaar 
201277
general
sex with another 
man in the past 
12 months
N 439 South Africa
30 32·3† NR NR NR 2010 CS online SAQ NR NR NR 87.0% NR NR NR NR NR NR NR NR Y Ever test
Wendi 
201678
general NR N 318 Lesotho Maseru NR 23·6 NR NR NR 2014 CS RDS FTFI NR NR NR 80·8% NR NR NR NR NR NR NR NR N NA
44 Cape Town NR NR NR NR NR cohort snowball CASI NR NR NR NR NR NR NR NR 25·0% (HIV+ MSM)
Current NR NR
84 Soweto NR NR NR NR NR cohort snowball CASI NR NR NR NR NR NR NR NR 27·4% (HIV+ MSM)
Current NR NR
Western Africa
NR 26 Mauritania NR NR NR NR NR NR 2006 NR NR NR NR NR NR NR 15·4% 12 NR NR NR NR NR NR Y Recent test
NR 879 Nigeria NR NR NR NR NR NR 2007 NR NR NR NR NR NR NR 30·2% 12 NR NR NR NR NR NR Y Recent test
Adebajo 
201479
general
anal or oral sex 
with another man 
in the past 12 
months
N 712 Nigeria Abuja, Lagos and Ibadan
23 NR NR 49·9% 6 months 2010 CS RDS ACASI/FTFI
NR NR NR 54·9% NR NR NR NR NR NR NR NR N NA
Aho 
201480
general
anal or oral sex 
with another man 
in the past 12 
months
N 601 Cote d'Ivoire Abidjan
23 25·2† NR 29·3% 12 months 2011 CS RDS FTFI NR NR NR NR 32·1%‖ 12 NR NR NR NR NR NR Y Recent test
Bakai 
201681
general NR NR 724 Togo 25 31·3† NR NR NR 2011 CS snowball FTFI NR NR NR 63.0% NR NR NR NR NR NR NR NR Y Ever test
Baral 
201582
general
anal sex with 
another man in 
the past 12 
months
N 707 Nigeria Abuja NR 25·0† 46·3%‖ NR NR 2014 cohort RDS FTFI NR 20·5% 12·8% 58·1% NR NR 28·3% 67·3% (ever 
CD4 test)
30·6% (HIV+ 
MSM)
Current NR NR Y
Recent test, 
HIV+ status 
awareness, 
engagement in 
care
Bouscaillou 
201683
PWID ever had sex 
with another man N
41 Cote 
d'Ivoire Abidjan
29 33·5 39·0%‖ 46·3% 12 months 2014 CS RDS FTFI NR NR NR NR 37·5% 12 NR NR NR NR NR NR Y Recent test
Charurat 
201584
general
anal sex with 
another man in 
the past 12 
months
N 393 Nigeria Abuja NR 28·2† 47·3% NR NR 2013 cohort RDS FTFI NR 37·5% 19·6% NR NR NR NR NR 31·2% (HIV+ MSM)
Current
80·4% (MSM 
currently on 
ART)
<200 copies 
per mL Y
Viral 
suppression
Drame 
201385
MSM 
organisations
anal sex with 
another man in 
the past 12 
months
N 119 Senegal Dakar NR 28.0 36.0% 50.0% ever 2012 cohort NR NR NR NR NR 88.0% NR NR 48·8% NR NR NR NR NR Y
Ever test, HIV+ 
status 
awareness
general 314 Cross River 22 27·3† NR 19.0% 6 months CS RDS FTFI NR NR NR 37·9%‖ NR NR NR NR NR NR NR NR
general 217 FCT 24 28·9† NR 43·1% 6 months CS RDS FTFI NR NR NR 47·3%‖ NR NR NR NR NR NR NR NR
general 275 Kaduna 25 28·9† NR 36.0% 6 months CS RDS FTFI NR NR NR 58·7%‖ NR NR NR NR NR NR NR NR
general 299 Kano 26 29·7† NR 64·8% 6 months CS RDS FTFI NR NR NR 70·9%‖ NR NR NR NR NR NR NR NR
general 220 Lagos 23 26·2† NR 39·7% 6 months CS RDS FTFI NR NR NR 59·5%‖ NR NR NR NR NR NR NR NR
general 233 Oyo 24 27·1† NR 28·7% 6 months CS RDS FTFI NR NR NR 46·3%‖ NR NR NR NR NR NR NR NR
anal sex with 
another man in 
the past 12 
months
N
NR NR
anal sex with 
another man in 
the past 6 
months
N
Stahlman 
201573
Stahlman 
201641
Eluwa 
201586
2010Nigeria
Zhang 
201840
Adam 
20097
anal sex with 
another man in 
the past 12 
months
N
ever anal sex 
with another man N
Y
South 
Africa
Ever test
Y ART useHIV+ MSM 2016
12
self-reported 
HIV-negative
65 Greater Accra NR 24·6 39·3%‖ NR NR CS RDS FTFI NR NR NR 84·6% 62·6%‖ 12 NR NR NR NR NR NR
self-reported 
HIV-negative
126 Ashanti 
Region
NR 25·9 23·0%‖ NR NR CS RDS FTFI NR NR NR 49·1% 28·9%‖ 12 NR NR NR NR NR NR
Goodman 
201688
general
anal sex with 
another man in 
the past 12 
months
N 672 Burkina Faso
Bobo 
Dioulasso, 
Ouagadougou
NR 28·4† 4·8% NR NR 2013 CS RDS FTFI 19·94% NR NR 75·5% NR NR NR NR NR NR NR NR Y Ever test
Hakim 
201589
general
anal or oral sex 
with another man 
in the past 12 
months
N 601 Cote d'Ivoire Abidjan
23 25·2† 18·0%‖ 29·3% 12 months 2011 CS RDS FTFI NR NR NR 62·6%‖ NR NR 13·6%‖ NR NR NR NR NR Y
Ever test, HIV+ 
status 
awareness
Hakim 
201790
general
anal or oral sex 
with another man 
in the past 6 
months
N 552 Mali Bamako NR 26·5† 13·7%‖ NR NR 2014 CS RDS FTFI NR NR NR NR NR NR 13·3%‖ NR NR NR NR NR Y HIV+ status awareness
6·3% (HIV+ 
MSM)
Current NR NR
20·0% (MSM 
aware of HIV+ 
status)
Current NR NR
25·0% (HIV+ 
MSM)
Current NR NR
80·0% (MSM 
aware of HIV+ 
status)
Current NR NR
0·0% (HIV+ 
MSM)
Current NR NR
0·0% (MSM 
aware of HIV+ 
status)
Current NR NR
6·2% (HIV+ 
MSM)
Current NR NR
40·0% (MSM 
aware of HIV+ 
status)
Current NR NR
53 Accra NR 26·6† NR NR NR CS snowball FTFI NR NR NR 88·7% NR NR NR NR NR NR NR NR
51 Kumasi NR 23·3† NR NR NR CS snowball FTFI NR NR NR 33·3% NR NR NR NR NR NR NR NR
33 Manya Krobo NR 26·1† NR NR NR CS snowball FTFI NR NR NR 87·9% NR NR NR NR NR NR NR NR
Lahuerta 
201893
general
anal or oral sex 
with another man 
in the past 6 
months
N 552 Mali Bamako NR 25·9† 13·7%‖ 14·1% 6 months 2014 CS RDS FTFI 18·1% 0·7% 8.0% 71·6%‖ 47·1%‖ 12 8·9%‖ NR NR NR NR NR Y Ever test, recent test
Lieber 
201894
general
ever anal or oral 
sex with another 
man
N 107 Liberia Monrovia NR 27·3 NR NR NR NR CS purposive FTFI NR NR NR 77·6% NR NR NR NR NR NR NR NR Y Ever test
11·0% (HIV+ 
MSM)
Ever
82·8% (MSM 
aware of HIV+ 
status)
Ever
10·0% (HIV+ 
MSM)
Current
75·9% (MSM 
aware of HIV+ 
status)
Current
Mason 
201396
general
anal sex with 
another man in 
the past 12 
months
N 207 The Gambia
20 22.0 9·8% NR NR 2011 CS snowball FTFI NR 15·3% 3·9% NR NR NR 5.0% NR NR NR NR NR Y HIV+ status awareness
general 293 Lagos 22 25·7† 17·4%‖ 25·5% 6 months CS RDS FTFI NR NR NR 40·9%‖ NR NR NR NR NR NR NR NR
general 293 Kano 22 26·6† 9·3%‖ 36·1% 6 months CS RDS FTFI NR NR NR 17·7%‖ NR NR NR NR NR NR NR NR
general 293 Cross River 22 24·4† 1·1%‖ 36.0% 6 months CS RDS FTFI NR NR NR 26·7%‖ NR NR NR NR NR NR NR NR
87.0% 12
64·1% 6
25.0% 3
NRNR
Nelson 
201598
2012Ghana
Accra, 
Kumasi, and 
Manya 
CS snowball SAQ
Holland 
201691
Burkina 
Faso
Togo
NR
0·6%
18·4%
Lyons 
201795
2014Senegal Dakar, Mbour, Thies
CS
NRNR NR NR
sexually active 
with another man 
in the past 6 
months
Y
anal sex with 
another man in 
the past 12 
months
N
anal or oral sex 
with another man 
in the past 12 
months
N
anal sex with 
another man in 
the past 12 
months
general
general
329
343
329
15·4%
NR
NR
NRCS
93·8%
RDS
NR
NR
CS
50.0%
86·2%
NR
NR
NR
31·3%
0.0%
75.0%NR
NR
Girault 
201587
2013Ghana
354
Bobo 
Dioulasso
Ouagadougou
Kara
Lome
N
NRNRRDS FTFICS
NR 26·0†
NR 25·7†
general
general
4·7%
4·9%
NR
NR
FTFI
Recent test
Y
Y
N
Y
HIV+ status 
awareness, 
ART use
HIV+ status 
awareness, 
ART use
NA
HIV+ status 
awareness, 
ART use
2013
2013
Y
Ever testY2012Ghanageneral
Kushwaha 
201792
FTFI23·5%‖ NR
Y
NRNR
NR NR NR
NR
NR NR
RDS
RDS
NR
NR
NR
NR
RDS/
purposive
Y Ever test, recent test
Y Ever test
<1000 copies 
per mL
NR
NR
NR
HIV+ status 
awareness, 
engagement in 
care, ART use, 
viral 
suppression
Merrigan 
201197
2007Nigeria
NR NR137general NR NR 68·9% NR NR NRNR
63·6% (MSM 
currently on 
ART)
NR NR NR
NR
NR
general NR
FTFI
FTFI
NR
NR
31·3%NR NRNR
NR
13·2% 58·6% (ever 
CD4 test)
NR
724
NR
NR
CS
anal sex with 
another man in 
the past 6 
months
N
sexually active 
with another man 
in the past 6 
N
13
Nowak 
201699
general
anal sex with 
another man in 
the past 12 
months
N 154 Nigeria Abuja 25 25·8† 58·4% NR NR 2013 cohort RDS FTFI NR NR NR NR NR NR NR NR 43·3% (HIV+ MSM)
Current NR NR N NA
Nowak 
2017100
NR NR N 130 Nigeria Abuja NR NR 57·7% NR NR 2013 cohort RDS FTFI NR NR NR NR NR NR NR NR 45·3% (HIV+ MSM)
Current NR NR N NA
36·7% (HIV+ 
MSM)
<1000 copies 
per mL
88·0% (MSM 
currently on 
ART)
<1000 copies 
per mL
Ogunbajo 
2017102
general
ever anal or oral 
sex with another 
man
N 30 Ghana Accra NR 29·07 NR NR NR 2015 CS convenience FTFI NR NR NR NR NR NR NR
70·0% 
(engaged in 
care at start 
of study)
NR NR NR NR Y Engagement in care
Ramadhani 
2017103
general NR N 492 Nigeria 24 26·6† 57·3% NR NR 2014 cohort RDS FTFI NR NR NR NR NR NR 69·1% NR NR NR NR NR N NA
Ramadhani 
2018104
general
anal sex with 
another man in 
the past 12 
months
N 1506 Nigeria Abuja, Lagos 24 27·4† 31·3% NR NR 2015 cohort RDS FTFI 24·2% 13.0% NR 64·5% NR NR NR NR NR NR NR NR N NA
Rodriguez-
Hart 
2016105
general
anal sex with 
another man in 
the past 12 
months
N 433 Nigeria Abuja NR 24·7 41·4%‖ NR NR 2014 cohort RDS FTFI NR NR NR NR NR NR 47.0% NR NR NR NR NR N NA
Rodriguez-
Hart 
2018106
general
anal sex with 
another man in 
the past 12 
months
N 1480 Nigeria NR 28·4† NR NR NR 2014 cohort RDS FTFI NR NR NR 68·8% NR NR NR NR NR NR NR NR Y Ever test
Ruiseñor-
Escudero 
2017107
general
anal sex with 
another man in 
the past 12 
months
N 354 Togo Lome 22 26·1† 9·2%‖ NR NR 2013 CS RDS FTFI 15·8% NR 24.0% 62·1%‖ NR NR NR NR 6·6% (HIV+ MSM)
Current NR NR Y Ever test
Schwartz 
2015108
general
anal sex with 
another man in 
the past 12 
months
N 707 Nigeria Abuja NR 25·1† 49·0%‖ NR NR 2014 cohort RDS FTFI NR 20·5% NR 58·1% NR NR NR NR 31·3% (HIV+ MSM)
Current 19·3% (HIV+ 
MSM)
<50 copies 
per mL Y
ART use, viral 
suppression
Sheehy 
2013109
general
anal or oral sex 
with another man 
in the past 12 
months
N 712 Nigeria Abuja, Lagos and Ibadan
23 25·4† 22·1% 60·5% 6 months 2010 CS RDS FTFI NR NR NR 56·2% NR NR NR NR NR NR NR NR N NA
Stahlman 
2016110
general
anal sex with 
another man in 
the past 12 
months
N 1555
The 
Gambia, 
Burkina 
Faso, Togo
Kara, Lome, 
Ouagadougou
, Bobo-
Dioulasso, 
The Gambia
NR 23.0 7·7% NR NR 2012 CS RDS/
snowball
FTFI NR NR NR NR NR NR 23·5% NR NR NR NR NR N NA
Stahlman 
2016111
general
anal sex with 
another man in 
the past 12 
months
N 1370 Nigeria NR 26·6† 34·9% NR NR 2014 cohort RDS FTFI 23·5% NR NR NR NR NR 94·9% NR
56·4% (MSM 
aware of HIV+ 
status)
Current
33·8% (Aware 
of HIV+ 
status)
<200 copies 
per mL Y
ART use, viral 
suppression
Stromdahl 
2012112
general ever anal sex 
with another man N
297 Nigeria Abuja 26·1 26.0 NR 61·7% ever 2008 CS convenience FTFI NR 28·3% NR 65·2% NR NR NR NR NR NR NR NR Y Ever test
Teclessou 
2017113
general
men who openly 
stated having 
had sex with 
other men
Y 491 Togo 23 25·7† 13.0% NR NR 2015 CS RDS FTFI NR 34·3% NR 68.0% NR NR NR NR NR NR NR NR Y Ever test
Tobin-West 
2017114
general
anal or oral sex 
with another man 
in the past 12 
months
N 101 Nigeria Port Harcourt NR 25·4 NR 45·5% ever 2014 CS purposive SAQ NR NR NR 69·3% 44·6% 6 NR NR NR NR NR NR Y Ever test, recent test
46·1% 12
17·6% 6
Nowak 
2018101
general 113 FTFI NR NR NR
Ever test, recent 
testYNRNR
NRNRNRsnowballcohort NR82·1%NRNRNRFTFI
Tun 
2018115
general 319 Nigeria 2017NRNR5·6%25.0NRLagos
NR 41·7% (HIV+ 
MSM)
CurrentNR NR NR NR NRNigeria Abuja NR 26·9† 53·1% NR 2013 cohort RDS NANR NR
anal sex with 
another man in 
the past 6 
months
N
N
14
general 194 Abuja 25 26·7† 34·9%‖ 43·3% 6 months CS RDS ACASI/FTFI
NR NR NR 55·8%‖ NR NR NR NR NR NR NR NR
general 210 Ibadan 23 25·5† 11·3%‖ 48·1% 6 months CS RDS ACASI/FTFI
NR NR NR 31·8%‖ NR NR NR NR NR NR NR NR
general 308 Lagos 21 22·9† 15·2%‖ 55·5% 6 months CS RDS ACASI/FTFI
NR NR NR 38·3%‖ NR NR NR NR NR NR NR NR
general 194 Abuja NR 26·7† 34·9%‖ 43·3% 6 months CS RDS ACASI/FTFI
NR NR NR 55·8%‖ NR NR NR NR NR NR NR NR
general 210 Ibadan NR 25·5† 11·3%‖ 48·1% 6 months CS RDS ACASI/FTFI
NR NR NR 31·8%‖ NR NR NR NR NR NR NR NR
general 308 Lagos NR 22·9† 15·2%‖ 55·5% 6 months CS RDS ACASI/FTFI
NR NR NR 38·3%‖ NR NR NR NR NR NR NR NR
Wade 
2005118
general ever had sex 
with another man N
463 Senegal 24 26·7† 21·5% 22·5% 1 month 2004 CS snowball FTFI NR NR NR 10·8% NR NR NR NR NR NR NR NR Y Ever test
Herce 
201819
general
anal sex with 
another man in 
the past 6 
months
Y 832 Angola, 
Malawi
Zomba, 
Benguela, 
Luanda
NR NR 2·7% NR NR 2017 CS time-venue FTFI NR NR NR 47·4% 19·8% 6 18·2% NR NR NR NR NR Y Recent test
Poteat 
2017119
general
anal sex with 
another man in 
the past 12 
months
Y 3649
Burkina 
Faso, Cote 
d'Ivoire, 
The 
Gambai, 
Lesotho, 
Malawi, 
Senegal, 
Swaziland, 
Togo
NR 24.0 13·8% NR NR 2013 CS RDS/
snowball
FTFI NR NR NR 74·6% 44·3% 12 24·6% NR NR NR NR NR N NA
28·4% (HIV+ 
MSM)
17·5% (MSM 
currently on 
ART)
Proportions in bold were self-calculated from reported numerators and denominators·
† mean age estimated from stratified age groups as the information was not reported in the article·
‡ midpoint between study start and finish·
§ in analysis chain-referral sampling and snowball sampling were grouped together as 'snowball sampling' , convenience and purposive sampling methods were grouped as "convenience/purposive",  RDS/snowball and snowball/time-venue were grouped as "mixed", and time-venue and cluster were grouped as cluster/time-venue·
¶ ACASI, CASI, SAQ and PBS grouped as "confidential" methods for the analysis, and ACASI/FTFI as "mixed"
‖ RDS-weighted estimate
Vu 
2013117
2010Nigeria
Vu 
2013116
2010Nigeria
ACASI, audio computer-assisted self-interview; ART, anti-retroviral therapy; CASI, computer-assisted self-interview; CS, cross-sectional; FTFI, face-to-face interview; MSM, men-who-have-sex-with-men; MSW, male sex workers; NR, not reported; PBS, polling booth survey; PWID, people who inject drugs; RDS, respondent driven sampling; SAQ, self-administered questionnaire; SW, sex work
* general MSM include MSM recruited from the general population of MSM· Gay/bisexual-identifying MSM were also classed as general-risk in the analysis· High-risk MSM includes MSW, PWID, MSM recruited from drinking venues and STI clinics, and MSM identified as high-risk by study authors· MSM that were non-PWID or self-reported HIV-negative were classed as low-risk/general MSM· MSM 
recruited from MSM organisations or from HIV prevention activities for MSM, were grouped as MSM organsations· 
NR
Kenya, 
Malawi, 
South 
Africa
Kisumu, 
Blantyre, 
Cape Town, 
Soweto
NR 28·0† NR NR NR NR NR NR 34·4% (HIV+ 
MSM)
Current <400 copies 
per mL Y
Viral 
suppression
NR 2016 cohort snowball CASI NR NR NR
Y Ever test
N NA
Zhang 
201845
HIV+ MSM 183
anal or oral sex 
with another man 
in the past 12 
months
N
Never anal sex 
with another man
anal or oral sex 
with another man 
in the past 12 
months
N
Multiple Regions
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ARRESTS
Boussa 201846
Central African 
Republic NR
Same-sex relations legal since 
independence from France in 
1961
4 0 0 0 0 0 0 1 1 2 1 1 2 0 0 0 0 0 0 NO
Herce 201819 2017 7 1 0 0 1 0 2 1 1 2 1 1 2 1 0 0 0 0 1 NO
Kendall 201448 2011 7 1 0 0 1 0 2 1 1 2 1 1 2 1 0 0 0 0 1 NO
Rao 201750 2015 8 1 0 0 1 0 2 1 1 2 1 1 2 0 2 0 0 0 2 YES
Rao 201750 2013 8 1 0 0 1 0 2 1 1 2 1 1 2 0 2 0 0 0 2 YES
Holland 201547, Park 201451 2011 8 1 0 0 1 0 2 1 1 2 1 1 2 0 2 0 0 0 2 YES
Lorente 201249 2008 8 1 0 0 1 0 2 1 1 2 1 1 2 0 2 0 0 0 2 YES
Chapman 201113 Rwanda 2009
Same-sex relations legalised 
1980 5 0 0 0 1 0 1 1 1 2 1 1 2 0 0 0 0 0 0 NO
Horth 201522 Mozambique 2011
Same-sex relations legalised 
2012 (enforced 2015)
NGO ban removed 1991
Anti-Discrimination legislation 
passed 2007
6 1 1 0 1 0 2 0 1 1 1 1 2 1 0 0 0 0 1 NO
Kunzweiler 201726, Fogel 
201817, Zhang 201845
2016 8 1 0 0 1 0 2 1 1 2 1 1 2 0 2 0 0 0 2 YES
Shangani 201740 2014 8 1 0 0 1 0 2 1 1 2 1 1 2 0 2 0 0 0 2 YES
Bhattacharjee 201512, Musyoki 
201832
2013 8 1 0 0 1 0 2 1 1 2 1 1 2 0 2 0 0 0 2 YES
McKinnon 201328, Muraguri 
201531
2010 8 1 0 0 1 0 2 1 1 2 1 1 2 0 2 0 0 0 2 YES
Graham 201318, Luchters 
201127, Moller 201530
2008 8 1 0 0 1 0 2 1 1 2 1 1 2 0 2 0 0 0 2 YES
Sanders 200738 2006 8 1 0 0 1 0 2 1 1 2 1 1 2 0 2 0 0 0 2 YES
Adam 20097 Mauritius 2004
Same-sex relations illegal 
since 1838
Anti-Discrimination legislation 
passed 2008
8 1 0 0 1 0 2 1 1 2 1 1 2 0 2 0 0 0 2 NO
Coulaud 201614 Burundi 2014
Same-sex relations illegal 
since 2009
Same-sex marriage ban 2005
9 1 0 0 1 1 3 1 1 2 1 1 2 0 2 0 0 0 2 NO
LACK OF PROGRESSIVE 
(1 point for each if true, max 2 
points)
Arrests in 
last 3 yrs
Fines/ 
community 
service 
(1 point)
Prison <20 
years 
(2 points)
Prison ≥20 
years 
(3 points)
Corporal 
Punishment 
(4 points)
Death 
penalty 
(5 points)  Total
Absence of anti-
discrimination 
Laws 
Absence of 
recognition 
of incitement 
to hatred  Total
Global score 
(max 14 
points)
Angola
Study Reference Country
Study 
midpoint 
year Years of legislation change
PENALTIES 
(only one of the five penalties can apply at once, with score in red next 
to the penalty, max 5 points)
Homo-
sexuality 
illegal
LGBT-
friendly 
NGO 
ban
 Gay 
promotion/ 
propaganda 
ban
Unequal 
age of 
consent
Laws 
prohibiting 
same sex 
rights (SSM 
or SSA)  Total 
Absence of 
laws 
permitting 
SSM 
Absence of 
laws 
permitting 
SSA Total
REPRESSIVE 
(1 point for each if true, max 5 points)
LACK OF PROTECTIVE 
(1 point for each if true, max 2 points)
EASTERN AFRICA
CENTRAL AFRICA
Cameroon Same-sex relations illegal since 1965
Same-sex relations Illegal 
since 1886
Kenya Same-sex relations illegal since 1897
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Table S4. Anti-LGBT legislation index. Each study was scored on 4 quantitative areas of anti-LGBT legislation (repressive, lack of protective, lack of progressive, and penalties) and a single binary variable of 
arrests in the last 3 years (2014-2017), with scores differing between countries, over time, and within countries where a law change occurred between the end of one study and start of another. The studies are 
ordered by global score on the index within each region of Africa.
Hladik 201721, Wanyenze 
201642
2013 10 1 0 0 1 1 3 1 1 2 1 1 2 0 0 3 0 0 3 YES
Hladik 201220 2008 10 1 0 0 1 1 3 1 1 2 1 1 2 0 0 3 0 0 3 YES
Kajubi 200824, Raymond 
200935
2004 9 1 0 0 1 0 2 1 1 2 1 1 2 0 0 3 0 0 3 YES
Herce 201819 2017 11 1 1 0 1 0 3 1 1 2 1 1 2 0 0 0 4 0 4 YES
Fogel 201817, Zhang 201845 2016 11 1 1 0 1 0 3 1 1 2 1 1 2 0 0 0 4 0 4 YES
Wirtz 201744 2014 11 1 1 0 1 0 3 1 1 2 1 1 2 0 0 0 4 0 4 YES
Wirtz 201343 2011 11 1 1 0 1 0 3 1 1 2 1 1 2 0 0 0 4 0 4 YES
Baral 200910, Fay 201116 2008 11 1 1 0 1 0 3 1 1 2 1 1 2 0 0 0 4 0 4 YES
Ntata 200833 2006 11 1 1 0 1 0 3 1 1 2 1 1 2 0 0 0 4 0 4 YES
Mmbaga 201829 2014 11 1 1 1 1 0 4 1 1 2 1 1 2 0 0 3 0 0 3 YES
Rominjinders 201636, Ross 
201437
2012 11 1 1 1 1 0 4 1 1 2 1 1 2 0 0 3 0 0 3 YES
Khatib 201725 2011 11 1 1 1 1 0 4 1 1 2 1 1 2 0 0 3 0 0 3 YES
Khatib 201725 2007 11 1 1 1 1 0 4 1 1 2 1 1 2 0 0 3 0 0 3 YES
Nyoni 201234 NR 11 1 1 1 1 0 4 1 1 2 1 1 2 0 0 3 0 0 3 YES
Elmahy 201852 Egypt 2016
Same-sex relations not 
explicitly illegal, but this is just 
a technical distinction as same-
sex relations, and related 
expression, have been 
criminalised under 
debauchery, indecency and 
other public-morality 
legislation since 1937
9 1 1 1 0 0 3 1 1 2 1 1 2 0 2 0 0 0 2 YES
Valadez 201353 Libya 2010
Same-sex relations illegal 
since 1953 (amended 1976) 10 1 1 1 1 0 4 1 1 2 1 1 2 0 2 0 0 0 2 YES
Fogel 201817, Zhang 201845 2016 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 NO
Lippman 201868 2015 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 NO
Siegler 201572, Lane 201467, 
Batist 201358, Rebe 201569
2012 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 NO
Wagenaar 201277, Eaton 201361 2010 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 NO
Tun 201276 2009 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 NO
Knox 201163, Lane 201166 2008 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 NO
Sandfort 200871, Lane 200865 2004 2 0 0 0 1 0 1 0 0 0 1 0 1 0 0 0 0 0 0 NO
Stahlman 2015a73, Stahlman 
2015b74
2014 4 0 0 0 0 0 0 1 1 2 1 1 2 0 0 0 0 0 0 NO
Baral 200910, Fay 201116 2009 5 1 0 0 1 0 1 1 1 2 1 1 2 0 0 0 0 0 0 NO
Baral 200910, Fay 201116 Namibia 2008
Same-sex relations illegal 
since 1920
Anti-Discrimination laws 
passed in 1992 but redacted 
2007 (sexual orientation was 
removed from the 2007 
Labour Act")
6 1 0 0 1 0 2 1 1 2 1 1 2 0 0 0 0 0 0 NO
Tanzania 
Same-sex relations illegal 
since 1899 (1864 in Zanzibar)
Gay promotion Ban since 
1981
South Africa
Lesotho Same-sex relations legalised 2010 (enforced 2012)
Same-sex relations legalised 
1998 
Anti-discrimation legislation 
passed 1998
Same-sex adoption legalised 
2002
Same-sex marriage legalised 
2006
Age of consent for 
heterosexual and homosexual 
sex equalised 2007
NORTHERN AFRICA
SOUTHERN AFRICA
Malawi Same-sex relations since 1891NGO ban passed 2000 
Uganda
Same-sex relations illegal 
since 1894
Same-sex marriage banned 
2005
NGO ban passed 2016
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Baral 200910, Fay 201116 Botswana 2008
Same-sex relations illegal 
since 1886
Anti-Discrimination legislation 
passed 2010
8 1 0 0 1 0 2 1 1 2 1 1 2 0 2 0 0 0 2 NO
Rao 201750 2014 8 1 0 0 1 0 2 1 1 2 1 1 2 0 2 0 0 0 2 YES
Grover 201662 2011 8 1 0 0 1 0 2 1 1 2 1 1 2 0 2 0 0 0 2 YES
Goodman 201688, Holland 
201691
Burkina Faso 2013
Same-sex relations were never 
illegal
Same sex marriage ban 2011
4 0 0 0 0 0 0 1 1 2 1 1 2 0 0 0 0 0 0 NO
Hakim 201790, Lahuerta 201894 Mali 2014
Same-sex relations were never 
illegal
Same-sex adoption ban in 
2011
4 0 0 0 0 0 0 1 1 2 1 1 2 0 0 0 0 0 0 NO
Bouscaillou 201683 2014 5 0 0 0 1 0 1 1 1 2 1 1 2 0 0 0 0 0 0 NO
Hakim 201589, Aho 201480 2011 5 0 0 0 1 0 1 1 1 2 1 1 2 0 0 0 0 0 0 NO
Ogunbajo 2017102 2015 8 1 0 0 1 0 2 1 1 2 1 1 2 0 2 0 0 0 2 NO
Girault 201587 2013 8 1 0 0 1 0 2 1 1 2 1 1 2 0 2 0 0 0 2 NO
Kushwaha 201792, Nelson 
201598
2012 8 1 0 0 1 0 2 1 1 2 1 1 2 0 2 0 0 0 2 NO
Mason 201396 Gambia 2011
Same-sex relations illegal 
since 1888 8 1 0 0 1 0 2 1 1 2 1 1 2 0 2 0 0 0 2 YES
Lieber 201894 Liberia NR
Same-sex relations illegal 
since 1978 8 1 0 0 1 0 2 1 1 2 1 1 2 0 2 0 0 0 2 NO
Lyons 201795 2014 8 1 0 0 1 0 2 1 1 2 1 1 2 0 2 0 0 0 2 YES
Drame 201385 2012 8 1 0 0 1 0 2 1 1 2 1 1 2 0 2 0 0 0 2 YES
Wade 2005118 2004 8 1 0 0 1 0 2 1 1 2 1 1 2 0 2 0 0 0 2 YES
Teclessou 2017113 2015 8 1 0 0 1 0 2 1 1 2 1 1 2 0 2 0 0 0 2 NO
Holland 201691, Ruisenor-
Escudero 2017107
2013 8 1 0 0 1 0 2 1 1 2 1 1 2 0 2 0 0 0 2 NO
Tun 2018115 2017 11 1 1 1 1 1 5 1 1 2 1 1 2 0 2 0 0 0 2 YES
Stahlman 2016c111, Baral 
201582, Tobin-West 2017114
2014 11 1 1 1 1 1 5 1 1 2 1 1 2 0 2 0 0 0 2 YES
Eluwa 201586, Adebajo 201479 2010 7 1 0 0 1 0 1 1 1 2 1 1 2 0 2 0 0 0 2 YES
Stromdahl 2012112 2008 7 1 0 0 1 0 1 1 1 2 1 1 2 0 2 0 0 0 2 YES
Merrigan 201197, Adam 20097
2007 7 1 0 0 1 0 1 1 1 2 1 1 2 0 2 0 0 0 2 YES
Eluwa 201586 2010 11 1 0 0 1 0 2 1 1 2 1 1 2 0 0 0 0 5 5 YES
Merrigan 201197 2007 11 1 0 0 1 0 2 1 1 2 1 1 2 0 0 0 0 5 5 YES
Adam 20097 Mauritania 2006
Same-sex relations illegal 
since 1983 12 1 1 0 1 0 3 1 1 2 1 1 2 0 0 0 0 5 5 YES
NGO, non-governmental organisation; SSA, same-sex adoption; SSM, same-sex marriage
Nigeria 
(Northern 
States - Kano, 
Kaduna)
As above +  Sharia law 
adopted Kano 2000, Kaduna 
2001
Senegal Same-sex relations illegal since 1965
WESTERN AFRICA
Nigeria
Same-sex relations illegal 
since 1901
Same-sex marriage ban, gay 
promotion ban & NGO ban 
2013 
Togo Same-sex relations illegal since 1884
Cote d'Ivoire Same-sex relations were never illegal
eSwatini Same-sex relations illegal since 1907
Ghana Same-sex relations illegal since 1860
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Figure S2. Map of Africa. The 28 countries where the 75 included studies were conducted are shown, with the number of unique 
studies (Ns) conducted in each country and UN region, including Central (Ns=7), Eastern (Ns=26), Northern (Ns=2), Southern 
(Ns=19) and Western (Ns=23) Africa. Fifty-five studies were conducted in 21 different countries where same-sex sexual relations 
were illegal (red) at study midpoint and 21 studies in 8 countries where legal (blue). There were no studies in 26 countries, 13 
where same-sex sexual relations are illegal. In Lesotho one study was conducted before a change in legislation decriminalising 
same-sex sexual relations and one after. * in Egypt same-sex relations are not explicitly illegal, but are treated as such in our 
analysis as LGBT persons have been liberally criminalised under public morality legislation in recent years and face up to 5 years 
in prison.1  
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Table S5. Table of pooled estimates. 95% prediction intervals (PrI) are provided in addition to 95% confidence intervals (CI). 
Cascade outcome Ne Pooled estimate (%) 95% CI 95% PrI I
2 
HIV testing (among all MSM) 132     
Ever 81 61·0 56·2 – 65·7 20·2 – 94·3 98% 
Recently 51     
past 12 months 39 46·2 39·6 – 52·9 10·9 – 83·8 97% 
past 6 months 8 38·8 26·0 – 52·4 6·1 – 78·6 96% 
past 3 months 4 44·9 11·3 – 81·3 0·0 – 100·0 99% 
HIV+ aware 35     
Among MSM living with HIV 35 18·2 13·0 – 23·9 0·0 – 53·4 91% 
Engagement in Care (among MSM living with HIV) 6     
Ever* 2 33·7 0·0 – 92·5 0·0 – 100·0 99% 
Current† 2 40·4 0·9 – 91·0 0·0 – 100·0 97% 
Linked within 30 days of diagnosis 2 15·3 9·3 – 22·3 8·1 – 24·1 26% 
ART use 29     
Among MSM living with HIV 20     
Ever 6 2·0 0·0 – 6.9 0·0 – 18·3 91% 
Current 14 23·9 15·7 – 33·1 1·6 – 59·1 90% 
Among MSM HIV+ aware 9     
Ever 3 37·3 0·0 – 90·3 0·0 – 100·0 94% 
Current 6 53·4 36·9 – 69·5 16·6 – 88·4 86% 
Viral suppression 11     
Among MSM living with HIV 4 24·7 18·8 – 31·2 15·1 – 35·8 49% 
Among MSM HIV+ aware 3 34·4 28·3 – 40·7 28·3 – 40·8 0% 
Among MSM currently on ART 4 75·6 64·4 – 85·5 56·5 – 90·9 45% 
ART, antiretroviral therapy; CI, confidence interval; HIV, human immunodeficiency virus; MSM, men who have sex with men; Ne, number of estimates; PrI, 
prediction interval 
 
HIV status of MSM living with HIV and MSM HIV+ aware was confirmed in the studies with an HIV test. 
 
* includes ever received a CD4 test 
† includes currently using cotrimoxazole and engaged in care at the start of the study 
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Table S6. Ever tested. Results of univariate meta-regression and bivariate (adjusted for study year (continuous variable)) meta-
regression analyses of the association between participant characteristics, stigma, and anti-LGBT legislation with the proportion 
of MSM ever tested for HIV (Ne=81). 
 
 
 
Number of 
estimates 
Ne 
Pooled 
estimate 
(%) or 
slope* 95% CI 
Univariate Bivariate (time-adjusted)†**  
Variance 
explained 
R2 p-value 
Variance 
explained R2 
(variable only) 
Variance 
explained R2 
(variable+time) p-value 
a. Participant Characteristics 
Population (missing=1)    0% 0·088 0% 10% 0·10 
General MSM 72 59·5 54·3 – 64·6 - - - - - 
High-risk MSM‡ 4 65·9 46·1 – 83·3 - - - - - 
Low risk/general MSM§ 2 67·7 30·8 – 95·2 - - - - - 
MSM organisations¶ 2 91·8 82·7 – 97·8 - - - - - 
Region of Africa    0% 0·14 21% 29% 0·0011 
Central 6 60·7 43·5 – 76·6 - - - - - 
Eastern 30 58·6 50·1 – 67·0 - - - - - 
Northern 1 34·5 30·2 – 38·9 - - - - - 
Southern 14 72·6 65·3 – 79·3 - - - - - 
Western 30 58·3 50·0 – 66·5 - - - - - 
Mean age (missing=12) 69 0·005 -0·02 – 0·03 0% 0·70 0% 16% 0·31 
HIV Prevalence (missing=31) 50 0·67 0·17 – 1·16 8% 0·0087 25% 48% <0·0001 
Proportion ever sold sex (missing=66) 4% 0·41 8% 38% 0·13 
≤ 37% 7 66·8 50·6 – 81·2 - - - - - 
> 37% 8 59·0 47·2 – 70·2 - - - - - 
Proportion recently sold sex (missing=57)||  0% 0·92 0% 78% 0·94 
≤ 40% 12 52·2 40·7 – 63·5 - - - - - 
> 40% 12 51·0 33·0 – 68·9 - - - - - 
b. Stigma Variables         
Proportion disclosed MSM status to HCW (missing=63) 0% 0·069 82% 79% <0·0001 
≤ 21% 5 58·9 46·1 – 71·2 - - - - - 
> 21% 4 76·7 60·4 – 89·8 - - - - - 
Proportion disclosed MSM status to family (missing=71) 0% 0·50 0% 0% 0·50 
≤ 20% 5 67·5 51·8 – 81·4 - - - - - 
> 20% 6 60·0 43·7 – 75·2 - - - - - 
Proportion blackmailed because MSM (missing=71) 0% 0·89 0% 0% 0·35 
≤ 20% 5 63·3 50·2 – 75·4 - - - - - 
> 20% 5 64·4 54·6 – 73·7 - - - - - 
c. Anti-LGBT Legislation Variables        
Repressive    0% 0·14 0% 9% 0·082 
0 10 73·8 63·1 – 83·3 - - - - - 
1 16 52·3 42·3 – 62·2 - - - - - 
2 32 62·5 53·8 – 70·7 - - - - - 
3 – 5 23 59·0 50·4 – 67·3 - - - - - 
Lack of Protective    0% 0·033 10% 19% 0·0015 
0 11 73·2 63·9 – 81·5 - - - - - 
1 – 2 70 58·9 53·5 – 64·1 - - - - - 
Lack of Progressive    0% 0·038 1% 11% 0·016 
0 9 74·4 61·5 – 85·5 - - - - - 
1 – 2 72 59·2 54·1 – 64·2 - - - - - 
Penalties    3% 0·026 12% 21% 0·0010 
0 17 70·9 65·0 – 76·4 - - - - - 
1 6 49·9 40·5 – 59·3 - - - - - 
2 36 62·1 53·4 – 70·3 - - - - - 
3 – 5 22 53·8 44·8 – 62·6 - - - - - 
Arrests    0% 0·0089 0% 8% 0·020 
Yes 47 55·4 47·7 – 62·9 - - - - - 
No 34 67·9 63·1 – 72·6 - - - - - 
Global score    0% 0·064 8% 17% 0·0056 
≤ 5 16 71·6 65·5 – 77·3 - - - - - 
6 – 8 38 58·7 50·5 – 66·6 - - - - - 
≥ 9 27 57·4 49·4 – 65·1 - - - - - 
Continuous 81 -0·01 -0·03 – 0·00 0% 0·038 7% 16% 0·0026 
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Table S6 continued… 
 
 
Number of 
estimates 
Ne 
Pooled 
estimate 
(%) or 
slope* 95% CI 
Univariate Bivariate (time-adjusted)†**  
Variance 
explained 
R2 p-value 
Variance 
explained R2 
(variable only) 
Variance 
explained R2 
(variable+time) p-value 
d. Study characteristics         
Study year (midpoint) (missing=2)   8% 0·0020 - - - 
2011 onwards 44 67·3 62·1 – 72·4 - - - - - 
Pre-2011 35 52·5 44·2 – 60·8 - - - - - 
Continuous 79 0·02 0·01 – 0·04 10% 0·0025 - - - 
Sampling method (missing=2)    5% 0·033 4% 13% 0·0052 
RDS (weighted) 32 51·1 43·4 – 58·7 - - - - - 
RDS (unweighted) 14 63·5 57·6 – 69·1 - - - - - 
Cluster/time-venue (unweighted) 5 64·4 37·9 – 86·9 - - - - - 
Snowball 14 67·9 51·8 – 82·2 - - - - - 
Convenience/purposive 12 67·9 55·4 – 79·2 - - - - - 
Mix 4 76·5 61·2 – 89·0 - - - - - 
CI, confidence interval; HCW, health care worker; LGBT, lesbian, gay, bisexual and transgender; MSM, men who have sex with men; MSW, male sex worker; 
PWID, people who inject drugs; RDS, respondent driven sampling; STI, sexually transmitted infection. Continues variables were dichotomised at the median value. 
p-values in bold were significant at the 0·05 level 
* pooled estimate given for categorical variables and slope given for continuous variables 
† two estimates missing from bivariate analysis for not reporting study year 
‡ high-risk MSM includes MSW, PWID, MSM recruited from drinking venues and STI clinics, and MSM identified as high-risk by study authors  
§ low-risk includes non-PWID and MSM self-reported to be HIV-negative 
¶ MSM organisations includes MSM recruited from MSM/LGBT organisations/prevention activities 
|| recently sold sex includes in the past 12, 6, or 3 months 
** adjusted for time (continuous variable) and the relevant participant/study characteristic, or stigma/anti-LGBT legislation variable 
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Table S7. Tested in the past 12 months. Results of univariate and bivariate (adjusted for study year (continuous variables)) meta-
regression analyses of the association of participant characteristics, stigma, and anti-LGBT legislation with the proportion of MSM 
tested for HIV in the past 12 months (Ne=39). 
 
 
Number of 
estimates 
Ne 
Pooled 
estimate (%) 
or slope* 95% CI 
Univariate Bivariate (time-adjusted) || 
 
Variance 
explained R2 p-value 
Variance 
explained R2 
(variable only) 
Variance 
explained R2 
(variable+time) p-value 
a. Participant Characteristics 
Population (missing=2)    0% 0·27 0% 18% 0·29 
General MSM 32 46·9 39·6 – 54·2 - - - - - 
High-risk MSM† 2 47·1 32·1 – 62·4 - - - - - 
Low risk‡ 2 45·3 15·1 – 77·4 - - - - - 
MSM organisations§ 1 86·2 75·2 – 94·4 - - - - - 
Region of Africa    0% 0·061 1% 23% 0·040 
Central 5 59·7 34·4 – 82·7 - - - - - 
Eastern 17 37·1 26·9 – 47·8 - - - - - 
Northern 1 45·6 38·2 – 53·1 - - - - - 
Southern 7 61·2 48·8 – 72·9 - - - - - 
Western 9 43·4 32·3 – 54·9 - - - - - 
Mean age (missing=6) 33 0·01 -0·02 – 0·04 0% 0·58 0% 20% 0·58 
HIV Prevalence (missing=12) 27 0·32 -0·18 – 0·81 2% 0·21 3% 15% 0·26 
Proportion ever sold sex (missing=37) - - - - - 
≤ 31% 1 54·5 48·0 – 60·9 - - - - - 
> 31% 1 71·1 63·4 – 78·2 - - - - - 
Proportion recently sold sex (missing=27)¶  0% 0·25 7% 41% 0·15 
≤ 34% 6 43·4 33·9 – 53·2 - - - - - 
> 34% 6 33·3 19·5 – 48·7 - - - - - 
b· Stigma Variables         
Proportion disclosed MSM status to HCW (missing=33)  0% 0·22 23% 8% 0·034 
≤ 21% 3 47·3 25·1 – 70·2 - - - - - 
> 21% 3 67·4 44·8 – 86·5 - - - - - 
Proportion disclosed MSM status to family (missing=32)  0% 0·48 0% 0% 0·64 
≤ 45% 4 54·8 31·0 – 77·5 - - - - - 
> 45% 3 68·1 38·2 – 91·7 - - - - - 
Proportion blackmailed because MSM (missing=34)  78% 0·0014 73% 59% 0·015 
≤ 37% 3 51·2 45·6 – 56·8 - - - - - 
> 37% 2 81·0 60·8 – 95·2 - - - - - 
c· Anti-LGBT Legislation Variables        
Repressive    0% 0·076 0% 22% 0·023 
0 4 55·9 42·8 – 68·6 - - - - - 
1 5 40·0 30·0 – 50·5 - - - - - 
2 16 54·3 43·1 – 65·2 - - - - - 
3 – 5 14 35·5 22·9 – 49·2 - - - - - 
Lack of Protective    0% 0·31 0% 19% 0·43 
0 4 55·9 42·8 – 68·6 - - - - - 
1 – 2 35 45·0 37·7 – 52·3 - - - - - 
Lack of Progressive    0% 0·31 0% 19% 0·43 
0 4 55·9 42·8 – 68·6 - - - - - 
1 – 2 35 45·0 37·7 – 52·3 - - - - - 
Penalties    4% 0·0014 10% 29% 0·00024 
0 8 49·3 41·0 – 57·5 - - - - - 
1 4 33·5 27·6 – 39·6 - - - - - 
2 16 59·1 47·8 – 70·1 - - - - - 
3 – 5 11 28·7 14·3 – 45·6 - - - - - 
Arrests    0% 0·69 0% 19% 0·59 
Yes 22 44·7 34·6 – 55·1 - - - - - 
No 17 47·6 39·7 – 55·6 - - - - - 
Global score    0% 0·086 5% 25% 0·010 
≤ 5 8 49·3 41·0 – 57·5 - - - - - 
6 – 8 17 52·7 42·0 – 63·3 - - - - - 
≥ 9 14 35·5 22·9 – 49·2 - - - - - 
Continuous 39 -0·02 -0·04 – 0·002 0% 0·11 0% 21% 0·078 
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Table S7 continued… 
 
 
Number of 
estimates 
Ne 
Pooled 
estimate (%) 
or slope* 95% CI 
Univariate Bivariate (time-adjusted) || 
 
Variance 
explained R2 p-value 
Variance 
explained R2 
(variable only) 
Variance 
explained R2 
(variable+time) p-value 
d· Study characteristics         
Study year (midpoint)   9% 0·021 - - - 
2011 onwards 31 50·1 42·4 – 57·8 - - - - - 
Pre-2011 8 32·2 21·6 – 43·7 - - - - - 
Continuous 39 0·04 0·01 – 0·06 22% 0·0015 - - - 
Sampling method (missing=2)    23% <0·0001 12% 31% 0·00027 
RDS (weighted) 21 37·8 29·8 – 46·1 - - - - - 
RDS (unweighted) 7 47·1 36·7 – 57·6 - - - - - 
Snowball 6 74·9 56·7 – 89·5 - - - - - 
Convenience/purposive 3 60·1 38·2 – 80·2 - - - - - 
Mix 2 16·1 0·09 – 25·3 - - - - - 
CI, confidence interval; HCW, health care worker; LGBT, lesbian, gay, bisexual and transgender; MSM, men who have sex with men; MSW, male sex workers; 
PWID, people who inject drugs; RDS, respondent driven sampling; STI, sexually transmitted infection. Continuous variables were dichotomised at the median 
value. p-values in bold were significant at the 0·05 level 
* pooled estimate given for categorical variables and slope given for continuous variables 
† high-risk MSM includes MSW, PWID, MSM recruited from drinking venues and STI clinics, and MSM identified as high-risk by study authors  
‡ low-risk includes non-PWID and MSM self-reported to be HIV-negative 
§ MSM organisations includes MSM recruited from MSM/LGBT organisations/prevention activities 
¶ recently sold sex includes in the past 12, 6, or 3 months 
|| adjusted for time (continuous variable) and the relevant participant/study characteristic, or stigma/anti-LGBT legislation variable 
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Table S8. HIV+ Aware. Results of univariate meta-regression analyses of the association of participant characteristics, stigma, 
and anti-LGBT legislation with the proportion of MSM HIV+ aware (Ne=35). This outcome was not associated with study year, 
therefore only results of univariate regression are presented. 
 Number of 
estimates 
Ne 
Pooled estimate 
(%) or slope* 95% CI 
Univariate  
Variance  
explained R2 p-value 
a. Participant Characteristics    
Population    9% 0·032 
General MSM 30 15·5 10·4 – 21·3 - - 
High-risk MSM† 4 34·7 24·3 – 46·0 - - 
MSM organisations‡ 1 48·8 33·5 – 64·2 - - 
Region of Africa    14% 0·046 
Central 3 29·0 15·1 – 45·0 - - 
Eastern 13 10·1 3·3 – 19·5 - - 
Southern 10 26·4 17·1 – 36·7 - - 
Western 9 20·4 13·2 – 28·7 - - 
Mean age (missing=9) 26 0·00 -0·05 – 0·05 0% 0·96 
HIV Prevalence (missing=4) 31 0·25 -0·42 – 0·93 9% 0·46 
Proportion ever sold sex (missing=26) 0% 0·39 
≤ 37% 4 15·9 6·7 – 27·7 - - 
> 37% 5 25·5 9·3 – 46·0 - - 
Proportion recently sold sex (missing=29)  0% 0·64 
≤ 31% 3 19·4 7·9 – 33·9 - - 
> 31% 3 24·9 9·0 – 45·0 - - 
b. Stigma Variables      
Proportion disclosed MSM status to healthcare workers (missing=26) 17% 0·067 
≤ 20% 4 11·2 5·0 – 19·1 - - 
> 20% 5 26·2 12·9 – 42·1 - - 
Proportion disclosed MSM status to family (missing=26)  0% 0·058 
≤ 21% 5 10·3 2·0 – 22·9 - - 
> 21% 4 30·2 13·6 – 49·8 - - 
Proportion blackmailed because MSM (missing=27)  43% 0·031 
≤ 18% 3 8·3 2·9 – 15·7 - - 
> 18% 5 28·4 14·7 – 44·5 - - 
c. Anti-LGBT Legislation Variables    
Repressive    4% 0·014 
0 7 22·8 12·6 – 34·7 - - 
1 4 18·4 10·2 – 28·0 - - 
2 14 25·9 18·2 – 34·5 - - 
3 – 5 10 6·7 0·6 – 17·0 - - 
Lack of Protective    0% 0·77 
0 6 20·0 9·8 – 32·5 - - 
1 – 2 29 17·8 12·0 – 24·4 - - 
Lack of Progressive    0% 0·77 
0 6 20·0 9·8 – 32·5 - - 
1 – 2 29 17·8 12·0 – 24·4 - - 
Penalties    41% 0·00023 
0 12 24·5 16·1 – 33·9 - - 
1 3 29·0 15·1 – 45·0 - - 
2 11 23·5 16·8 – 30·9 - - 
3 – 5 9 4·9 0·5 – 12·0 - - 
Arrests    3% 0·064 
Yes 18 13·6 7·2 – 21·5 - - 
No 17 23·8 16·9 – 31·4 - - 
Global score    5% 0·0050 
≤ 5 11 22·0 14·1 – 31·0 - - 
6 – 8 14 25·9 18·2 – 34·5 - - 
≥ 9 10 6·7 0·6 – 17·0 - - 
Continuous 35 -0·02 -0·03 – 0·00 4% 0·052 
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Table S8 continued… 
 
 Number of 
estimates 
Ne 
Pooled estimate 
(%) or slope* 95% CI 
Univariate  
Variance  
explained R2 p-value 
d. Study characteristics      
Study year (midpoint)    0% 0·92 
2011 onwards 28 18·3 12·5 – 24·9 - - 
Pre-2011 7 17·6 7·1 – 31·3 - - 
Continuous 35 0·01 -0·01 – 0·04 0% 0·38 
Sampling method    51% <0·0001 
RDS (weighted) 7 2·7 0·0 – 8·3 - - 
RDS (unweighted) 13 24·4 18·8 – 30·1 - - 
Cluster/time-venue (unweighted) 2 21·1 5·8 – 41·9 - - 
Snowball 9 26·5 15·6 – 39·0 - - 
Convenience/purposive 2 7·8 3·4 – 13·7 - - 
Mix 2 28·4 2·0 – 67·4 - - 
CI, confidence interval; HCW, health care worker; LGBT, lesbian, gay, bisexual and transgender; MSM, men who have sex with men; MSW, 
male sex workers; RDS, respondent driven sampling; STI, sexually transmitted infection. Continuous variables were dichotomised at the median 
value. p-values in bold were significant at the 0·05 level 
* pooled estimate given for categorical variables and slope given for continuous variables 
† high-risk MSM includes MSW, PWID, MSM recruited from drinking venues and STI clinics, and MSM identified as high-risk by study authors  
‡ MSM organisations includes MSM recruited from MSM/LGBT organisations/prevention activities 
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Figure S3. Forest plot showing results of subgroup analyses of pooled estimates. The proportions of MSM (a) ever tested, (b) 
tested in the past 12 months, and (c) HIV+ aware are stratified by whether the study was conducted before (white diamonds) or 
after (black diamonds) 2011. 
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Figure S4. Scatter plot of the changes over time in the proportions of MSM (a) ever tested, (b) tested in the past 12 months and 
(c) MSM HIV+ aware, stratified by region of Africa. Lines are regression lines fitted to data for each region. Ne, Number of 
estimates; p is the p-value of the slope.  
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Figure S5. Changes over time in the proportion of MSM (a) ever tested, (b) tested in the past 12 months and (c) MSM 
HIV+ aware stratified by country of Africa. Lines are regression lines (slope, 95%CI, p-value) fitted to data for each country in 
Eastern (green), Southern (blue) or Western (pink) Africa. Only countries with at least three estimates at three different time 
points are shown. 
 
a. Ever tested 
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b. Tested in the past 12 months 
  
 
 
c. MSM HIV+ aware 
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Figure S6. Country-level and study-level leave-one-out sensitivity analysis of the time-adjusted association between ever 
testing for HIV and the continuous score on the anti-LGBT Legislation Index. In the country-level analysis (a) we repeated 
the time-adjusted meta-regression analysis of the association between ever testing and the anti-LGBT Legislation Index score by 
excluding all studies from each individual country one at a time. We extracted the slope and 95%CI of the association with each 
country excluded. The dotted line represents a slope of zero (i.e. no association), and the solid line and shaded area represent the 
slope and 95% CI of the association with all countries included (slope = -0.021 (-0.035 – -0.0074). The magnitude of the 
association was only sensitive to the exclusion of South African studies; therefore we conducted a study-level sensitivity analysis 
(b) in which we repeated the time-adjusted meta-regression analysis by excluding each South African study one at a time and 
extracted the slope and 95%CI of the association with each South African study excluded. 
 
a. Country-level analysis 
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b. Study-level analysis 
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Figure S7. Forest plot of pooled estimates of the proportions of all MSM (a) ever tested, and (b) tested in the past 12 months for 
HIV stratified by different levels of participant characteristics and structural variables that were statistically significantly (p<0·05) 
associated with ever having tested for HIV in bivariate (time-adjusted) meta-regression. The estimates are further stratified by 
whether the study was conducted before (white) or after (black) 2011.  
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b. Tested in the past 12 months 
  
Study design
1. 
Was the study 
specifically designed 
to estimate the 
cascade outcome of 
interest?
(yes/no)
2. 
Was the sampling 
method used 
appropriate for 
capturing a 
representative 
sample of the target 
population?
(yes for for 
cluster/time-venue, 
RDS, or snowball, 
no for other e.g. 
convenience/
purposive)
3.
Did the study use a 
complex study 
design with 
appropriate 
stastical 
adjustment for 
study design?
(yes for 
cluster/time-
venue/RDS studies 
where derived 
estimates take into 
account the 
weights and 
clustering, no 
otherwise)
4. 
Inclusion criteria 
clearly defined?
(yes/no)
5. 
Study population 
reflected 
community of 
wider MSM?
(yes/no)
6.
Were the study 
participants MSM 
only or were 
transgender women 
included (yes if 
MSM only, no if 
transgender women 
included or NR)
7. 
Was the response 
rate raise adequate 
enough not to raise 
concerns?
(yes if ≥60%, no if 
<60% or NR)
8.
Measures taken 
to address and 
categorise non-
responders?
(yes/no)
9. 
Was the study 
based on 
confidential 
interview 
methods?
(yes/no)
10. 
Outcomes 
confirmed with 
biological test (yes) 
or self-reported 
(no)?
11. 
Methods 
sufficiently 
described to be 
repeated?
(yes/no)
12. 
Basic data 
adequately 
described?
(yes/no)
13. 
Results 
internally 
consistent?
(yes/no)
14. 
Proportions self-
calculated (yes) 
or directly 
reported (no)?
15. 
Was the 
outcome first 
reported in the 
text/table (yes) 
or abstract (no)
Herce 201819 Angola, Luanda YES YES NO YES YES YES NO NO NO NO YES NO YES NO YES 8 7
Herce 201819 Angola, Benguela YES YES NO YES YES YES NO NO NO NO YES NO YES NO YES 8 7
Holland 201547 Cameroon, Douala YES YES YES YES YES NO NO NO NO NO YES YES NO NO YES 8 7
Holland 201547 Cameroon, Yaoundé YES YES YES YES YES NO NO NO NO NO YES YES NO NO YES 8 7
Kendall 201448 Angola NO YES NO YES YES NO YES NO NO NO NO NO NO NO YES 5 10
Lorente 201249 Cameroon YES YES NO NO YES NO NO NO NO NO YES YES YES NO NO 6 9
Chapman 201113 Rwanda NO YES NO YES YES NO NO NO NO NO YES YES YES YES YES 8 7
Coulaud 201614 Burundi YES NO NO NO NO NO NO NO YES NO YES YES YES YES YES 7 8
Fay 201116 Malawi YES YES NO YES YES NO NO NO NO NO YES YES NO NO YES 7 8
Herce 201819 Malawi YES YES NO YES YES YES NO NO NO NO YES NO YES NO YES 8 7
Hladik 201220 Uganda NO YES YES YES YES NO NO NO NO NO YES YES NO NO YES 7 8
Hladik 201721 Uganda NO YES YES YES YES NO NO NO YES NO YES YES NO NO YES 8 7
Horth 201522 Mozambique, Maputo YES YES NO YES YES NO NO NO NO NO NO YES YES NO NO 6 9
Horth 201522 Mozambique, Beira YES YES NO YES YES NO NO NO NO NO NO YES YES NO NO 6 9
Horth 201522 Mozambique, Nampula/Nacala YES YES NO YES YES NO NO NO NO NO NO YES YES NO NO 6 9
Kajubi 200824 Uganda NO YES YES YES NO NO NO NO NO NO YES NO YES NO YES 6 9
Khatib 201725 Tanzania (2011) NO YES YES YES YES NO NO NO NO NO YES YES NO NO YES 7 8
Khatib 201725 Tanzania (2007) NO YES YES YES YES NO NO NO NO NO YES YES NO NO YES 7 8
Luchters 201127 Kenya NO YES NO YES NO NO YES NO NO NO YES YES NO YES YES 7 8
McKinnon 201328 Kenya NO NO NO NO NO NO NO NO NO NO NO YES NO NO YES 2 13
Mmbaga 201829 Tanzania YES YES NO YES YES NO NO NO NO NO YES YES NO NO YES 7 8
Moller 201530 Kenya NO NO NO YES NO NO YES NO NO NO YES YES YES NO YES 6 9
Muraguri 201531 Kenya NO YES NO YES YES NO NO NO NO NO YES YES NO YES YES 7 8
Musyoki 201832 Kenya YES YES NO NO YES NO YES NO YES NO YES YES YES NO NO 8 7
Ntata 200833 Malawi NO YES NO NO YES NO NO NO NO NO NO NO YES NO YES 4 11
Nyoni 201234 Tanzania YES NO NO NO NO NO NO NO NO NO NO NO YES NO YES 3 12
Romijnders 201636 Tanzania NO YES NO NO YES NO NO NO YES NO NO YES NO NO YES 5 10
Sanders 200738 Kenya NO NO NO NO YES NO NO NO NO NO NO YES NO NO YES 3 12
Wanyenze 201642 Uganda YES YES NO NO YES NO NO NO NO NO YES YES YES NO YES 7 8
Wirtz 201744 Malawi, Blantyre NO YES YES YES YES NO NO NO NO NO YES YES YES YES YES 9 6
Wirtz 201744 Malawi, Chikwana NO YES YES YES YES NO NO NO NO NO YES YES YES YES YES 9 6
Wirtz 201744 Malawi, Lilongwe NO YES YES YES YES NO NO NO NO NO YES YES YES YES YES 9 6
Wirtz 201744 Malawi, Mangochi NO YES YES YES YES NO NO NO NO NO YES YES YES YES YES 9 6
Wirtz 201744 Malawi, Mulanje NO YES YES YES YES NO NO NO NO NO YES YES YES YES YES 9 6
a. EVER TESTED
Selection bias
Total 
YES
Total
NO
Eastern Africa
Central Africa
Reporting bias
Reference Location
Measurement error Publication bias
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Supplement Table S9. Table of results of quality assessment analysis for the three main outcomes. The quality of each estimate was assessed using a series of 15 questions covering five different potential sources
of bias: 1) study design; 2) selection bias; 3) measurement error; 4) reporting bias, and; 5) publication bias, and a quality score that reflected the responses to the most important questions. An answer of “yes” to
a question is considered a positive response, and an answer of “no” a negative response. Quality assessment was done at estimate level rather than study level.
Wirtz 201744 Malawi, Mzuzu NO YES YES YES YES NO NO NO NO NO YES YES YES YES YES 9 6
Wirtz 201744 Malawi, Nkhata Bay NO YES YES YES YES NO NO NO NO NO YES YES YES YES YES 9 6
Elmahy 201852 Egypt YES NO NO NO NO NO NO NO NO NO NO YES YES NO NO 3 12
Arnold 201354 South Africa YES YES NO NO YES NO NO NO NO NO NO YES YES NO YES 6 9
Batist 201358 South Africa NO NO NO YES YES NO NO NO YES NO NO YES YES NO YES 6 9
Eaton 201361 South Africa NO NO NO NO NO NO NO NO YES NO YES YES NO NO YES 4 11
Fay 201116 Botswana YES YES NO YES YES NO NO NO NO NO YES YES YES NO YES 8 7
Fay 201116 Namibia YES YES NO YES YES NO NO NO NO NO YES YES NO NO YES 7 8
Knox 201163 South Africa YES NO NO YES YES NO NO NO YES NO YES YES YES NO YES 8 7
Lane 200865 South Africa NO NO NO YES YES NO NO NO NO NO YES NO YES YES YES 6 9
Lane 201466 South Africa, Gert Sibande YES YES YES YES YES NO NO NO NO NO YES YES YES NO NO 8 7
Lane 201466 South Africa, Ehlanzeni YES YES YES YES YES NO NO NO NO NO YES YES YES NO NO 8 7
Sandfort 200871 South Africa YES NO NO NO YES NO NO NO YES NO YES YES YES NO NO 6 9
Siegler 201572 South Africa YES YES NO YES YES NO NO NO NO NO NO NO NO YES NO 5 10
Stahlman 2015a73 Lesotho NO YES NO YES YES NO NO NO NO NO YES YES YES YES YES 8 7
Tun 201276 South Africa YES YES YES YES YES NO NO NO NO NO YES YES YES NO YES 9 6
Wagenaar 201277 South Africa NO NO NO YES YES NO NO NO YES NO YES YES YES NO YES 7 8
Drame 201385 Senegal NO NO NO YES NO NO NO NO NO NO NO YES NO NO YES 3 12
Eluwa 201586 Nigeria, Cross River NO YES YES YES YES NO NO NO NO NO YES YES NO NO YES 7 8
Eluwa 201586 Nigeria, FCT NO YES YES YES YES NO NO NO NO NO YES YES NO NO YES 7 8
Eluwa 201586 Nigeria, Kaduna NO YES YES YES YES NO NO NO NO NO YES YES NO NO YES 7 8
Eluwa 201586 Nigeria, Kano NO YES YES YES YES NO NO NO NO NO YES YES NO NO YES 7 8
Eluwa 201586 Nigeria, Lagos NO YES YES YES YES NO NO NO NO NO YES YES NO NO YES 7 8
Eluwa 201586 Nigeria, Oyo NO YES YES YES YES NO NO NO NO NO YES YES NO NO YES 7 8
Bakai 201681 Togo NO YES NO NO YES NO NO NO NO NO NO YES YES YES YES 6 9
Girault 201587 Ghana, Greater Accra YES YES NO YES NO NO NO NO NO NO YES YES YES NO YES 7 8
Girault 201587 Ghana, Ashanti Region YES YES NO YES NO NO NO NO NO NO YES YES YES NO YES 7 8
Goodman 201688 Burkina Faso YES YES NO YES YES NO NO NO NO NO YES YES YES YES YES 9 6
Hakim 201589 Cote d'Ivoire NO YES YES YES YES NO NO NO NO NO YES YES YES NO YES 8 7
Kushwaha 201792 Ghana, Accra NO YES NO YES YES YES NO NO NO NO YES YES NO NO YES 7 8
Kushwaha 201792 Ghana, Kumasi NO YES NO YES YES YES NO NO NO NO YES YES YES NO YES 8 7
Kushwaha 201792 Ghana, Manya Krobo NO YES NO YES YES YES NO NO NO NO YES YES YES NO YES 8 7
Lahuerta 201893 Mali NO YES YES YES YES NO NO NO NO NO YES YES YES YES YES 9 6
Lieber 201894 Liberia NO NO NO YES YES YES NO NO NO NO YES NO YES NO YES 6 9
Merrigan 201197 Nigeria, Lagos NO YES YES YES YES NO YES NO NO NO NO YES YES NO YES 8 7
Merrigan 201197 Nigeria, Kano NO YES YES YES YES NO YES NO NO NO NO YES YES NO YES 8 7
Merrigan 201197 Nigeria, Cross River NO YES YES YES YES NO YES NO NO NO NO YES YES NO YES 8 7
Rodriguez-Hart 2018106 Nigeria YES YES NO YES YES YES NO NO NO NO YES YES YES NO YES 9 6
Ruiseñor-Escudero 2017107 Togo NO YES YES YES YES NO YES NO NO NO YES YES YES NO YES 9 6
Stromdahl 2012112 Nigeria NO NO NO YES YES YES NO YES NO NO YES YES YES NO YES 8 7
Teclessou 2017113 Togo YES YES NO YES YES NO NO NO NO NO YES YES NO YES YES 8 7
Tobin-West 2017114 Nigeria YES YES NO YES YES YES NO NO YES NO YES YES YES NO NO 9 6
Tun 2018115 Nigeria YES YES NO YES YES YES NO YES NO NO YES YES YES NO NO 9 6
Vu 2013a116 Nigeria, Lagos YES YES YES YES YES YES NO NO YES NO YES YES YES NO YES 11 4
Vu 2013a116 Nigeria, Ibadan YES YES YES YES YES YES NO NO YES NO YES YES YES NO YES 11 4
Vu 2013a116 Nigeria, Abuja YES YES YES YES YES YES NO NO YES NO YES YES YES NO YES 11 4
Wade 2005118 Senegal NO YES NO YES YES YES YES NO NO NO NO YES YES NO YES 8 7
Kendall 201448 Angola NO YES NO YES YES NO YES NO NO NO NO NO NO YES YES 6 9
Park 201451 Cameroon, Douala YES YES YES YES YES NO NO NO NO NO YES YES YES NO NO 8 7
Park 201451 Cameroon, Yaoundé YES YES YES YES YES NO NO NO NO NO YES YES YES NO NO 8 7
b. RECENTLY TESTED (PAST 12 MONTHS)
Central Africa
Southern Africa
Western Africa
Northern Africa
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Rao 201750 Cameroon, Yaoundé (2015) NO YES YES YES YES NO NO NO NO NO YES YES YES NO YES 8 7
Rao 201750 Cameroon, Yaoundé (2013) NO YES NO YES YES NO NO NO NO NO YES YES YES NO YES 7 8
Adam 20097 Mauritius YES NO NO NO NO NO NO NO NO NO NO NO YES NO YES 3 12
Coulaud 201614 Burundi YES NO NO NO NO NO NO NO YES NO YES YES YES YES YES 7 8
Hladik 201721 Uganda NO YES YES YES YES NO NO NO YES NO YES YES NO NO YES 8 7
Horth 201522 Mozambique, Maputo YES YES YES YES YES NO NO NO NO NO NO YES YES NO NO 7 8
Horth 201522 Mozambique, Beira YES YES YES YES YES NO NO NO NO NO NO YES YES NO NO 7 8
Horth 201522 Mozambique, Nampula/Nacala YES YES YES YES YES NO NO NO NO NO NO YES YES NO NO 7 8
Khatib 201725 Tanzania NO YES YES YES YES NO NO NO NO NO YES YES NO NO NO 6 9
Khatib 201725 Tanzania NO YES YES YES YES NO NO NO NO NO YES YES NO NO NO 6 9
Muraguri 201531 Kenya NO YES NO YES YES NO NO NO NO NO YES YES NO YES YES 7 8
Shangani 201740 Kenya YES YES NO YES YES NO YES NO NO NO YES YES YES NO NO 8 7
Wirtz 201744 Malawi NO YES YES YES YES NO NO NO NO NO YES YES YES YES YES 9 6
Valadez 201353 Libya NO YES YES YES YES NO NO NO NO NO YES YES YES YES YES 9 6
Baral 2011b56 Lesotho YES YES NO YES YES YES NO NO NO NO YES YES YES NO NO 8 7
Grover 201662 eSwatini YES YES NO YES YES NO NO NO NO NO NO YES YES NO YES 7 8
Knox 201163 South Africa YES NO NO YES YES YES NO NO YES NO YES YES YES NO YES 9 6
Lippman 201868 South Africa, Gert Sibande YES YES NO YES YES NO YES YES NO NO YES YES YES YES YES 11 4
Lippman 201868 South Africa, Ehlanzeni YES YES NO YES YES NO YES YES NO NO YES YES YES YES YES 11 4
Rao 201750 eSwatini NO YES NO YES YES NO NO NO NO NO YES YES YES NO YES 7 8
Rebe 201569 South Africa NO NO NO YES NO NO NO NO NO NO NO YES YES NO YES 4 11
Adam 20097 Mauritania YES NO NO NO NO NO NO NO NO NO NO NO YES NO YES 3 12
Adam 20097 Nigeria YES YES YES NO NO NO NO NO NO NO NO NO YES NO YES 5 10
Aho 201480 Cote d'Ivoire NO YES YES YES YES NO NO NO NO NO YES YES YES YES YES 9 6
Bouscaillou 201683 Cote d'Ivoire NO YES NO YES NO NO NO NO NO NO YES YES YES NO YES 6 9
Girault 201587 Ghana, Greater Accra YES YES YES YES NO NO NO NO NO NO YES YES YES NO YES 8 7
Girault 201587 Ghana, Ashanti Region YES YES YES YES NO NO NO NO NO NO YES YES YES NO YES 8 7
Lahuerta 201893 Mali NO YES YES YES YES NO NO NO NO NO YES YES YES YES YES 9 6
Nelson 201598 Ghana NO YES NO YES YES NO NO NO YES NO YES YES NO YES YES 8 7
Tun 2018115 Nigeria YES YES NO YES YES NO NO YES NO NO YES YES YES YES YES 10 5
Herce 201819 Angola, Luanda YES YES NO YES YES YES NO NO NO NO YES NO NO NO YES 7 8
Herce 201819 Angola, Benguela YES YES NO YES YES YES NO NO NO NO YES NO NO NO YES 7 8
Kendall 201448 Angola NO YES NO YES YES NO YES NO NO NO NO NO NO YES YES 6 9
Baral 200910 Malawi NO YES NO YES YES NO NO NO NO NO NO YES YES NO YES 6 9
Fogel 201817 Kenya YES YES NO YES NO NO NO NO YES NO NO YES YES YES NO 7 8
Fogel 201817 Malawi YES YES NO YES NO NO NO NO YES NO NO YES YES YES NO 7 8
Hladik 201720 Uganda NO YES NO YES YES NO NO NO YES NO YES YES NO NO NO 6 9
Kunzweiler 201726 Kenya YES YES NO YES YES NO YES YES YES NO YES YES YES NO NO 10 5
Muraguri 201531 Kenya NO YES NO YES YES NO NO NO NO NO YES YES NO YES YES 7 8
Ross 201437 Tanzania NO YES NO NO YES NO NO NO YES NO YES YES YES NO NO 6 9
Sanders 200738 Kenya NO NO NO NO YES NO NO NO NO NO NO YES NO YES YES 4 11
Wirtz 201744 Malawi YES YES YES YES YES NO NO NO NO NO YES YES NO NO YES 8 7
Baral 200910 Botswana NO YES NO YES YES NO NO NO NO NO NO YES NO NO YES 5 10
Baral 200910 Namibia NO YES NO YES YES NO NO NO NO NO NO YES NO NO YES 5 10
Baral 2011a55 South Africa NO NO NO YES YES YES NO NO NO NO YES YES YES NO NO 6 9
Brown 201659 eSwatini NO YES NO YES YES NO NO NO NO NO NO YES YES YES YES 7 8
c. HIV+ AWARE
Western Africa
Eastern Africa
Central Africa
Southern Africa
Eastern Africa
Northern Africa
Southern Africa
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Fogel 201817 South Africa, Cape Town YES YES NO YES NO NO NO NO YES NO NO YES YES YES NO 7 8
Fogel 201817 South Africa, Soweto YES YES NO YES NO NO NO NO YES NO NO YES YES YES NO 7 8
Lane 201166 South Africa NO YES NO YES YES NO NO NO NO NO YES YES YES YES YES 8 7
Lane 201467 South Africa, Gert Sibande YES YES NO YES YES NO NO NO NO NO YES YES YES NO NO 7 8
Lane 201467 South Africa, Ehlanzeni YES YES NO YES YES NO NO NO NO NO YES YES YES NO NO 7 8
Stahlman 2015b74 Lesotho NO YES NO YES YES NO NO NO NO NO YES YES YES YES YES 8 7
Baral 201582 Nigeria NO YES NO YES YES NO NO NO NO NO NO YES YES NO NO 7 10
Drame 201385 Senegal NO NO NO YES NO NO NO NO NO NO NO YES NO YES YES 7 11
Hakim 201589 Cote d'Ivoire NO YES YES YES YES NO NO NO NO NO YES YES YES NO NO 8 8
Hakim 201790 Mali NO YES YES YES YES NO NO NO NO NO YES YES YES NO NO 0 8
Holland 201691 Burkina Faso, Bobo Dioulasso YES YES NO YES YES NO NO NO NO NO NO NO YES NO YES 5 9
Holland 201691 Burkina Faso, Ouagadougou YES YES NO YES YES NO NO NO NO NO NO NO YES NO YES 4 9
Holland 201691 Togo YES YES NO YES YES NO NO NO NO NO NO NO YES NO YES 7 9
Lyons 201795 Senegal YES YES NO YES YES NO NO NO NO NO NO NO YES NO YES 7 9
Mason 201396 The Gambia NO YES NO YES YES NO NO NO NO NO YES YES YES YES YES 6 7
Western Africa
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Figure S8. Forest plots showing pooled estimates of the proportions of: (a) all MSM ever tested for HIV; (b) all MSM recently 
tested for HIV in the past 12 months; and, (c) MSM HIV+ aware, stratified by whether the answer was yes (white diamonds) or no 
(black diamonds) to study quality questions. The p-value represents the strength of the association between the quality indicators 
and testing and treatment outcomes in univariate meta-regression. * Confidential interview methods included ACASI, SAQ or PBS. 
** Quality score totalled the number of answers of “YES” to the three questions in bold, with 3 representing higher quality and 0 
representing estimates from lower quality studies. Quality assessment was done at the estimate level, not study level. 
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c. HIV+ aware 
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Figure S9. Funnel plots of the proportions of (a) MSM ever tested, (b) tested in the past 12 months, and (c) MSM HIV+ aware. 
The vertical black line represents the pooled estimate and the dotted lines the pseudo 95% CI (the area within which 95% of 
estimates would be expected to lie in the absence of bias and heterogeneity). Red circles represent estimates self-calculated from 
available data within the paper whereas black circles are estimates extracted directly as proportions. There was no evidence of 
publication bias for study estimates of the proportions of MSM ever tested (p=0·97), tested in the past 12 months (p=0·21), or 
MSM HIV+ aware (p=0·56).  
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Figure S10. Trends over time and by region in MSM compared to all men. Estimates among all men (open circles) of (a) ever 
testing, (b) testing in the past 12 months, and (c) current ART use are compared with estimates among MSM (closed circles) from 
our review. Estimates are only shown for countries from Central (red), Eastern (green), Southern (blue) and Western (purple) 
Africa for which estimates were available for both populations. Estimates of ever testing and testing in the past 12 months among 
all men were from DHS reports.120 Estimates of current ART use among all men living with HIV were from UNAIDS data from 
2010-2018.121,122 
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c. MSM living with HIV currently on ART 
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   Assessment of confounding (eg,  
   comparability of cases and controls in  
   studies where appropriate 
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7-8
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6
Reporting Criteria Reported (Yes/No) Reported on Page No. 
   Assessment of study quality, including  
   blinding of quality assessors;  
   stratification or regression on possible  
   predictors of study results 
  
   Assessment of heterogeneity   
   Description of statistical methods (eg,  
   complete description of fixed or random  
   effects models, justification of whether     
   the chosen models account for predictors  
   of study results, dose-response models,  
   or cumulative meta-analysis) in sufficient  
   detail to be replicated 
  
   Provision of appropriate tables and  
   graphics 
  
Reporting of Results   
   Table giving descriptive information for  
   each study included 
  
   Results of sensitivity testing (eg,  
   subgroup analysis) 
  
   Indication of statistical uncertainty of  
   findings 
  
Reporting of Discussion   
   Quantitative assessment of bias (eg,  
   publication bias) 
  
   Justification for exclusion (eg, exclusion  
   of non–English-language citations) 
  
   Assessment of quality of included studies   
Reporting of Conclusions   
   Consideration of alternative explanations  
   for observed results 
  
   Generalization of the conclusions (ie,  
   appropriate for the data presented and  
   within the domain of the literature review) 
  
   Guidelines for future research   
   Disclosure of funding source   
 
Once you have completed this checklist, please save a copy and upload it as part of your submission. DO NOT include this 
checklist as part of the main manuscript document. It must be uploaded as a separate file. 
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 PRISMA 2009 Checklist  
Section/topic   #  Checklist item   
Reported 
on page #   
TITLE       
Title   1  Identify the report as a systematic review, meta-analysis, or both.   1 
ABSTRACT       
Structured summary   2  Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, 
participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications 
of key findings; systematic review registration number.   
2-3 
INTRODUCTION       
Rationale   3  Describe the rationale for the review in the context of what is already known.   4-5 
Objectives   4  Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, 
outcomes, and study design (PICOS).   
5 
METHODS       
Protocol and registration   5  Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide 
registration information including registration number.   
- 
Eligibility criteria   6  Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, 
language, publication status) used as criteria for eligibility, giving rationale.   
6 
Information sources   7  Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify 
additional studies) in the search and date last searched.   
6 
Search   8  Present full electronic search strategy for at least one database, including any limits used, such that it could be 
repeated.   
Supp. 
Study selection   9  State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, 
included in the meta-analysis).   
6 
Data collection process   10  Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for 
obtaining and confirming data from investigators.   
6 
Data items   11  List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and 
simplifications made.   
6-7, Supp. 
Risk of bias in individual 
studies   
12  Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done 
at the study or outcome level), and how this information is to be used in any data synthesis.   
8, Supp. 
Summary measures   13  State the principal summary measures (e.g., risk ratio, difference in means).   6 
Synthesis of results   14  Describe the methods of handling data and combining results of studies, if done, including measures of consistency 
(e.g., I2) for each meta-analysis.   
7 
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 PRISMA 2009 Checklist  
Section/topic   #  Checklist item   
Reported 
on page #   
Risk of bias across studies   15  Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective 
reporting within studies).   
8 
Additional analyses   16  Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating 
which were pre-specified.   
7-8 
RESULTS       
Study selection   17  Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at 
each stage, ideally with a flow diagram.   
9, Fig. 1 
Study characteristics   18  For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and 
provide the citations.   
9-10, 
Tab.1, 
Supp. 
Risk of bias within studies   19  Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).   11-12, 
Supp. 
Results of individual studies   20  For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each 
intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.   
10, Fig. 3, 
Fig. 4 
Synthesis of results   21  Present results of each meta-analysis done, including confidence intervals and measures of consistency.   10, Fig. 3, 
Tab.2 
Risk of bias across studies   22  Present results of any assessment of risk of bias across studies (see Item 15).   11-12, 
Supp. 
Additional analysis   23  Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).   10-12, 
Supp. 
DISCUSSION       
Summary of evidence   24  Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to 
key groups (e.g., healthcare providers, users, and policy makers).   
13-14 
Limitations   25  Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of 
identified research, reporting bias).   
14-15 
Conclusions   26  Provide a general interpretation of the results in the context of other evidence, and implications for future research.   17 
FUNDING       
Funding   27  Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the 
systematic review.   
17 
  
From:  Moher D, Liberati A, Tetzlaff  J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Review s and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097.  
doi:10.1371/journal.pmed1000097  For more information, visit: www.prisma-statement.org.   
Research in context 
Evidence before this study 
Gay, bisexual and other men who have sex with men (MSM) are disproportionately burdened with HIV 
globally, with particularly high prevalence in Africa. MSM living with HIV on suppressive antiretroviral 
therapy (ART) do not transmit infection to their sexual partners. However, achieving and maintaining 
viral suppression depends on engagement in all stages of the HIV treatment cascade including testing, 
status awareness, engagement in care, and ART use. This may be particularly challenging in many 
African countries where existing legislation criminalises same-sex relations. Although several studies 
have reported negative effects of specific anti-LGBT legislation on HIV treatment and care in countries 
including Uganda and Nigeria, no study has systematically reviewed the evidence on the influence of 
legislation on HIV testing and the treatment cascade across Africa. Additionally, although the HIV 
treatment cascade has been summarised among MSM in developed countries including the US, UK 
and Canada, it has never been comprehensively reviewed and summarised for MSM in Africa. The 
most recent literature review of the treatment cascade among key populations (conducted in 2015) 
reported on MSM, sex workers and people who inject drugs globally, but only three studies on MSM in 
Africa were included. As more studies have been published in recent years, we aimed to fill this gap by 
conducting the first systematic review and meta-analysis of the engagement of MSM in Africa with HIV 
testing and all stages of the HIV treatment cascade, and by assessing progress over time and the 
relationship between HIV testing and treatment and the severity of anti-LGBT legislation. We searched 
Embase, Global Health, MEDLINE, Scopus and Web of Science between January 1st, 1980, and 
October 10th8, 2018, for studies reporting on HIV testing and the HIV treatment cascade among MSM 
in Africa. 
Added value of this study 
We included data from 75 independent studies from 28 countries and estimated pooled proportion of 
HIV testing, status awareness, engagement in care, ART use, and viral suppression for 44,993 MSM. 
Our analysis of available HIV testing data over time suggests that after 2011, pooled estimates of levels 
of testing ever (67%) and in the past 12 months (50%) were significantly higher than before 2011, with 
the greatest increases in Western Africa. Despite this, pooled estimates of status awareness after 2011 
suggest that this is still low (18%). Our pooled post-2011 estimates also suggested that MSM on ART 
can achieve relatively high levels of viral suppression (76%). However, among all MSM living with HIV, 
current ART use (24%) and viral suppression (25%) remains extremely low. We found that more severe 
anti-LGBT legislation was statistically significantly associated with lower levels of testing and status 
awareness. We also showed that despite a substantial increase in the number of studies on the HIV 
treatment cascade among MSM in Africa over the past few years, data remains scarce for all outcomes 
except HIV testing, especially from Central and Northern Africa.  
Implications of all the available evidence 
Despite improvements in HIV testing among MSM in Africa, particularly in recent years, and levels of 
testing among MSM exceeding those among all men in all regions, HIV status awareness, ART 
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coverage and overall viral suppression have remained very low, with HIV status awareness and ART 
coverage much lower than levels among all men, despite higher testing. Additional efforts are urgently 
needed to reach the UNAIDS 90-90-90 targets among MSM across Africa. Furthermore, our findings 
support previous evidence suggesting an association between anti-LGBT legislation and access to 
testing and treatment. Further research is needed to assess the effect of repealing such legislation on 
access to HIV services for MSM. Additionally, in spite of an increase over time in the number of studies, 
more data is still needed on the engagement of MSM in all stages of the HIV treatment cascade, 
particularly status awareness, engagement in care, ART use and viral suppression, and more research 
needs to be done in Northern and Central Africa, where few data were available.  
 
Figures Legends for Main Text 
 
Figure 1. PRISMA flowchart.  
We included 113 articles reporting on 75 independent studies in the principal meta-analysis. (Ns=Number of 
studies, Na=Number of articles). Na can exceed Ns since more than one article can be published on the 
same study. One study estimating ART use only among “all MSM” was excluded. Abstracts of non-English 
articles were translated, where possible, and full-texts received and translated, if potentially relevant. We 
did not make exclusions based on language.  
 
Figure 2. Forest plot of the proportions of African MSM ever tested 
Weighted (blank squares) and unweighted (filled squares) study estimates and their 95% CIs and pooled 
estimates (diamonds) and their 95% CIs are shown for proportions of MSM in Africa ever tested for HIV, 
overall and stratified by region of Africa. Numerators and denominators of weighted study estimates were 
derived from the effective sample size (see appendix p 3-4). All testing history was self-reported. Estimates 
that were self-calculated are indicated by a *. 
 
Figure 3. Forest plot of the proportions of African MSM recently tested in the past 12, 6, and 3 
months 
Weighted (blank squares) and unweighted (filled squares) study estimates and their 95% CIs and pooled 
estimates (diamonds) and their 95% CIs are shown for proportions of MSM in Africa recently tested for HIV 
in the past 12 months (black), 6 months (red), and 3 months (blue), overall and stratified by region of Africa. 
Numerators and denominators of weighted study estimates were derived from the effective sample size 
(see appendix p 3-4). All testing history was self-reported. Estimates that were self-calculated are indicated 
by a *.  
 
Figure 4. Forest plot of the proportions of African MSM HIV+ aware 
Weighted (blank squares) and unweighted (filled squares) study estimates and their 95% CIs and pooled 
estimates (diamonds) and their 95% CIs are shown for proportions of MSM in Africa HIV+ aware, overall 
and stratified by region of Africa. MSM HIV+ aware are those who reported living with HIV before testing 
positive during the study. Numerators and denominators of weighted study estimates were derived from the 
effective sample size (see appendix p 3-4). Estimates that were self-calculated are indicated by a *. 
 
Figure 5. Forest plot of the proportions of African MSM living with HIV ever or currently engaged in 
care, or linked to care within 30 days of diagnosis 
Study estimates and their 95% CIs and pooled estimates (diamonds) and their 95% CIs are shown for 
proportions of MSM in Africa living with HIV ever or currently engaged in care, or linked to care within 30 
days of diagnosis, overall and stratified by region of Africa. All study estimates were unweighted. All 
engagement in care was self-reported. MSM living with HIV are those who tested positive during the study. 
Estimates that were self-calculated are indicated by a *. 
 
Figure 6. Forest plot of the proportions of African MSM living with HIV ever or currently on ART 
Weighted (blank squares) and unweighted (filled squares) study estimates and their 95% CIs and pooled 
estimates (diamonds) and their 95% CIs are shown for proportions of MSM in Africa living with HIV ever or 
currently on ART, overall and stratified by region of Africa. All ART use was self-reported. MSM living with 
HIV are those who tested positive during the study. Numerators and denominators of weighted study 
estimates were derived from the effective sample size (see appendix p 3-4). Estimates that were self-
calculated are indicated by a *. 
 
Figure 7. Forest plot of the proportions of African MSM HIV+ aware ever or currently on ART 
Weighted (blank squares) and unweighted (filled squares) study estimates and their 95% CIs and pooled 
estimates (diamonds) and their 95% CIs are shown for proportions of MSM in Africa HIV+ aware ever or 
currently on ART, overall and stratified by region of Africa. All ART use was self-reported. MSM HIV+ aware 
are those who reported living with HIV before testing positive during the study. Numerators and 
denominators of weighted study estimates were derived from the effective sample size (see appendix p 3-
4). Estimates that were self-calculated are indicated by a *. 
 
Figure 8. Forest plot of the proportions of African MSM living with HIV, HIV+ aware, and currently on 
ART that were virally suppressed. 
Weighted (blank squares) and unweighted (filled squares) study estimates and their 95% CIs and pooled 
estimates (diamonds) and their 95% CIs are shown for proportions of MSM in Africa living with HIV, HIV+ 
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aware, and currently on ART that were virally suppressed, overall and stratified by region of Africa. All ART 
use was self-reported. MSM living with HIV are those who tested positive during the study. MSM HIV+ 
aware are those who reported living with HIV before testing positive during the study. Numerators and 
denominators of weighted study estimates were derived from the effective sample size (see appendix p 3-
4). Viral suppression was measured within studies with viral load testing using thresholds defined by the 
study authors. Estimates that were self-calculated are indicated by a *. 
Figure 2. Map of Africa.  
The 28 countries where the 75 included studies were conducted are shown, with the number of unique 
studies (Ns) conducted in each country and UN region, including Eastern (Ns=26), Central (Ns=7), Northern 
(Ns=2), Southern (Ns=19) and Western (Ns=23) Africa. Fifty-five studies were conducted in 21 different 
countries where same-sex sexual relations were illegal (red) at study midpoint and 21 studies in 8 countries 
where legal (blue). There were no studies in 26 countries, 13 where same-sex sexual relations are illegal. 
In Lesotho one study was conducted before a change in legislation decriminalising same-sex sexual 
relations and one after. 
 
Figure 3. Forest plots of proportions of African MSM engaging with HIV testing and the different 
stages of the HIV treatment cascade.  
Weighted (blank squares) and unweighted (filled squares) study estimates and their 95% CIs and pooled 
estimates (diamonds) and their 95% CIs are shown for proportions of MSM in Africa (a) ever tested for HIV, 
(b) recently tested for HIV in the past 12 months (black), 6 months (red), and 3 months (blue), and (c) HIV+ 
aware, (d) living with HIV ever or currently engaged in care, or linked to care within 30 days of diagnosis, 
(e) living with HIV ever or currently on ART, (f) HIV+ aware ever or currently on ART, and (g) living with 
HIV, HIV+ aware, and currently on ART that were virally suppressed. Pooled estimates are given overall 
and stratified by region of Africa. All testing history, engagement in care, and ART use was self-reported. 
MSM living with HIV are those who tested positive during the study. Viral suppression was measured within 
studies with viral load testing using thresholds defined by the study authors. Estimates that were self-
calculated are indicated by a *. 
 
Figure 4. Forest plot showing results of subgroup analyses of pooled estimates. 
The proportions of MSM (a) ever tested, (b) tested in the past 12 months, and (c) HIV+ aware are stratified 
by whether the study was conducted before (white diamonds) or after (black diamonds) 2011. 
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TABLES 
Table legends: 
Table 1. Summary of (a) HIV testing and treatment cascade outcomes, (b) participant 
characteristics; (c) stigma variables; (d) anti-LGBT legislation variables of studies 
included in the analyses, and (e) study characteristics and quality indicators.  
Table 2. Pooled estimates of the proportions of African MSM accessing HIV testing 
and different stages of the treatment cascade.  
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Table 1. 
 Total unique 
studies* 
(Ns=75) References 
a. Testing and Treatment Cascade Outcomes 
HIV testing   
Ever 54 32,43–95 
Recently tested 33  
Past 12 months 28 32,46,48–51,62,73,78,82,85,96–107 
Past 6 months 8 43,46,76,78,80,101,106,108 
Past 3 months 4 46,62,106,109 
HIV+ Aware 23  
Self-reported 23 32,43,48,51,58,62,68,87,88,110–122 
Engagement in Care 5  
Ever 2 116,118 
Currently 2 123,124 
Linked within 30 days of diagnosis 1 68 
ART use 13  
MSM living with HIV 12  
Ever 4 48,116,122,124 
Currently 9 32,68,102,116,118,119,125,126 
MSM HIV+ aware 8  
Ever 3 48,116,122 
Currently 6 32,68,116,119,127,128 
Viral suppression 5  
MSM living with HIV 4 32,122,125,129 
MSM HIV+ aware 3 32,122,128 
MSM currently on ART 4 32,116,125,130 
b. Participant Characteristics 
Population   
General MSM 60 32,43–45,47–51,53,56–59,62–70,72–84,86,88–96,98–101,103, 
104,106,107,109–120,122,123,127–130 
High-risk MSM† 9 52,54,55,71,102,103,121,124–126 
Low-risk MSM‡ 1 85 
MSM organisations§ 2 46,87 
NR 3 61,97 
Region of Africa¶   
Eastern 27 32,43–61,77,97,108–111,121,122,124,125 
Central 7 43,62–64,98,99,126 
Eastern 27 32,43–61,77,97,108–111,121,122,124,125 
Northern 2 65,10 
Southern 19 57,66–76,98,101–104,111–115,121,125,127 
Western 23 78–82,84–95,97,105–107,116–120,123,128–130 
Mean or median age¶   
≤25 40 32,46–48,50,52,53,55–57,60,61,63,64,66,67,69,73,76–80,82, 
83,85,86,88–91,93,96,97,99,100,103,107,108,110–114, 
116–120,126 
>25 37 44,45,49,51,54,57–59,65,68,70–
73,75,81,84,87,92,94,95,98,101,102,104,105,109,111,115,119, 
121–125,127–130 
NR 4 43,62,97 
HIV prevalence¶   
≤20% 26 32,43,48–51,54,56,57,62,66,68,74,78,79,82–
84,88,90,93,100,101,103,107,111–113,115,117,119,120,122 
>20% 22 45,47,48,51,52,57,58,63,66–68,70,81,85,87,90,94,99,101, 
102,105,110–112,114,116,118,126,128–130 
NR 33 44,46,53,55,59–61,64,65,69,71–73,75–77,80,86,89,91,92, 
95–98,104,106,108,109,121,123–125,127 
Proportion ever sold sex¶   
≤35% 9 53,57,59,60,68,69,101,104,108,111,114,127 
>35% 9 32,44,49,56,57,74,80,87,92,109,111,115 
NR 58 43,45–52,54,55,58,61–67,70–73,75–79,81–86,88–91,93–100, 
102,103,105–107,110,112,113,116–126,128–130 
Proportion sold sex recently¶ ||   
≤41% 12 50,53,66,72,82,88,91,93,97,100,102,103,107,112,113,117,122 
>41% 10 44,49,50,54,58,90–92,105,109 
 3 
NR 55 32,43,45–48,51,52,55–57,59–65,67–71,73–81,83–87,89,94–99, 
101,104,106,108,110,111,114–116,118–121,123–130 
c. Stigma Variables 
Proportion disclosed MSM status to healthcare workers¶ 
≤20% 6 57,66,82–84,111,112,114,117,119 
>20% 8 32,48,56,57,81,98,104,111,118,128-130 
NR 62 43–55,58–65,67–80,85–103,105–110,113,115,116,120–127 
Proportion disclosed MSM status to family¶ 
≤20% 4 32,57,66,82,111,112,117 
>20% 12 48,57,65,69,79,81,92,98,103,104,111,113,118,128–130 
NR 60 43–56,58–64,67,68,70–78,80,83–91,93–97,99–102,105–109, 
110,114–116,119–127 
Proportion blackmailed because MSM¶ 
≤20% 6 46,57,59,81,82,111,117,118,120,128–130 
>20% 7 57,66,83,98,103,104,111–113,119 
NR 63 32,43–45,47–56,58,60–65,67–80,84–102,105–109,110, 
114–116,119,121–127 
d. Anti-LGBT Legislation   
Same-sex relations illegal¶   
Yes 55 32,43–52,54–65,77–81,83,85–87,89–100,103,104,106,108–111, 
113,116,118–125,128–130 
No 21 53,66–76,82,83,88,101,102,105,107,112,114,115,117,119,121, 
125–127 
Repressive¶   
0 13 66–74,101,102,112,114,115,121,125,126 
1 13 75,76,82,84,88,90–93,97,104,105,107,117,119 
2 35 43,44,50–52,54,55,57,58,60,62–64,79,83,85–87,89,91,93–99, 
103,106,108,109,111,113,116,119–125 
3 – 5 20 32,43,45–49,56,57,59,61,65,77,78,80,81,97,100,110–111,118, 
121,125,128–130 
Indeterminable 1 127 
Lack of Protective¶   
0 14 67–76,101,102,114,115,121,125 
1 – 2 62 32,43–52,54–66,77–100,103–113,116–126,127–130 
Indeterminable 1 127 
Lack of Progressive¶   
0 11 67–74,101,102,114,115,121,125 
1 – 2 64 32,43–66,75–100,103–113,116–126,128–130 
Indeterminable 1 127 
Penalties¶   
0 23 53,57,66–
76,82,84,88,101,102,104,105,107,111,112,114,115,117,119, 
121,125,126 
1 3 43,50,62 
2 39 44,46,51,52,54,55,57,58,63–65,78–81,83,85–87,89–100,103, 
106,109,111,113,116,118–125,128–130 
3 – 5 17 32,43,45,47–49,56,57,59–61,77,91,93,97,108,110,111,121,125 
Indeterminable 1 127 
Arrests 2014-2017¶   
Yes 43 32,43–45,47–49,51,52,54–61,63–65,77,78,80,81,87,90–94, 
96–100,103,108–111,113,116,118,120–122,124,125,128–130 
No 35 43,46,50,53,57,62,66–76,79,82,83–86,88,89,95,97,101,102, 
104–107,111,112,114,115,117,119,121,123,125–127 
Global score¶   
≤5 21 53,66–76,82,84,88,101,102,104,105,107,112,114,115,117,119, 
121,125,126 
6 – 8 37 43,44,50–52,54,55,57,58,62–64,83,85–87,89–99,103,106,109, 
111,113,116,119–125 
≥9 23 32,43,45–49,56,57,59–61,65,77,78,80,81,91,93,97,100,108, 
110–111,118,121,125,128–130 
Indeterminable 1 127 
e. Study Characteristics and Quality Indicators 
Study year   
Pre-2011 30 49,51–55,57–60,64,70–76,90–94,97,100,104,108,111,114, 
115,124 
2011 onwards 41 32,43–50,56,62,63,65–69,77–89,96,98,99,101–103,105–107, 
109–110,112,113,116–123,125,128–130 
 4 
NR 4 61,95,126,127 
Study design¶   
Cross-sectional 64 32,43–51,53,55–57,59–77,79,80,82–86,88–100,102–117,119, 
120,123,126,127 
Cohort – baseline 10 52,54,58,78,81,87,101,118,121,122,124,125,128–130 
NR 2 97 
Sampling method   
RDS 30 32,45,47–51,56,60,62,63,66,68,72,74,79,81–85,88,90,91,93, 
97–101,103,105,107,108,110,112,113,115,117–119,128–130 
Cluster/time-venue 3 43,44,55,108 
Snowball 18 53,57,59,64,67,77,78,86,89,94,96,98,104,106,111,120–122, 
124,125 
Purposive/convenience 17 46,54,58,65,69–71,73,75,80,92,95,102,114,123,126,127 
Mix 3 52,76,116 
NR 4 61,87,97 
Interview method¶   
FTFI 54 43,45,48–55,57–60,62–64,66–68,72,74,76–79,81–85,88,89, 
91–105,107,108,110–120,123,126,128–130 
Confidential** 16 32,44,46,47,56,65,69–
71,73,75,80,86,106,109,110,121,122,125,127 
ACASI/FTFI mix 2 90,124 
NR 4 61,87,97 
ACASI, audio computer-assisted self-interview software; ART, anti-retroviral therapy; FTFI, face-to-face interview; 
LGBT, lesbian, gay, bisexual and transgender; MSM, men who have sex with men; MSW, male sex workers; NR, 
not reported; PBS, polling booth survey; PWID, people who inject drugs; RDS, respondent-driven sampling; SAQ, 
self-administered questionnaire 
 
Continuous variables were dichotomised at the median value.  
 
* number of referenced articles differs from the number of studies when multiple articles report on the same study 
and provide different estimates for different testing and/or cascade outcomes or a single article reports on multiple 
studies 
† high-risk MSM includes male sex workers, people who inject drugs, MSM recruited from drinking venues and 
STI clinics, and MSM identified as high-risk by study authors 
‡ low-risk MSM includes non-PWID and MSM self-reported to be HIV-negative 
§ MSM organisations includes MSM recruited from MSM/LGBT organisations/prevention activities 
¶ same study included in more than one subcategory when a study reports multiple estimates across different 
levels of the variable 
|| proportion sold sex recently includes MSM who have sold sex in the past 12, 6 or 3 months 
** confidential interview methods include ACASI (N=53), pooling booth surveys (N=1), and self-administered 
questionnaires (N=108). All continuous variables dichotomised at the median 
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Table 2. 
Cascade outcome Ne Pooled estimate (%) 95% CI I2 
HIV testing (among all MSM) 132    
Ever 81 61.·0 56.·2 – 65.·7 98% 
Recently 51    
past 12 months 39 46.·2 39.·6 – 52.·9 97% 
past 6 months 8 38.·8 26.·0 – 52.·4 96% 
past 3 months 4 44.·9 11.·3 – 81.·3 99% 
HIV+ aware 35    
Among MSM living with HIV 35 18.·2 13.·0 – 23.·9 91% 
Engagement in Care (among MSM living with HIV) 6    
Ever* 2 33.·7 0.·0 – 92.·5 99% 
Current† 2 40.·4 0.·9 – 91.·0 97% 
Linked within 30 days of diagnosis 2 15.·3 9.·3 – 22.·3 26% 
ART use 29    
Among MSM living with HIV 20    
Ever 6 2.·5 0.·1 – 7.·4 91% 
Current 14 23.·7 15.·5 – 33.·0 90% 
Among MSM HIV+ aware 9    
Ever 3 37.·3 0.·0 – 90.·3 94% 
Current 6 53.·4 36.·9 – 69.·5 86% 
Viral suppression 11    
Among MSM living with HIV 4 24.·7 18.·8 – 31.·2 50% 
Among MSM HIV+ aware 3 34.·4 28.·3 – 40.·7 0% 
Among MSM currently on ART 4 75.·6 64.·4 – 85.·5 45% 
ART, antiretroviral therapy; CI, confidence interval; HIV, human immunodeficiency virus; MSM, men who have sex with men; Ne, number of 
estimates 
 
HIV status of MSM living with HIV and MSM HIV+ aware was confirmed in the studies with an HIV test. 
 
* includes ever received a CD4 test 
† includes currently using cotrimoxazole and engaged in care at the start of the study 
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